CA2558160A1 - Antisense oligonucleotide targeting myostatin or fox01 for treatment of muscle wasting - Google Patents
Antisense oligonucleotide targeting myostatin or fox01 for treatment of muscle wasting Download PDFInfo
- Publication number
- CA2558160A1 CA2558160A1 CA002558160A CA2558160A CA2558160A1 CA 2558160 A1 CA2558160 A1 CA 2558160A1 CA 002558160 A CA002558160 A CA 002558160A CA 2558160 A CA2558160 A CA 2558160A CA 2558160 A1 CA2558160 A1 CA 2558160A1
- Authority
- CA
- Canada
- Prior art keywords
- myostatin
- oligonucleotide
- composition
- gene
- muscle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091034117 Oligonucleotide Proteins 0.000 title claims abstract description 315
- 108010056852 Myostatin Proteins 0.000 title claims abstract description 192
- 201000000585 muscular atrophy Diseases 0.000 title claims abstract description 75
- 206010028289 Muscle atrophy Diseases 0.000 title claims abstract description 73
- 239000000074 antisense oligonucleotide Substances 0.000 title claims description 89
- 238000012230 antisense oligonucleotides Methods 0.000 title claims description 89
- 102000004472 Myostatin Human genes 0.000 title abstract description 169
- 238000011282 treatment Methods 0.000 title abstract description 47
- 230000008685 targeting Effects 0.000 title description 3
- 239000000203 mixture Substances 0.000 claims abstract description 210
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 199
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims abstract description 114
- 238000000034 method Methods 0.000 claims abstract description 95
- 230000037257 muscle growth Effects 0.000 claims abstract description 39
- 230000009368 gene silencing by RNA Effects 0.000 claims description 128
- 108091030071 RNAI Proteins 0.000 claims description 124
- 241001465754 Metazoa Species 0.000 claims description 75
- 108090000994 Catalytic RNA Proteins 0.000 claims description 36
- 102000053642 Catalytic RNA Human genes 0.000 claims description 36
- 108091092562 ribozyme Proteins 0.000 claims description 36
- 125000003729 nucleotide group Chemical group 0.000 claims description 34
- 239000002773 nucleotide Substances 0.000 claims description 32
- 108091027757 Deoxyribozyme Proteins 0.000 claims description 29
- 229910019142 PO4 Inorganic materials 0.000 claims description 22
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 21
- 239000010452 phosphate Substances 0.000 claims description 21
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 15
- 108020003589 5' Untranslated Regions Proteins 0.000 claims description 14
- 230000000295 complement effect Effects 0.000 claims description 14
- 241000282414 Homo sapiens Species 0.000 claims description 13
- 241000124008 Mammalia Species 0.000 claims description 13
- 101000886562 Homo sapiens Growth/differentiation factor 8 Proteins 0.000 claims description 12
- 108020005345 3' Untranslated Regions Proteins 0.000 claims description 10
- 125000002637 deoxyribonucleotide group Chemical group 0.000 claims description 8
- 125000002652 ribonucleotide group Chemical group 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 7
- 108091028664 Ribonucleotide Proteins 0.000 claims description 6
- 239000005547 deoxyribonucleotide Substances 0.000 claims description 6
- 239000002336 ribonucleotide Substances 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- CHPSSLNPALYQLK-UHFFFAOYSA-N (2,2-dimethoxy-2-propoxyethyl) hypofluorite Chemical compound CCCOC(OC)(OC)COF CHPSSLNPALYQLK-UHFFFAOYSA-N 0.000 claims description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 3
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- 239000000460 chlorine Substances 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 3
- 239000011630 iodine Substances 0.000 claims description 3
- 229910052740 iodine Inorganic materials 0.000 claims description 3
- 230000001737 promoting effect Effects 0.000 claims description 2
- 230000014509 gene expression Effects 0.000 description 100
- 210000003205 muscle Anatomy 0.000 description 95
- 150000007523 nucleic acids Chemical class 0.000 description 70
- 102000039446 nucleic acids Human genes 0.000 description 67
- 108020004707 nucleic acids Proteins 0.000 description 67
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 64
- 210000004027 cell Anatomy 0.000 description 56
- 241000699670 Mus sp. Species 0.000 description 53
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 49
- 208000035475 disorder Diseases 0.000 description 40
- 230000000694 effects Effects 0.000 description 40
- 230000001965 increasing effect Effects 0.000 description 36
- 230000037396 body weight Effects 0.000 description 33
- 102000040430 polynucleotide Human genes 0.000 description 32
- 108091033319 polynucleotide Proteins 0.000 description 32
- 239000002157 polynucleotide Substances 0.000 description 32
- 230000001632 homeopathic effect Effects 0.000 description 29
- 241000699666 Mus <mouse, genus> Species 0.000 description 26
- 206010006895 Cachexia Diseases 0.000 description 24
- -1 Atrogin-l Proteins 0.000 description 23
- 108020004414 DNA Proteins 0.000 description 23
- 235000015872 dietary supplement Nutrition 0.000 description 23
- 108020003175 receptors Proteins 0.000 description 23
- 102000005962 receptors Human genes 0.000 description 23
- 101001023030 Toxoplasma gondii Myosin-D Proteins 0.000 description 22
- 239000007788 liquid Substances 0.000 description 22
- 201000010099 disease Diseases 0.000 description 21
- 108020004999 messenger RNA Proteins 0.000 description 21
- 230000004048 modification Effects 0.000 description 21
- 238000012986 modification Methods 0.000 description 21
- 235000021317 phosphate Nutrition 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 21
- 208000024891 symptom Diseases 0.000 description 20
- 230000003247 decreasing effect Effects 0.000 description 18
- 206010028980 Neoplasm Diseases 0.000 description 17
- 206010012601 diabetes mellitus Diseases 0.000 description 17
- 239000000047 product Substances 0.000 description 17
- 230000015556 catabolic process Effects 0.000 description 16
- 238000002347 injection Methods 0.000 description 16
- 239000007924 injection Substances 0.000 description 16
- 230000001225 therapeutic effect Effects 0.000 description 16
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 15
- 239000002253 acid Substances 0.000 description 14
- 235000013305 food Nutrition 0.000 description 14
- 208000001076 sarcopenia Diseases 0.000 description 14
- 101710163270 Nuclease Proteins 0.000 description 13
- 230000008901 benefit Effects 0.000 description 12
- 239000003826 tablet Substances 0.000 description 12
- 201000011510 cancer Diseases 0.000 description 11
- 238000006731 degradation reaction Methods 0.000 description 11
- 238000011161 development Methods 0.000 description 11
- 230000018109 developmental process Effects 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 230000027455 binding Effects 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
- 201000006938 muscular dystrophy Diseases 0.000 description 10
- 210000002027 skeletal muscle Anatomy 0.000 description 10
- 230000014616 translation Effects 0.000 description 10
- 108010085238 Actins Proteins 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 102000040945 Transcription factor Human genes 0.000 description 9
- 108091023040 Transcription factor Proteins 0.000 description 9
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 9
- 102100040247 Tumor necrosis factor Human genes 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 9
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 8
- 102000007469 Actins Human genes 0.000 description 8
- 108010069091 Dystrophin Proteins 0.000 description 8
- 241000294754 Macroptilium atropurpureum Species 0.000 description 8
- 230000000692 anti-sense effect Effects 0.000 description 8
- 230000003197 catalytic effect Effects 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 230000002441 reversible effect Effects 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 238000001262 western blot Methods 0.000 description 8
- 101100239693 Dictyostelium discoideum myoD gene Proteins 0.000 description 7
- 241000287828 Gallus gallus Species 0.000 description 7
- 239000000969 carrier Substances 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 235000013330 chicken meat Nutrition 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 235000019688 fish Nutrition 0.000 description 7
- 102000054677 human MSTN Human genes 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 241000251468 Actinopterygii Species 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- 208000008589 Obesity Diseases 0.000 description 6
- 241000282898 Sus scrofa Species 0.000 description 6
- 230000000903 blocking effect Effects 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 235000019197 fats Nutrition 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 230000002452 interceptive effect Effects 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- 235000020824 obesity Nutrition 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 239000013589 supplement Substances 0.000 description 6
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 5
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical group OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 5
- 102000001039 Dystrophin Human genes 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- 102000008934 Muscle Proteins Human genes 0.000 description 5
- 108010074084 Muscle Proteins Proteins 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 210000000577 adipose tissue Anatomy 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 101150046266 foxo gene Proteins 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 208000015122 neurodegenerative disease Diseases 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000001243 protein synthesis Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 208000020431 spinal cord injury Diseases 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- 210000003462 vein Anatomy 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- BCOSEZGCLGPUSL-UHFFFAOYSA-N 2,3,3-trichloroprop-2-enoyl chloride Chemical compound ClC(Cl)=C(Cl)C(Cl)=O BCOSEZGCLGPUSL-UHFFFAOYSA-N 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 108090000397 Caspase 3 Proteins 0.000 description 4
- 102100029855 Caspase-3 Human genes 0.000 description 4
- 102100031780 Endonuclease Human genes 0.000 description 4
- 108010042407 Endonucleases Proteins 0.000 description 4
- 108060002716 Exonuclease Proteins 0.000 description 4
- 108010009306 Forkhead Box Protein O1 Proteins 0.000 description 4
- 102100035427 Forkhead box protein O1 Human genes 0.000 description 4
- 101000637850 Homo sapiens Tolloid-like protein 2 Proteins 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 241001494479 Pecora Species 0.000 description 4
- 238000010240 RT-PCR analysis Methods 0.000 description 4
- 101100437153 Rattus norvegicus Acvr2b gene Proteins 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 208000022531 anorexia Diseases 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 206010061428 decreased appetite Diseases 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 102000013165 exonuclease Human genes 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 210000003098 myoblast Anatomy 0.000 description 4
- 230000004770 neurodegeneration Effects 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 150000004713 phosphodiesters Chemical class 0.000 description 4
- 230000004962 physiological condition Effects 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 210000003314 quadriceps muscle Anatomy 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000011200 topical administration Methods 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 3
- 108010059616 Activins Proteins 0.000 description 3
- 102000005606 Activins Human genes 0.000 description 3
- 101100480489 Arabidopsis thaliana TAAC gene Proteins 0.000 description 3
- 206010003694 Atrophy Diseases 0.000 description 3
- 201000006935 Becker muscular dystrophy Diseases 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 241000238557 Decapoda Species 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000283073 Equus caballus Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108090001102 Hammerhead ribozyme Proteins 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 3
- 102100038380 Myogenic factor 5 Human genes 0.000 description 3
- 101710099061 Myogenic factor 5 Proteins 0.000 description 3
- 102100032970 Myogenin Human genes 0.000 description 3
- 108010056785 Myogenin Proteins 0.000 description 3
- 102000003945 NF-kappa B Human genes 0.000 description 3
- 108010057466 NF-kappa B Proteins 0.000 description 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 3
- 108020004459 Small interfering RNA Proteins 0.000 description 3
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 3
- 102100031997 Tolloid-like protein 2 Human genes 0.000 description 3
- 102100029709 Tripartite motif-containing protein 54 Human genes 0.000 description 3
- 101710154817 Tripartite motif-containing protein 54 Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 239000000488 activin Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Chemical group OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000037444 atrophy Effects 0.000 description 3
- 238000002869 basic local alignment search tool Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 238000007385 chemical modification Methods 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 230000008029 eradication Effects 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000003061 homeopathic agent Substances 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 238000003119 immunoblot Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000007479 molecular analysis Methods 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 239000008196 pharmacological composition Substances 0.000 description 3
- 230000001766 physiological effect Effects 0.000 description 3
- 230000036515 potency Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000012762 unpaired Student’s t-test Methods 0.000 description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 3
- UBWXUGDQUBIEIZ-UHFFFAOYSA-N (13-methyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl) 3-phenylpropanoate Chemical compound CC12CCC(C3CCC(=O)C=C3CC3)C3C1CCC2OC(=O)CCC1=CC=CC=C1 UBWXUGDQUBIEIZ-UHFFFAOYSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 2
- YRIZYWQGELRKNT-UHFFFAOYSA-N 1,3,5-trichloro-1,3,5-triazinane-2,4,6-trione Chemical compound ClN1C(=O)N(Cl)C(=O)N(Cl)C1=O YRIZYWQGELRKNT-UHFFFAOYSA-N 0.000 description 2
- SNBCLPGEMZEWLU-QXFUBDJGSA-N 2-chloro-n-[[(2r,3s,5r)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl]acetamide Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CNC(=O)CCl)[C@@H](O)C1 SNBCLPGEMZEWLU-QXFUBDJGSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 2
- 108010039627 Aprotinin Proteins 0.000 description 2
- 241000237519 Bivalvia Species 0.000 description 2
- 101100000858 Caenorhabditis elegans act-3 gene Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241000238366 Cephalopoda Species 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102100025014 E3 ubiquitin-protein ligase TRIM63 Human genes 0.000 description 2
- 101710164910 E3 ubiquitin-protein ligase TRIM63 Proteins 0.000 description 2
- 108700039887 Essential Genes Proteins 0.000 description 2
- 102100040669 F-box only protein 32 Human genes 0.000 description 2
- 101710191029 F-box only protein 32 Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 241000237858 Gastropoda Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 description 2
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 description 2
- 101000666730 Homo sapiens T-complex protein 1 subunit alpha Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 101000844802 Lacticaseibacillus rhamnosus Teichoic acid D-alanyltransferase Proteins 0.000 description 2
- 239000012097 Lipofectamine 2000 Substances 0.000 description 2
- FSNCEEGOMTYXKY-JTQLQIEISA-N Lycoperodine 1 Natural products N1C2=CC=CC=C2C2=C1CN[C@H](C(=O)O)C2 FSNCEEGOMTYXKY-JTQLQIEISA-N 0.000 description 2
- 102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 description 2
- 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 description 2
- 208000029549 Muscle injury Diseases 0.000 description 2
- 102100038379 Myogenic factor 6 Human genes 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 108020005067 RNA Splice Sites Proteins 0.000 description 2
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- 108091081021 Sense strand Proteins 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 241000251131 Sphyrna Species 0.000 description 2
- 102100038410 T-complex protein 1 subunit alpha Human genes 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 description 2
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 108091023045 Untranslated Region Proteins 0.000 description 2
- 229910052770 Uranium Inorganic materials 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical group O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical group CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 229960004405 aprotinin Drugs 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- KDKYADYSIPSCCQ-UHFFFAOYSA-N but-1-yne Chemical compound CCC#C KDKYADYSIPSCCQ-UHFFFAOYSA-N 0.000 description 2
- 230000001612 cachectic effect Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- BFPSDSIWYFKGBC-UHFFFAOYSA-N chlorotrianisene Chemical compound C1=CC(OC)=CC=C1C(Cl)=C(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 BFPSDSIWYFKGBC-UHFFFAOYSA-N 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000002301 combined effect Effects 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 229940104302 cytosine Drugs 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000002716 delivery method Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000009795 derivation Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000003197 gene knockdown Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000014101 glucose homeostasis Effects 0.000 description 2
- 150000002334 glycols Chemical class 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 230000004220 muscle function Effects 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 230000001114 myogenic effect Effects 0.000 description 2
- 108010084677 myogenic factor 6 Proteins 0.000 description 2
- 210000001087 myotubule Anatomy 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 238000000554 physical therapy Methods 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 238000002731 protein assay Methods 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 230000005588 protonation Effects 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 230000004096 skeletal muscle tissue growth Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 208000016261 weight loss Diseases 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- JEOQACOXAOEPLX-WCCKRBBISA-N (2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid;1,3-thiazolidine-4-carboxylic acid Chemical compound OC(=O)C1CSCN1.OC(=O)[C@@H](N)CCCN=C(N)N JEOQACOXAOEPLX-WCCKRBBISA-N 0.000 description 1
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical group CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 1
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical group CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical group CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- WRGQSWVCFNIUNZ-GDCKJWNLSA-N 1-oleoyl-sn-glycerol 3-phosphate Chemical group CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)(O)=O WRGQSWVCFNIUNZ-GDCKJWNLSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 108010037497 3'-nucleotidase Proteins 0.000 description 1
- 102100039217 3-ketoacyl-CoA thiolase, peroxisomal Human genes 0.000 description 1
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- SXIFAEWFOJETOA-UHFFFAOYSA-N 4-hydroxy-butyl Chemical group [CH2]CCCO SXIFAEWFOJETOA-UHFFFAOYSA-N 0.000 description 1
- 241000023308 Acca Species 0.000 description 1
- 206010048998 Acute phase reaction Diseases 0.000 description 1
- 102000014777 Adipokines Human genes 0.000 description 1
- 108010078606 Adipokines Proteins 0.000 description 1
- 102000011690 Adiponectin Human genes 0.000 description 1
- 108010076365 Adiponectin Proteins 0.000 description 1
- 235000009899 Agrostemma githago Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000269328 Amphibia Species 0.000 description 1
- 241000243818 Annelida Species 0.000 description 1
- 241000269350 Anura Species 0.000 description 1
- 241000473391 Archosargus rhomboidalis Species 0.000 description 1
- 241000237528 Arcidae Species 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 241000238017 Astacoidea Species 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108010027344 Basic Helix-Loop-Helix Transcription Factors Proteins 0.000 description 1
- 102000018720 Basic Helix-Loop-Helix Transcription Factors Human genes 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 102000015280 CCAAT-Enhancer-Binding Protein-beta Human genes 0.000 description 1
- 108010064535 CCAAT-Enhancer-Binding Protein-beta Proteins 0.000 description 1
- QCMYYKRYFNMIEC-UHFFFAOYSA-N COP(O)=O Chemical class COP(O)=O QCMYYKRYFNMIEC-UHFFFAOYSA-N 0.000 description 1
- 101150071146 COX2 gene Proteins 0.000 description 1
- 101001059929 Caenorhabditis elegans Forkhead box protein O Proteins 0.000 description 1
- 101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 description 1
- 101100275473 Caenorhabditis elegans ctc-3 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000252229 Carassius auratus Species 0.000 description 1
- 241001609213 Carassius carassius Species 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 102100035904 Caspase-1 Human genes 0.000 description 1
- 108090000426 Caspase-1 Proteins 0.000 description 1
- 102000004225 Cathepsin B Human genes 0.000 description 1
- 108090000712 Cathepsin B Proteins 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 241000251556 Chordata Species 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 244000072510 Claytonia virginica Species 0.000 description 1
- 102000008169 Co-Repressor Proteins Human genes 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 108020004394 Complementary RNA Proteins 0.000 description 1
- 241000252099 Conger myriaster Species 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- KQLDDLUWUFBQHP-UHFFFAOYSA-N Cordycepin Natural products C1=NC=2C(N)=NC=NC=2N1C1OCC(CO)C1O KQLDDLUWUFBQHP-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241001274613 Corvus frugilegus Species 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 241000270722 Crocodylidae Species 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 108010016788 Cyclin-Dependent Kinase Inhibitor p21 Proteins 0.000 description 1
- 102000000578 Cyclin-Dependent Kinase Inhibitor p21 Human genes 0.000 description 1
- 241000252233 Cyprinus carpio Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- 208000035810 Denervation atrophy Diseases 0.000 description 1
- 241000723298 Dicentrarchus labrax Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000004129 EU approved improving agent Substances 0.000 description 1
- 241000258955 Echinodermata Species 0.000 description 1
- 241000257465 Echinoidea Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241000239366 Euphausiacea Species 0.000 description 1
- 241001235208 Farfantepenaeus paulensis Species 0.000 description 1
- 206010051998 Febrile infection Diseases 0.000 description 1
- 102000016970 Follistatin Human genes 0.000 description 1
- 108010014612 Follistatin Proteins 0.000 description 1
- 102000039539 Fos family Human genes 0.000 description 1
- 108091067362 Fos family Proteins 0.000 description 1
- 101150033270 Gadd45a gene Proteins 0.000 description 1
- 241000767091 Gaidropsarus ensis Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Chemical group OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 108091027874 Group I catalytic intron Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241000724709 Hepatitis delta virus Species 0.000 description 1
- JNPRQUIWDVDHIT-GYIPPJPDSA-N Herculin Chemical compound CCC\C=C\CCCC\C=C\C(=O)NCC(C)C JNPRQUIWDVDHIT-GYIPPJPDSA-N 0.000 description 1
- JNPRQUIWDVDHIT-UHFFFAOYSA-N Herculin Natural products CCCC=CCCCCC=CC(=O)NCC(C)C JNPRQUIWDVDHIT-UHFFFAOYSA-N 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241000251511 Holothuroidea Species 0.000 description 1
- 101100153048 Homo sapiens ACAA1 gene Proteins 0.000 description 1
- 101000799189 Homo sapiens Activin receptor type-1B Proteins 0.000 description 1
- 101000911659 Homo sapiens Dermcidin Proteins 0.000 description 1
- 101000804764 Homo sapiens Lymphotactin Proteins 0.000 description 1
- 101000957437 Homo sapiens Mitochondrial carnitine/acylcarnitine carrier protein Proteins 0.000 description 1
- 101000621344 Homo sapiens Protein Wnt-2 Proteins 0.000 description 1
- 101000595467 Homo sapiens T-complex protein 1 subunit gamma Proteins 0.000 description 1
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 102000019145 JUN kinase activity proteins Human genes 0.000 description 1
- 102000039537 Jun family Human genes 0.000 description 1
- 108091067369 Jun family Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 241001417534 Lutjanidae Species 0.000 description 1
- 102100035304 Lymphotactin Human genes 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 102100038738 Mitochondrial carnitine/acylcarnitine carrier protein Human genes 0.000 description 1
- 102100033127 Mitogen-activated protein kinase kinase kinase 5 Human genes 0.000 description 1
- 101710164337 Mitogen-activated protein kinase kinase kinase 5 Proteins 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000238367 Mya arenaria Species 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 102000005604 Myosin Heavy Chains Human genes 0.000 description 1
- 108010084498 Myosin Heavy Chains Proteins 0.000 description 1
- 241000237536 Mytilus edulis Species 0.000 description 1
- 241000097679 Myzomela rosenbergii Species 0.000 description 1
- GHAZCVNUKKZTLG-UHFFFAOYSA-N N-ethyl-succinimide Natural products CCN1C(=O)CCC1=O GHAZCVNUKKZTLG-UHFFFAOYSA-N 0.000 description 1
- HDFGOPSGAURCEO-UHFFFAOYSA-N N-ethylmaleimide Chemical compound CCN1C(=O)C=CC1=O HDFGOPSGAURCEO-UHFFFAOYSA-N 0.000 description 1
- 101100005280 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cat-3 gene Proteins 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 208000011623 Obstructive Lung disease Diseases 0.000 description 1
- 241000238413 Octopus Species 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 239000012570 Opti-MEM I medium Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- 101150000187 PTGS2 gene Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 241000935974 Paralichthys dentatus Species 0.000 description 1
- 241000237503 Pectinidae Species 0.000 description 1
- 241000238552 Penaeus monodon Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000269908 Platichthys flesus Species 0.000 description 1
- 241000861915 Plecoglossus Species 0.000 description 1
- 241001600434 Plectroglyphidodon lacrymatus Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 241001529596 Pontinus kuhlii Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102100022805 Protein Wnt-2 Human genes 0.000 description 1
- 241000287531 Psittacidae Species 0.000 description 1
- 244000086363 Pterocarpus indicus Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 240000003793 Rhizophora mangle Species 0.000 description 1
- 108090000621 Ribonuclease P Proteins 0.000 description 1
- 102000004167 Ribonuclease P Human genes 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 241000231739 Rutilus rutilus Species 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 101150050559 SOAT1 gene Proteins 0.000 description 1
- 241000975357 Salangichthys microdon Species 0.000 description 1
- 241000277331 Salmonidae Species 0.000 description 1
- 241000269851 Sarda sarda Species 0.000 description 1
- 241001125046 Sardina pilchardus Species 0.000 description 1
- 241000269821 Scombridae Species 0.000 description 1
- 241000238371 Sepiidae Species 0.000 description 1
- 241000727771 Solenocera melantho Species 0.000 description 1
- 241001658874 Squilla Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 102100036049 T-complex protein 1 subunit gamma Human genes 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- 241000270666 Testudines Species 0.000 description 1
- 241001441724 Tetraodontidae Species 0.000 description 1
- 241001441726 Tetraodontiformes Species 0.000 description 1
- 240000006474 Theobroma bicolor Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 102000001767 Tolloid-Like Metalloproteinases Human genes 0.000 description 1
- 108010054774 Tolloid-Like Metalloproteinases Proteins 0.000 description 1
- 241001504592 Trachurus trachurus Species 0.000 description 1
- 102100023132 Transcription factor Jun Human genes 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 241000894431 Turbinidae Species 0.000 description 1
- 244000178320 Vaccaria pyramidata Species 0.000 description 1
- 241000863480 Vinca Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 108010023082 activin A Proteins 0.000 description 1
- 230000004658 acute-phase response Effects 0.000 description 1
- 239000000478 adipokine Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940045686 antimetabolites antineoplastic purine analogs Drugs 0.000 description 1
- 229940045688 antineoplastic antimetabolites pyrimidine analogues Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 235000020639 clam Nutrition 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- OFEZSBMBBKLLBJ-BAJZRUMYSA-N cordycepin Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@H]1O OFEZSBMBBKLLBJ-BAJZRUMYSA-N 0.000 description 1
- OFEZSBMBBKLLBJ-UHFFFAOYSA-N cordycepine Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)CC1O OFEZSBMBBKLLBJ-UHFFFAOYSA-N 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 230000027832 depurination Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 239000005546 dideoxynucleotide Substances 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 235000001434 dietary modification Nutrition 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical group [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 210000003020 exocrine pancreas Anatomy 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000007897 gelcap Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000009229 glucose formation Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 108090001052 hairpin ribozyme Proteins 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 102000057953 human TLL2 Human genes 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 238000002664 inhalation therapy Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 108040006858 interleukin-6 receptor activity proteins Proteins 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002960 lipid emulsion Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 241000238565 lobster Species 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 235000020640 mackerel Nutrition 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- CAAULPUQFIIOTL-UHFFFAOYSA-N methyl dihydrogen phosphate Chemical class COP(O)(O)=O CAAULPUQFIIOTL-UHFFFAOYSA-N 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000009753 muscle formation Effects 0.000 description 1
- 235000020638 mussel Nutrition 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 208000018360 neuromuscular disease Diseases 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229940079938 nitrocellulose Drugs 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 229940038580 oat bran Drugs 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- LRMQCJCMKQSEJD-UHFFFAOYSA-N oligo b Polymers O1C(N2C3=NC=NC(N)=C3N=C2)C(OC)C(OC(=O)C=2C=C3C4(OC(=O)C3=CC=2)C2=CC=C(O)C=C2OC2=CC(O)=CC=C24)C1COP(O)(=O)OC1C(C(O2)N3C(N=C(N)C(C)=C3)=O)OCC12COP(O)(=O)OC(C1OC)C(COP(O)(=O)OC2C3(COP(O)(=O)OC4C(C(OC4COP(O)(=O)OC4C(C(OC4COP(O)(=O)OC4C(C(OC4COP(O)(=O)OC4C5(COP(O)(=O)OC6C(C(OC6COP(O)(=O)OC6C7(COP(O)(=O)OC8C(C(OC8COP(O)(=O)OC8C9(CO)COC8C(O9)N8C(N=C(N)C(C)=C8)=O)N8C(NC(=O)C=C8)=O)OC)COC6C(O7)N6C(N=C(N)C(C)=C6)=O)N6C(N=C(N)C=C6)=O)OC)COC4C(O5)N4C(N=C(N)C(C)=C4)=O)N4C5=NC=NC(N)=C5N=C4)OC)N4C5=C(C(NC(N)=N5)=O)N=C4)OC)N4C5=C(C(NC(N)=N5)=O)N=C4)OC)COC2C(O3)N2C(N=C(N)C(C)=C2)=O)OC1N1C=CC(=O)NC1=O LRMQCJCMKQSEJD-UHFFFAOYSA-N 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000003905 phosphatidylinositols Chemical group 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000032361 posttranscriptional gene silencing Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 208000026526 progressive weakness Diseases 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 239000002342 ribonucleoside Substances 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 235000019512 sardine Nutrition 0.000 description 1
- 235000020637 scallop Nutrition 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000002023 somite Anatomy 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 108010068698 spleen exonuclease Proteins 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 101150075675 tatC gene Proteins 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 108091006108 transcriptional coactivators Proteins 0.000 description 1
- 108091006105 transcriptional corepressors Proteins 0.000 description 1
- 108091008023 transcriptional regulators Proteins 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The application provides compositions of oligonucleotides targeted at genes involved in muscle wasting and/or muscle growth such as the myostatin or Fox01 gene. In some embodiments, the oligonucleotides are modified. In some embodiments, the compositions contain one, or more than one, oligonucleotide. The application also provides methods and kits using the compositions of the invention for the treatment of muscle wasting conditions and/or the promotion of muscle growth.
Description
WSGR Docket No. 31249-722.601 COMPOSITIONS AND METHODS FOR THE TREATMENT OF MUSCLE WASTING
BACKGROUND
Increase in muscle growth has been an important field both for treatment of muscle wasting conditions and for farm and food animals. The muscle wasting conditions include Duchenne muscular dystrophy (DMD), multiple types of limb girdle MD (LCIVID) and other congenital MDs (CMD), sarcopenia, cancer cachexia, Diabetes mellitus.
Progressive muscle damage and muscle loss, tissue inflammation and replacement of healthy muscle with fibrous and fatty tissues result in disability and fatality.
In animal husbandry, such as for food animals, any methods that increase the proportion and weight of muscle will greatly benefit the industry. However, there have been no effective means to treat muscle wasting conditions and to promote muscle growth in animals.
SUMMARY OF INVENTION
In one aspect, the invention provides compositions and methods for treatment of muscle wasting conditions and/or promotion of muscle growth using compositions containing one or more oligonucleotides. In some embodiments the invention provides compositions suitable for administration to an animal containing a modified oligonucleotide containing 7 to 75 contiguous ribose groups linked by achiral 5' to 3' internucleoside phosphate linkages, where the modified oligonucleotide is complementary to a region of a gene selected from the group consisting of the 5' UTR region, translational start site, the 3' UTR, and translational termination site, and wherein the gene is related to a muscle wasting condition. In some embodiments, the modified oligonucleotide has a Tm of about 75-115 C. at a concentration of 1 mM and a length of 10 to 26 bases, or a Tm of about 40 C to 85 C at a concentration of 1 pM and a length of 10 to 26 bases.
In some embodiments, the oligonucleotide comprises a nucleotide selected from the group consisting of ribonucleotides and deoxyribonucleotides. In some embodiments, the oligonucleotide contains one or more nucleotides in which the 2' position comprises a substituent, for example, hydrogen, methoxy, propoxy, methoxy-ethoxy, fluorine, chlorine, bromine and iodine. In some embodiments, the modified oligonucleotide is 3' and/or 5' end-modified. In some embodiments, the modified oligonucleotide is 3' and/or 5' end-blocked. In some embodiments, the oligonucleotide is an antisense oligonucleotide, e.g., an antisense oligonucleotide complementary to a myostatin gene, for example, an animal, mammalian, or human myostatin gene. In some embodiments, the oligonucleotide comprises a sequence WSGR Docket No. 31249-722.601 selected from the group consisting of SEQ ID NOS 1-191. In some embodiments, the oligonucleotide comprises an RNAi, ribozyme or deoxyribozyme. In some embodiments, the composition contains a plurality of modified oligonucleotides, e.g., two modified oligonucleotides.
In some embodiments, the invention provides a method of treating a muscle wasting condition comprising administering to an individual suffering from a muscle wasting condition an effective amount a composition of the invention. In some embodiments, the invention provides a method of promoting muscle growth in an individual comprising administering to the individual an effective amount of a composition of the invention. In some embodiments, the individual is a mammal. In some embodiments, the individual is a human.
In some embodiments, the oligonucleotide comprises 7 to 75 modified nucleotides containing contiguous ribose groups linked by achiral 5' to 3' internucleoside phosphate linkages, wherein the modified oligonucleotide is complementary to a region of genes involved in muscle wasting conditions. In some embodiments, the composition contains two, three, four, five, or more than five different modified oligonucleotides. In some embodiments, the modified oligonucleotide is complementary to a region of the gene selected from the group consisting of the 5' UTR region, translational start site, the 3' UTR, and translational termination site. In some embodiments, the modified oligonucleotide has a Tn, of about 75-115 C at a concentration of 1 mM and a length of 10 to 26 bases, or a Tm of about 40 C to 85 C at a concentration of 1 pM
and a length of 10 to 26 bases. The preferred compositions contain either antisense oligonucleotides or siRNA. The invention provides compositions and methods for treatment of muscle wasting conditions for human and animals. The invention also provides methods for use of compositions in food dietary supplement. The present invention provides compositions and methods for the modulation of expression of genes that code for gene products that are involved in muscle wasting and/or muscle growth conditions.
In one aspect, the invention provides compositions. In some embodiments, the invention provides a composition suitable for administration to an animal comprising a modified oligonucleotide containing contiguous ribose groups linked by achiral 5' to 3' internucleoside phosphate linkages, wherein the modified oligonucleotide is complementary to a region of a gene coding for myostatin or a myostatin receptor. In some embodiments, the composition contains two, three, four, five, or more than five different modified oligonucleotides. In some embodiments, the oligonucleotide comprises about seven to seventy-five nucleotides containing seven or more contiguous ribose groups linked by achiral 5' to 3' internucleoside phosphate linkages. In some embodiments, the modified oligonucleotide is complementary to a region of the gene selected from the group consisting of the 5' UTR region, translational start site, the 3'
BACKGROUND
Increase in muscle growth has been an important field both for treatment of muscle wasting conditions and for farm and food animals. The muscle wasting conditions include Duchenne muscular dystrophy (DMD), multiple types of limb girdle MD (LCIVID) and other congenital MDs (CMD), sarcopenia, cancer cachexia, Diabetes mellitus.
Progressive muscle damage and muscle loss, tissue inflammation and replacement of healthy muscle with fibrous and fatty tissues result in disability and fatality.
In animal husbandry, such as for food animals, any methods that increase the proportion and weight of muscle will greatly benefit the industry. However, there have been no effective means to treat muscle wasting conditions and to promote muscle growth in animals.
SUMMARY OF INVENTION
In one aspect, the invention provides compositions and methods for treatment of muscle wasting conditions and/or promotion of muscle growth using compositions containing one or more oligonucleotides. In some embodiments the invention provides compositions suitable for administration to an animal containing a modified oligonucleotide containing 7 to 75 contiguous ribose groups linked by achiral 5' to 3' internucleoside phosphate linkages, where the modified oligonucleotide is complementary to a region of a gene selected from the group consisting of the 5' UTR region, translational start site, the 3' UTR, and translational termination site, and wherein the gene is related to a muscle wasting condition. In some embodiments, the modified oligonucleotide has a Tm of about 75-115 C. at a concentration of 1 mM and a length of 10 to 26 bases, or a Tm of about 40 C to 85 C at a concentration of 1 pM and a length of 10 to 26 bases.
In some embodiments, the oligonucleotide comprises a nucleotide selected from the group consisting of ribonucleotides and deoxyribonucleotides. In some embodiments, the oligonucleotide contains one or more nucleotides in which the 2' position comprises a substituent, for example, hydrogen, methoxy, propoxy, methoxy-ethoxy, fluorine, chlorine, bromine and iodine. In some embodiments, the modified oligonucleotide is 3' and/or 5' end-modified. In some embodiments, the modified oligonucleotide is 3' and/or 5' end-blocked. In some embodiments, the oligonucleotide is an antisense oligonucleotide, e.g., an antisense oligonucleotide complementary to a myostatin gene, for example, an animal, mammalian, or human myostatin gene. In some embodiments, the oligonucleotide comprises a sequence WSGR Docket No. 31249-722.601 selected from the group consisting of SEQ ID NOS 1-191. In some embodiments, the oligonucleotide comprises an RNAi, ribozyme or deoxyribozyme. In some embodiments, the composition contains a plurality of modified oligonucleotides, e.g., two modified oligonucleotides.
In some embodiments, the invention provides a method of treating a muscle wasting condition comprising administering to an individual suffering from a muscle wasting condition an effective amount a composition of the invention. In some embodiments, the invention provides a method of promoting muscle growth in an individual comprising administering to the individual an effective amount of a composition of the invention. In some embodiments, the individual is a mammal. In some embodiments, the individual is a human.
In some embodiments, the oligonucleotide comprises 7 to 75 modified nucleotides containing contiguous ribose groups linked by achiral 5' to 3' internucleoside phosphate linkages, wherein the modified oligonucleotide is complementary to a region of genes involved in muscle wasting conditions. In some embodiments, the composition contains two, three, four, five, or more than five different modified oligonucleotides. In some embodiments, the modified oligonucleotide is complementary to a region of the gene selected from the group consisting of the 5' UTR region, translational start site, the 3' UTR, and translational termination site. In some embodiments, the modified oligonucleotide has a Tn, of about 75-115 C at a concentration of 1 mM and a length of 10 to 26 bases, or a Tm of about 40 C to 85 C at a concentration of 1 pM
and a length of 10 to 26 bases. The preferred compositions contain either antisense oligonucleotides or siRNA. The invention provides compositions and methods for treatment of muscle wasting conditions for human and animals. The invention also provides methods for use of compositions in food dietary supplement. The present invention provides compositions and methods for the modulation of expression of genes that code for gene products that are involved in muscle wasting and/or muscle growth conditions.
In one aspect, the invention provides compositions. In some embodiments, the invention provides a composition suitable for administration to an animal comprising a modified oligonucleotide containing contiguous ribose groups linked by achiral 5' to 3' internucleoside phosphate linkages, wherein the modified oligonucleotide is complementary to a region of a gene coding for myostatin or a myostatin receptor. In some embodiments, the composition contains two, three, four, five, or more than five different modified oligonucleotides. In some embodiments, the oligonucleotide comprises about seven to seventy-five nucleotides containing seven or more contiguous ribose groups linked by achiral 5' to 3' internucleoside phosphate linkages. In some embodiments, the modified oligonucleotide is complementary to a region of the gene selected from the group consisting of the 5' UTR region, translational start site, the 3'
-2-WSGR Docket No. 31249-722.601 UTR, and translational termination site. In some embodiments, the modified oligonucleotide has a Tm of about 75-115 C at a concentration of 1 mM and a length of 10 to 26 bases, or a Tm of about 40 C to 85 C at a concentration of 1 pM and a length of 10 to 26 bases. In some embodiments, the ribose group of the oligonucleotide has a modified 2' substituent; in some embodiments the modified substituent is selected from the group consisting of hydrogen, methoxy, propoxy, methoxy-ethoxy, fluorine, chlorine, bromine and iodine. In some embodiments, the modified oligonucleotide is 3' end-blocked. In some embodiments, the modified oligonucleotide is 5' end-blocked.
The invention also provides a pharmaceutical composition comprising a composition suitable for administration to an animal comprising a modified oligonucleotide containing contiguous ribose groups linked by achiral 5' to 3' internucleoside phosphate linkages, wherein the modified oligonucleotide is complementary to a region of a gene coding for myostatin or a myostatin receptor, and a pharmaceutically acceptable excipient.
hi some embodiments, the invention provides an antisense oligonucleotide that inhibits the expression of myostatin or myostatin receptor genes, wherein the oligonucleotide is selected from the group consisting of SEQ ID NOS: 1- 191.
In other embodiments, the invention provides a composition comprising an interfering RNA (RNAi) that modulates expression of myostatin or a myostatin receptor. In some embodiments, the RNAi composition comprises double-stranded RNA of 21 -25 nucleotides with overhangs of 2 nucleotides at both 3' ends. 30 - 52% of the G+C content of the double stranded region, A/U base-pairing in positions 15 -19 in sense strand, and no internal repeats.
In yet other embodiments, the invention provides a composition comprising a DNAzyme, wherein the DNAzyme modulates expression of myostatin or a myostatin receptor.
In some embodiments, the DNAzyme comprises a catalytic domain that comprises the nucleotide sequence GGCTAGCTACAACGA and specifically cleaves mRNA coding for myostatin or a myostatin receptor at any purine:pyrimidine site to which the catalytic domain is directed, a first binding domain contiguous with the 5'end of the catalytic domain, and a second binding domain contiguous with the 3'end of the catalytic domain, wherein each binding domain hybridizes with a region immediately flanking the cleavage site.
In still other embodiments, the invention provides a composition for the modulation of expression of myostatin or myostatin receptors comprising two or more gene-modulating oligonucleotides, wherein at least one oligonucleotide is targeted to myostatin, and at least one oligonucleotide is targeted to a gene that is not myostatin. In some embodiments the composition contains gene-modulating oligonucleotides that comprise one or more oligonucleotides selected from the group consisting of antisense oligonucleotides, RNAi, and
The invention also provides a pharmaceutical composition comprising a composition suitable for administration to an animal comprising a modified oligonucleotide containing contiguous ribose groups linked by achiral 5' to 3' internucleoside phosphate linkages, wherein the modified oligonucleotide is complementary to a region of a gene coding for myostatin or a myostatin receptor, and a pharmaceutically acceptable excipient.
hi some embodiments, the invention provides an antisense oligonucleotide that inhibits the expression of myostatin or myostatin receptor genes, wherein the oligonucleotide is selected from the group consisting of SEQ ID NOS: 1- 191.
In other embodiments, the invention provides a composition comprising an interfering RNA (RNAi) that modulates expression of myostatin or a myostatin receptor. In some embodiments, the RNAi composition comprises double-stranded RNA of 21 -25 nucleotides with overhangs of 2 nucleotides at both 3' ends. 30 - 52% of the G+C content of the double stranded region, A/U base-pairing in positions 15 -19 in sense strand, and no internal repeats.
In yet other embodiments, the invention provides a composition comprising a DNAzyme, wherein the DNAzyme modulates expression of myostatin or a myostatin receptor.
In some embodiments, the DNAzyme comprises a catalytic domain that comprises the nucleotide sequence GGCTAGCTACAACGA and specifically cleaves mRNA coding for myostatin or a myostatin receptor at any purine:pyrimidine site to which the catalytic domain is directed, a first binding domain contiguous with the 5'end of the catalytic domain, and a second binding domain contiguous with the 3'end of the catalytic domain, wherein each binding domain hybridizes with a region immediately flanking the cleavage site.
In still other embodiments, the invention provides a composition for the modulation of expression of myostatin or myostatin receptors comprising two or more gene-modulating oligonucleotides, wherein at least one oligonucleotide is targeted to myostatin, and at least one oligonucleotide is targeted to a gene that is not myostatin. In some embodiments the composition contains gene-modulating oligonucleotides that comprise one or more oligonucleotides selected from the group consisting of antisense oligonucleotides, RNAi, and
-3-WSGR Docket No. 31249-722.601 DNAzymes. In some embodiments the composition contains antisense oligonucleotides. In some embodiments the non-myostatin gene is a gene coding for a protein selected from the group consisting of Activin A Receptor IIB, Tolloid metalloproteinase, NF-kappaB, TNF-alpha, MuRF1, Caspase-3, Atrogin-l, RAS, P38 MAPK, MKK 3, MKK 6, JNK, c-myc, c-jun, ASK-1, TAK-1, smad, cyclin dependent kinase inhibitor p21, Gadd45, IL-6, and PIF
(Table I and Table 2). In some embodiments the composition contains one or more antisense oligonucleotides targeted to myostatin is selected from the oligonucleotides shown in Tables 3,
(Table I and Table 2). In some embodiments the composition contains one or more antisense oligonucleotides targeted to myostatin is selected from the oligonucleotides shown in Tables 3,
4, and 5 and one or more antisense oligonucleotides targeted to a non-myostatin gene is selected from the oligonucleotides shown in Table 3 and Table 4.
In another aspect, the invention provides methods. In one embodiment, the invention provides a method of modulating expression of myostatin in a cell containing a myostatin-encoding polynucleotide comprising contacting the cell with an oligonucleotide that modulates the expression of said myostatin-encoding polynucleotide, wherein the oligonucleotide is an antisense oligonucleotide comprising contiguous ribose groups linked by achiral 5' to 3' internucleoside phosphate linkages.
In other embodiments, the invention provides a method of modulating expression of myostatin in a cell containing a myostatin-encoding polynucleotide comprising contacting the cell with an oligonucleotide that modulates the expression of said myostatin-encoding polynucleotide, wherein the oligonucleotide is selected from the group consisting of RNAi, ribozymes, and DNAzymes.
In other embodiments, the invention provides a method of modulating expression of myostatin in a cell containing a myostatin-encoding polynucleotide and a non-myostatin-encoding polynucleotide comprising contacting the cell with a first gene-modulating oligonucleotide and a second gene-modulating oligonucleotide, wherein the first oligonucleotide modulates the expression of said myostatin-encoding polynucleotide and the second oligonucleotide modulates the expression of a polynucleotide selected from the group consisting of said myostatin-encoding polynucleotide and said non-myostatin-encoding polynucleotide. In some of these embodiments, the oligonucleotides are selected from the group consisting of antisense oligonucleotides, RNAi, ribozymes, and DNAzymes. In some embodiments, the oligonucleotides comprise a first antisense oligonucleotide and a second antisense oligonucleotide In another embodiment, the invention provides a method of modulating expression of myostatin in an animal comprising administering to the animal an oligonucleotide that modulates the expression of a myostatin-encoding polynucleotide, wherein the oligonucleotide is WSGR Docket No. 31249-722.601 administered at a dose of 0.01 to 100 mg/kg . In some of these embodiments, the animal is a food animal and the administration results in increased muscle mass.
In another embodiment, the invention provides a method of modulating expression of myostatin in an animal comprising administering to the animal an oligonucleotide that modulates the expression of a myostatin-encoding polynucleotide, wherein the oligonucleotide is an antisense oligonucleotide comprising contiguous ribose groups linked by achiral 5' to 3' intemucleoside phosphate linkages. In some of these embodiments, the animal is a food animal and the administration results in increased muscle mass.
In yet another embodiment, the invention provides a method of modulating expression of myostatin in an animal comprising administering to the animal an oligonucleotide that modulates the expression of a myostatin-encoding polynucleotide, wherein the oligonucleotide is selected from the group consisting of RNAi, ribozymes, and DNAzymes. In some of these embodiments, the animal is a food animal and the administration results in increased muscle mass.
In still yet another embodiment, the invention provides a method of modulating expression of myostatin in an animal comprising administering to the animal a first gene-modulating oligonucleotide and a second gene-modulating oligonucleotide, wherein the first oligonucleotide modulates the expression of a myostatin-encoding polynucleotide and the second oligonucleotide modulates the expression of a polynucleotide selected from the group consisting of a myostatin-encoding polynucleotide and a non-myostatin-encoding polynucleotide. In some of these embodiments, the animal is a food animal and the administration results in increased muscle mass.
In another embodiment, the invention provides a method of treating an animal suffering from a muscle-wasting condition comprising administering to the animal an oligonucleotide that modulates the expression of a myostatin-encoding polynucleotide, wherein the oligonucleotide is administered at a dose of 0.001 to 100 mg/kg.
In another embodiment, the invention provides a method of treating an animal suffering from a muscle-wasting condition comprising administering to the animal an oligonucleotide that modulates the expression of a myostatin-encoding polynucleotide, wherein the oligonucleotide is an antisense oligonucleotide comprising contiguous ribose groups linked by achiral 5' to 3' intemucleoside phosphate linkages.
In still another embodiment, the invention provides a method of treating an animal suffering from a muscle-wasting condition comprising administering to the animal an oligonucleotide that modulates the expression of a myostatin-encoding polynucleotide, wherein the oligonucleotide is selected from the group consisting of RNAi, ribozymes, and DNAzymes
In another aspect, the invention provides methods. In one embodiment, the invention provides a method of modulating expression of myostatin in a cell containing a myostatin-encoding polynucleotide comprising contacting the cell with an oligonucleotide that modulates the expression of said myostatin-encoding polynucleotide, wherein the oligonucleotide is an antisense oligonucleotide comprising contiguous ribose groups linked by achiral 5' to 3' internucleoside phosphate linkages.
In other embodiments, the invention provides a method of modulating expression of myostatin in a cell containing a myostatin-encoding polynucleotide comprising contacting the cell with an oligonucleotide that modulates the expression of said myostatin-encoding polynucleotide, wherein the oligonucleotide is selected from the group consisting of RNAi, ribozymes, and DNAzymes.
In other embodiments, the invention provides a method of modulating expression of myostatin in a cell containing a myostatin-encoding polynucleotide and a non-myostatin-encoding polynucleotide comprising contacting the cell with a first gene-modulating oligonucleotide and a second gene-modulating oligonucleotide, wherein the first oligonucleotide modulates the expression of said myostatin-encoding polynucleotide and the second oligonucleotide modulates the expression of a polynucleotide selected from the group consisting of said myostatin-encoding polynucleotide and said non-myostatin-encoding polynucleotide. In some of these embodiments, the oligonucleotides are selected from the group consisting of antisense oligonucleotides, RNAi, ribozymes, and DNAzymes. In some embodiments, the oligonucleotides comprise a first antisense oligonucleotide and a second antisense oligonucleotide In another embodiment, the invention provides a method of modulating expression of myostatin in an animal comprising administering to the animal an oligonucleotide that modulates the expression of a myostatin-encoding polynucleotide, wherein the oligonucleotide is WSGR Docket No. 31249-722.601 administered at a dose of 0.01 to 100 mg/kg . In some of these embodiments, the animal is a food animal and the administration results in increased muscle mass.
In another embodiment, the invention provides a method of modulating expression of myostatin in an animal comprising administering to the animal an oligonucleotide that modulates the expression of a myostatin-encoding polynucleotide, wherein the oligonucleotide is an antisense oligonucleotide comprising contiguous ribose groups linked by achiral 5' to 3' intemucleoside phosphate linkages. In some of these embodiments, the animal is a food animal and the administration results in increased muscle mass.
In yet another embodiment, the invention provides a method of modulating expression of myostatin in an animal comprising administering to the animal an oligonucleotide that modulates the expression of a myostatin-encoding polynucleotide, wherein the oligonucleotide is selected from the group consisting of RNAi, ribozymes, and DNAzymes. In some of these embodiments, the animal is a food animal and the administration results in increased muscle mass.
In still yet another embodiment, the invention provides a method of modulating expression of myostatin in an animal comprising administering to the animal a first gene-modulating oligonucleotide and a second gene-modulating oligonucleotide, wherein the first oligonucleotide modulates the expression of a myostatin-encoding polynucleotide and the second oligonucleotide modulates the expression of a polynucleotide selected from the group consisting of a myostatin-encoding polynucleotide and a non-myostatin-encoding polynucleotide. In some of these embodiments, the animal is a food animal and the administration results in increased muscle mass.
In another embodiment, the invention provides a method of treating an animal suffering from a muscle-wasting condition comprising administering to the animal an oligonucleotide that modulates the expression of a myostatin-encoding polynucleotide, wherein the oligonucleotide is administered at a dose of 0.001 to 100 mg/kg.
In another embodiment, the invention provides a method of treating an animal suffering from a muscle-wasting condition comprising administering to the animal an oligonucleotide that modulates the expression of a myostatin-encoding polynucleotide, wherein the oligonucleotide is an antisense oligonucleotide comprising contiguous ribose groups linked by achiral 5' to 3' intemucleoside phosphate linkages.
In still another embodiment, the invention provides a method of treating an animal suffering from a muscle-wasting condition comprising administering to the animal an oligonucleotide that modulates the expression of a myostatin-encoding polynucleotide, wherein the oligonucleotide is selected from the group consisting of RNAi, ribozymes, and DNAzymes
-5-WSGR Docket No. 31249-722.601 The invention also provides a method of treating an animal suffering from a muscle-wasting condition comprising administering to the animal a first gene-modulating oligonucleotide and a second gene-modulating oligonucleotide, wherein the first oligonucleotide modulates the expression of a myostatin-encoding polynucleotide and the second oligonucleotide modulates the expression of a polynucleotide selected from the group consisting of a myostatin-encoding polynucleotide and a non-myostatin-encoding polynucleotide. In some embodiments, the oligonucleotides are selected from the group consisting of antisense oligonucleotides, RNAi, ribozymes, and DNAzymes.
In a further aspect, the invention provides kits that contain one or more of the compositions of the invention and, optionally, instructions for the use of the compositions.
INCORPORATION BY REFERENCE
All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
BRIEF DESCRIPTION OF THE DRAWINGS
The novel features of the invention are set forth with particularity in the appended claims.
A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:
Figure 1 is a bar graph representing muscle weight in three groups of mice treated with saline, mock, or RNA antisense oligonucleotides.
Figure 2 depicts the effect of RNA oligos targeted to Foxol on expression of MyoD and GDF-8 in nonnal mice. A, Western blots were perfonned on the effect of RNA
oligo on protein expression level of MyoD (C) and GDF-8 (B) in normal mice. Quantitative RT-PCR
analysis was done on the effect of RNA oligo on mRNA expression level of Foxol (D), GDF-8 (E) and MyoD (F) in normal mice. Data are mean SD (n=6), P<0.01 *.
Figure 3 depicts the effect of RNA oligos targeted to Foxol (GRR-7) and control on mass of muscles in S-180 tumor mice. Dissected muscle mass at the end of the study (n=6), P<0.01*.
Figure 4 depicts the effect of RNA oligos targeted to Foxo I on expression of M:yoD and GDF-8 in S180 mice. A, Western blots were performed on the effect of RNA oligo on protein expression level of GDF-8 (B) and MyoD (C) in S180 mice. Quantitative RT-PCR
analysis was
In a further aspect, the invention provides kits that contain one or more of the compositions of the invention and, optionally, instructions for the use of the compositions.
INCORPORATION BY REFERENCE
All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
BRIEF DESCRIPTION OF THE DRAWINGS
The novel features of the invention are set forth with particularity in the appended claims.
A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:
Figure 1 is a bar graph representing muscle weight in three groups of mice treated with saline, mock, or RNA antisense oligonucleotides.
Figure 2 depicts the effect of RNA oligos targeted to Foxol on expression of MyoD and GDF-8 in nonnal mice. A, Western blots were perfonned on the effect of RNA
oligo on protein expression level of MyoD (C) and GDF-8 (B) in normal mice. Quantitative RT-PCR
analysis was done on the effect of RNA oligo on mRNA expression level of Foxol (D), GDF-8 (E) and MyoD (F) in normal mice. Data are mean SD (n=6), P<0.01 *.
Figure 3 depicts the effect of RNA oligos targeted to Foxol (GRR-7) and control on mass of muscles in S-180 tumor mice. Dissected muscle mass at the end of the study (n=6), P<0.01*.
Figure 4 depicts the effect of RNA oligos targeted to Foxo I on expression of M:yoD and GDF-8 in S180 mice. A, Western blots were performed on the effect of RNA oligo on protein expression level of GDF-8 (B) and MyoD (C) in S180 mice. Quantitative RT-PCR
analysis was
-6-WSGR Docket No. 31249-722.601 done on the effect of RNA oligo on mRNA expression level of Foxo 1(D), GDF-8 (E) and MyoD (F) in normal mice. Data are mean SD (n=6), P<0.01**.
Figure 5 depicts the effect of RNA oligos targeted to myostatin on muscle mass in S-180 implanted mice: (A) Dissected muscle mass at the end of the study. Results showed that muscle mass was increased by 26% in mixed RNA oligos compared to control group (n=6, mean SD, p<0.05).5 (B) The ratio of muscle leg's mass to body. The results indicated that mixed RNA
oligos targeted to myostatin could increase muscle mass in S-180 tumor mice (mean SD, p<0.05). 5 (C and D) Quantitative RT-PCR analysis of myostatin and MyoD
expression at mRNA level in mouse model after injecting RNA oligos 2 weeks (P<0.01).
DETAILED DESCRIPTION OF THE INVENTION
The present invention provides compositions and methods for the modulation of expression of genes that code for gene products that are involved in muscle wasting and/or muscle growth conditions. Accordingly, the invention provides compositions and methods using the compositions, for enhancement of muscle growth and treatment of diseases associated with inadequate muscle growth, abnormal fat accumulation, or muscle wasting. The invention also provides compositions and methods using the compositions, for enhancing normal muscle growth where such enhancement is desired (e.g., in farm animals).
Generally, the compositions and methods of the invention utilize oligonucleotides that modulate gene expression, also referred to herein as "gene modulators" and "gene-modulating oligonucleotides." Exemplary gene modulators of the invention include antisense oligonucleotides, interfering RNA (RNAi), ribozymes, and DNAzymes. In some embodiments, the invention provides a single gene modulator targeted at a single gene involved in muscle growth and maintenance, e.g., myostatin. In other embodiments, the invention provides combinations of gene modulators. These combinations include: combinations of different types of gene modulators, combinations of gene modulators targeted to different parts of the same gene, and combinations of gene modulators targeted to different genes, as well as combinations of any of the aforementioned combinations.
The invention further provides modified oligonucleotides for use in any of the above compositions. In some preferred embodiments, oligonucleotides used in the invention can be, e.g., end-blocked, protonated, exhibit substantial acid resistance, substantial nuclease resistance, and/or contain achiral intemucleoside phosphate linkages and modified ribose or deoxyribose substituents.
Figure 5 depicts the effect of RNA oligos targeted to myostatin on muscle mass in S-180 implanted mice: (A) Dissected muscle mass at the end of the study. Results showed that muscle mass was increased by 26% in mixed RNA oligos compared to control group (n=6, mean SD, p<0.05).5 (B) The ratio of muscle leg's mass to body. The results indicated that mixed RNA
oligos targeted to myostatin could increase muscle mass in S-180 tumor mice (mean SD, p<0.05). 5 (C and D) Quantitative RT-PCR analysis of myostatin and MyoD
expression at mRNA level in mouse model after injecting RNA oligos 2 weeks (P<0.01).
DETAILED DESCRIPTION OF THE INVENTION
The present invention provides compositions and methods for the modulation of expression of genes that code for gene products that are involved in muscle wasting and/or muscle growth conditions. Accordingly, the invention provides compositions and methods using the compositions, for enhancement of muscle growth and treatment of diseases associated with inadequate muscle growth, abnormal fat accumulation, or muscle wasting. The invention also provides compositions and methods using the compositions, for enhancing normal muscle growth where such enhancement is desired (e.g., in farm animals).
Generally, the compositions and methods of the invention utilize oligonucleotides that modulate gene expression, also referred to herein as "gene modulators" and "gene-modulating oligonucleotides." Exemplary gene modulators of the invention include antisense oligonucleotides, interfering RNA (RNAi), ribozymes, and DNAzymes. In some embodiments, the invention provides a single gene modulator targeted at a single gene involved in muscle growth and maintenance, e.g., myostatin. In other embodiments, the invention provides combinations of gene modulators. These combinations include: combinations of different types of gene modulators, combinations of gene modulators targeted to different parts of the same gene, and combinations of gene modulators targeted to different genes, as well as combinations of any of the aforementioned combinations.
The invention further provides modified oligonucleotides for use in any of the above compositions. In some preferred embodiments, oligonucleotides used in the invention can be, e.g., end-blocked, protonated, exhibit substantial acid resistance, substantial nuclease resistance, and/or contain achiral intemucleoside phosphate linkages and modified ribose or deoxyribose substituents.
-7-W S GR Docket No. 31249-722.601 The invention further provides methods using the compositions of the invention.
Methods include methods of treating animals (e.g. mammals, humans) by modulating gene expression in cells by contacting cells with compositions of the invention.
Methods also include methods of treatment of disorders using the gene modulating compositions of the invention.
Disorders for treatment include muscle wasting disorders or disorders associated with decreased muscle mass and/or increased obesity. As used herein, the term "muscle wasting disorder," used synonymously herein with the term "muscle wasting condition," encompasses disorders or conditions in which muscle wasting is one of the primary symptoms, such as muscular dystrophy, spinal cord injury, neurodegenerative diseases, anorexia, sarcopenia, cachexia, muscular atrophy due to immobilization, prolonged bed rest, or weightlessness, and the like, as well as disorders in which an abnormally high fat-to-muscle ratio is implicated in a disease or pre-disease state, e.g., Type II diabetes or Syndrome X. In addition, the invention provides methods of increasing muscle mass in animals where such an increase is desirable, e.g., in food animals such as mammals and fish.
In addition, the invention provides kits that provide compositions of the invention, optionally including instructions for use of the compositions in methods of the invention.
The gene modulators of the invention include antisense oligonucleotides, interfering RNA (RNAi), ribozymes, and DNAzymes. Compositions of the invention contain one or more gene modulators that is/are targeted to one or more areas of one or more genes. A composition containing a nucleic acid "modulates" or is "capable of modulating" or is a "modulator" of gene expression if the nucleic acid modulates gene expression or if the nucleic acid encodes a gene product that modulates gene expression. As used herein, the term "modulate"
includes both inhibition and stimulation, as well as other changes (e.g., production of a modified gene product) in gene expression. The term "inhibition" is intended to include both complete and partial inhibition of expression. In various embodiments, gene expression is inhibited to a level of about 1-99%, or at least about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98%, or 99% lower than the wild type level of gene expression. In some embodiments, expression is inhibited to a level at least about 1-99%, or at least aboutl%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98%, or 99% lower than the wild type level of gene expression.
Genes may be chosen for modulation based on their involvement in one or more pathways that are altered in the disorder to be treated. In some embodiments, the invention provides compositions that contain a gene modulator targeted to one area of one gene, e.g., myostatin. In some embodiments, the invention provides gene modulators that are targeted to more than one area of one gene, e.g., myostatin. In some embodiments, the invention provides
Methods include methods of treating animals (e.g. mammals, humans) by modulating gene expression in cells by contacting cells with compositions of the invention.
Methods also include methods of treatment of disorders using the gene modulating compositions of the invention.
Disorders for treatment include muscle wasting disorders or disorders associated with decreased muscle mass and/or increased obesity. As used herein, the term "muscle wasting disorder," used synonymously herein with the term "muscle wasting condition," encompasses disorders or conditions in which muscle wasting is one of the primary symptoms, such as muscular dystrophy, spinal cord injury, neurodegenerative diseases, anorexia, sarcopenia, cachexia, muscular atrophy due to immobilization, prolonged bed rest, or weightlessness, and the like, as well as disorders in which an abnormally high fat-to-muscle ratio is implicated in a disease or pre-disease state, e.g., Type II diabetes or Syndrome X. In addition, the invention provides methods of increasing muscle mass in animals where such an increase is desirable, e.g., in food animals such as mammals and fish.
In addition, the invention provides kits that provide compositions of the invention, optionally including instructions for use of the compositions in methods of the invention.
The gene modulators of the invention include antisense oligonucleotides, interfering RNA (RNAi), ribozymes, and DNAzymes. Compositions of the invention contain one or more gene modulators that is/are targeted to one or more areas of one or more genes. A composition containing a nucleic acid "modulates" or is "capable of modulating" or is a "modulator" of gene expression if the nucleic acid modulates gene expression or if the nucleic acid encodes a gene product that modulates gene expression. As used herein, the term "modulate"
includes both inhibition and stimulation, as well as other changes (e.g., production of a modified gene product) in gene expression. The term "inhibition" is intended to include both complete and partial inhibition of expression. In various embodiments, gene expression is inhibited to a level of about 1-99%, or at least about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98%, or 99% lower than the wild type level of gene expression. In some embodiments, expression is inhibited to a level at least about 1-99%, or at least aboutl%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98%, or 99% lower than the wild type level of gene expression.
Genes may be chosen for modulation based on their involvement in one or more pathways that are altered in the disorder to be treated. In some embodiments, the invention provides compositions that contain a gene modulator targeted to one area of one gene, e.g., myostatin. In some embodiments, the invention provides gene modulators that are targeted to more than one area of one gene, e.g., myostatin. In some embodiments, the invention provides
-8-WSGR Docket No. 31249-722.601 gene modulators that are targeted to multiple genes, e.g., myostatin and myostatin receptor genes, as well as other genes described herein (Table I and Table 2). In these embodiments, more than one area of a gene may be targeted I. Compositions of the invention The compositions of the invention include one or more agents capable of modulating expression of a gene or genes associated with muscle wasting and/or muscle growth, and the conditions associated with them. Typically, the gene modulators of the invention are inhibitory to gene expression and include, without limitation, antisense oligonucleotides, interfering RNA
(RNAi), ribozymes, and DNAzymes. Compositions of the invention contain one or more gene modulators that is/are targeted to one or more areas of one or more genes. In some embodiments, the invention provides compositions that contain a gene modulator targeted to one area of one gene, e.g., myostatin. In some embodiments, the invention provides gene modulators that are targeted to more than one area of one gene, e.g., myostatin. In some embodiments, the invention provides gene modulators that are targeted to multiple genes, e.g., myostatin, myostatin receptor genes, and/or myostatin transcription factors. In these embodiments, more than one area of a gene may be targeted.
In preferred embodiments, the invention provides compositions that contain combinations of gene modulators for enhancement of muscle growth and treatment of diseases associated with inadequate muscle growth or muscle wasting, or for enhancing normal muscle growth (e.g., in farm animals). These combinations include: combinations of different types of gene modulators, combinations of gene modulators targeted to different parts of the same gene, and combinations of gene modulators targeted to different genes, as well as combinations of any of the aforementioned combinations.
The invention further provides modified oligonucleotides for use in any of the above combinations. In embodiments, oligonucleotides used in the invention can be, e.g., end-blocked, protonated, exhibit substantial acid resistance, substantial nuclease resistance, and/or contain achiral internucleoside phosphate linkages and modified ribose or deoxyribose substituents.
The compositions and methods of the invention may be applied to any gene for which it is desired to alter expression in order to provide a therapeutic effect in muscle wasting disorders, or to produce a desired increase in muscle mass. In general, the major targets are genes involved in muscle growth and maintenance; however, in the majority of cases, several pathways involving multiple genes are affected by a given disorder, and the invention provides not only compositions and methods targeted to single genes (e.g., myostatin) but also compositions and methods targeted to multiple genes, or to multiple areas on a single gene, or both.
(RNAi), ribozymes, and DNAzymes. Compositions of the invention contain one or more gene modulators that is/are targeted to one or more areas of one or more genes. In some embodiments, the invention provides compositions that contain a gene modulator targeted to one area of one gene, e.g., myostatin. In some embodiments, the invention provides gene modulators that are targeted to more than one area of one gene, e.g., myostatin. In some embodiments, the invention provides gene modulators that are targeted to multiple genes, e.g., myostatin, myostatin receptor genes, and/or myostatin transcription factors. In these embodiments, more than one area of a gene may be targeted.
In preferred embodiments, the invention provides compositions that contain combinations of gene modulators for enhancement of muscle growth and treatment of diseases associated with inadequate muscle growth or muscle wasting, or for enhancing normal muscle growth (e.g., in farm animals). These combinations include: combinations of different types of gene modulators, combinations of gene modulators targeted to different parts of the same gene, and combinations of gene modulators targeted to different genes, as well as combinations of any of the aforementioned combinations.
The invention further provides modified oligonucleotides for use in any of the above combinations. In embodiments, oligonucleotides used in the invention can be, e.g., end-blocked, protonated, exhibit substantial acid resistance, substantial nuclease resistance, and/or contain achiral internucleoside phosphate linkages and modified ribose or deoxyribose substituents.
The compositions and methods of the invention may be applied to any gene for which it is desired to alter expression in order to provide a therapeutic effect in muscle wasting disorders, or to produce a desired increase in muscle mass. In general, the major targets are genes involved in muscle growth and maintenance; however, in the majority of cases, several pathways involving multiple genes are affected by a given disorder, and the invention provides not only compositions and methods targeted to single genes (e.g., myostatin) but also compositions and methods targeted to multiple genes, or to multiple areas on a single gene, or both.
-9-WSGR Docket No. 31249-722.601 A. Expression-modulating compositions Any type of nucleic acid-based therapeutics that modulates expression of a gene may be used in the compositions and methods of the invention. These include antisense oligonucleotides, ribozymes, interfering RNA (RNAi), and DNAzymes. Each of these approaches has one central theme in common, that is, the recognition of their target DNA or mRNA sequences via Watson-Crick base-pairing. The present invention thus relates to polynucleotides that hybridize to any of the gene sequences described herein, preferably under stringent conditions. A stringent condition refers to a condition that allows nucleic acid duplexes to be distinguished based on their degree of mismatch. Such polynucleotides (e.g., antisense and RNAi) can be used to inhibit the expression of muscle wasting-associated gene product. Such polynucleotides can also serve as probes and primers for research and diagnostic purposes.
The term "oligonucleotides" as used herein, refers to a molecule comprising nucleotides (i.e., ribonucleotides, deoxyribonucleotides, or both). The term includes monomers and polymers of ribonucleotides and deoxyribonucleotides, or mixtures thereof, with the nucleotides being connected together via, for example 5' to 3' linkages, 5' to 2' linkages, etc.
The nucleotides used in the oligonucleotides may be naturally occurring or may be synthetically produced analogues that are capable of forming base-pair relationships with naturally occurring base pairs. Examples of non-naturally occurring bases that are capable of forming base-pairing relationships include, but are not limited to, aza and deaza pyrimidine analogues, aza and deaza purine analogues, and other heterocyclic base analogues, wherein one or more of the carbon and nitrogen atoms of the purine and pyrimidine rings have been substituted by heteroatoms, e.g., oxygen, sulfur, selenium, phosphorus, etc.
1. Antisense oligonucleotides Antisense oligonucleotides contain short, chemically synthesized DNA or RNA
oligonucleotides with base-pair homology against the mRNA target of interest.
Without wishing to be limited by theory, it is generally believed that antisense oligonucleotides act to inhibit gene expression by blocking translation of mRNA or by targeting the RNA for degradation by RNase H. Antisense oligonucleotides can block splicing, translation, or nuclear-cytoplasmic transport.
The mechanisms of action of antisense oligonucleotides vary depending on the backbone of the oligonucleotide. Antisense oligonucleotides can be complementary to an entire coding region or only to a portion thereof.
An antisense oligonucleotide herein can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, or more than 100 nucleotides in length.
Preferably, the
The term "oligonucleotides" as used herein, refers to a molecule comprising nucleotides (i.e., ribonucleotides, deoxyribonucleotides, or both). The term includes monomers and polymers of ribonucleotides and deoxyribonucleotides, or mixtures thereof, with the nucleotides being connected together via, for example 5' to 3' linkages, 5' to 2' linkages, etc.
The nucleotides used in the oligonucleotides may be naturally occurring or may be synthetically produced analogues that are capable of forming base-pair relationships with naturally occurring base pairs. Examples of non-naturally occurring bases that are capable of forming base-pairing relationships include, but are not limited to, aza and deaza pyrimidine analogues, aza and deaza purine analogues, and other heterocyclic base analogues, wherein one or more of the carbon and nitrogen atoms of the purine and pyrimidine rings have been substituted by heteroatoms, e.g., oxygen, sulfur, selenium, phosphorus, etc.
1. Antisense oligonucleotides Antisense oligonucleotides contain short, chemically synthesized DNA or RNA
oligonucleotides with base-pair homology against the mRNA target of interest.
Without wishing to be limited by theory, it is generally believed that antisense oligonucleotides act to inhibit gene expression by blocking translation of mRNA or by targeting the RNA for degradation by RNase H. Antisense oligonucleotides can block splicing, translation, or nuclear-cytoplasmic transport.
The mechanisms of action of antisense oligonucleotides vary depending on the backbone of the oligonucleotide. Antisense oligonucleotides can be complementary to an entire coding region or only to a portion thereof.
An antisense oligonucleotide herein can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, or more than 100 nucleotides in length.
Preferably, the
-10-WSGR Docket No. 31249-722.601 oligonucleotide is about five to about 75 nucleotides in length. The oligonucleotide can also be about eight to about 40, or at about 10 to about 30, or about 15 to about 30 sequential nucleotides. In one embodiment, the oligonucleotide is about 12 to about 26 nucleotides in length.
Typically, the procedure for making an antisense oligonucleotide composition includes:
(i) selecting an oligonucleotide that is adjacent to or overlaps a target region of a gene, (ii) determining the Gibbs Free energy value associated with the oligonucleotide in reference to the target gene, (iii) assessing T,,, in reference to the target gene, and (iv) performing a sequence database search to determine the oligonucleotide overlaps the 5' UTR, the translational start sequence, the 3' UTR, or the translational termination site of an mRNA of a gene different from the target gene. Accordingly, in some embodiments, the antisense oligonucleotides of the present invention can be directed to a translational start site, a 5' UTR, a 3' UTR, or a ternlination site.
Preferably, the oligonucleotide is adjacent to or overlaps the translational start site of the gene by at least about one base. Still preferred, the oligonucleotide overlaps the translational start site by at least about two bases. Still more preferred, the oligonucleotide overlaps the translational start site by at least about three bases.
It is generally preferable to design an RNA or DNA that has the same or similar base sequence as the portion of the complement of a gene that encodes the 5' end of an RNA.
However, a nucleic acid may also have, for example, a same or similar base sequence as other regions of the gene, such as the region encoding a translation start site or the 3' untranslated region. In another example, a nucleic acid may be designed to reflect the region around a splice donor or splice acceptor site, either with or without the intervening intron.
Of particular interest are nucleic acid molecules whose sequences comprise all or a fragment of the sequence of the complement of a gene that is over-expressed in individuals exhibiting the disease or condition.
The identification of overexpression of a gene can be through molecular means, e.g., detection of expression in affected tissue using conventional molecular techniques (e.g., Sambrook et al.
(1989) Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press).
Overexpression of a gene may also be detected using array technology, or inferred from the results of protein assays, such as ELISA.
Suitable antisense oligonucleotides for the present invention can be determined by evaluating the Delta G or Gibbs Free energy of oligonucleotide binding to the complementary RNA strand at 37 C. and the T,,,. The Gibbs Free energy and T. are measured from the part of the target gene that corresponds to the RNA oligonucleotide that is added.
These values can be calculated using, e.g., the program found on ftp://rna.chem.rochester.edu and are described in
Typically, the procedure for making an antisense oligonucleotide composition includes:
(i) selecting an oligonucleotide that is adjacent to or overlaps a target region of a gene, (ii) determining the Gibbs Free energy value associated with the oligonucleotide in reference to the target gene, (iii) assessing T,,, in reference to the target gene, and (iv) performing a sequence database search to determine the oligonucleotide overlaps the 5' UTR, the translational start sequence, the 3' UTR, or the translational termination site of an mRNA of a gene different from the target gene. Accordingly, in some embodiments, the antisense oligonucleotides of the present invention can be directed to a translational start site, a 5' UTR, a 3' UTR, or a ternlination site.
Preferably, the oligonucleotide is adjacent to or overlaps the translational start site of the gene by at least about one base. Still preferred, the oligonucleotide overlaps the translational start site by at least about two bases. Still more preferred, the oligonucleotide overlaps the translational start site by at least about three bases.
It is generally preferable to design an RNA or DNA that has the same or similar base sequence as the portion of the complement of a gene that encodes the 5' end of an RNA.
However, a nucleic acid may also have, for example, a same or similar base sequence as other regions of the gene, such as the region encoding a translation start site or the 3' untranslated region. In another example, a nucleic acid may be designed to reflect the region around a splice donor or splice acceptor site, either with or without the intervening intron.
Of particular interest are nucleic acid molecules whose sequences comprise all or a fragment of the sequence of the complement of a gene that is over-expressed in individuals exhibiting the disease or condition.
The identification of overexpression of a gene can be through molecular means, e.g., detection of expression in affected tissue using conventional molecular techniques (e.g., Sambrook et al.
(1989) Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press).
Overexpression of a gene may also be detected using array technology, or inferred from the results of protein assays, such as ELISA.
Suitable antisense oligonucleotides for the present invention can be determined by evaluating the Delta G or Gibbs Free energy of oligonucleotide binding to the complementary RNA strand at 37 C. and the T,,,. The Gibbs Free energy and T. are measured from the part of the target gene that corresponds to the RNA oligonucleotide that is added.
These values can be calculated using, e.g., the program found on ftp://rna.chem.rochester.edu and are described in
-11-WSGR Docket No. 31249-722.601 Matthews et al. (1999) J. Mol. Biol. 288, 911-940 and Matthews et al. (1999) RNA 5, 1458-1469.
Accordingly, some preferred embodiments of the invention provides a composition comprising an oligonucleotide, (i) wherein said oligonucleotide is about 10 to about 30 nucleotides in length, (ii) the Gibbs Free energy of the binding of said oligonucleotide/RNA
target duplex at 37 C. is -15 kCal, (iii) said oligonucleotide is complementary to a region within the target gene selected from the group consisting of 5' UTR, translational start site and translational termination site.
The Gibbs free energy is measured between that part of the target gene that corresponds to the oligonucleotide, that part typically being the 5'UTR, translational start site or the translational termination site. In a preferred embodiment, the Gibbs Free energy of the binding of said oligonucleotide/RNA target duplex at 37 C is G20 kCal. Also preferred, the Gibbs Free energy is G25 kCal. For 12-14 mer oligonucleotides, the Gibbs Free energy is preferably G15 kCal, for 15-17 mer oligonucleotides, the Gibbs Free energy is preferably <_-20 kCal, for 18-20 mer oligonucleotides, the Gibbs Free energy is preferably _-25 kCal, for 21-23 mer oligonucleotides, the Gibbs Free energy is G30 kCal, and for 24-26 mer oligonucleotides, the Gibbs Free energy is :5-35 kCal.
Further provided by the present invention is a composition comprising an oligonucleotide, (i) wherein said oligonucleotide is about 10 to about 30 nucleotides in length, (ii) the T,,, of said oligonucleotide to a target gene is about 65-90 C.., (iii) said oligonucleotide is complementary to a region within the target gene selected from the group consisting of 5' UTR, translational start site an termination site. Preferably, the oligonucleotide has a Tm of about 75-90 C.. Still preferred, the oligonucleotide has a T,T, of about 85-90 C. Still preferred, the T,,, of said oligonucleotide to a target gene at 1M monovalent cation concentration is about 65-90 C. The Gibbs free energy is measured between that part of the target gene that corresponds to the oligonucleotide, that part typically being the 5' UTR, 3'UTR, translational start site or the translational termination site.
The oligonucleotide sequence can be derived from any of the genes listed in Tables 1 and 2, or any other gene the modulation of whose expression is likely to produce a desirable therapeutic result in a muscle-wasting-associated condition. Table 3, 4 and 5 show representative antisense sequences that may be used in embodiments of the invention; these sequences are merely representative, and any sequence that acts as an antisense oligonucleotide and that modulates expression of a gene involved in a muscle-wasting condition may be used in compositions and methods of the invention.
Accordingly, some preferred embodiments of the invention provides a composition comprising an oligonucleotide, (i) wherein said oligonucleotide is about 10 to about 30 nucleotides in length, (ii) the Gibbs Free energy of the binding of said oligonucleotide/RNA
target duplex at 37 C. is -15 kCal, (iii) said oligonucleotide is complementary to a region within the target gene selected from the group consisting of 5' UTR, translational start site and translational termination site.
The Gibbs free energy is measured between that part of the target gene that corresponds to the oligonucleotide, that part typically being the 5'UTR, translational start site or the translational termination site. In a preferred embodiment, the Gibbs Free energy of the binding of said oligonucleotide/RNA target duplex at 37 C is G20 kCal. Also preferred, the Gibbs Free energy is G25 kCal. For 12-14 mer oligonucleotides, the Gibbs Free energy is preferably G15 kCal, for 15-17 mer oligonucleotides, the Gibbs Free energy is preferably <_-20 kCal, for 18-20 mer oligonucleotides, the Gibbs Free energy is preferably _-25 kCal, for 21-23 mer oligonucleotides, the Gibbs Free energy is G30 kCal, and for 24-26 mer oligonucleotides, the Gibbs Free energy is :5-35 kCal.
Further provided by the present invention is a composition comprising an oligonucleotide, (i) wherein said oligonucleotide is about 10 to about 30 nucleotides in length, (ii) the T,,, of said oligonucleotide to a target gene is about 65-90 C.., (iii) said oligonucleotide is complementary to a region within the target gene selected from the group consisting of 5' UTR, translational start site an termination site. Preferably, the oligonucleotide has a Tm of about 75-90 C.. Still preferred, the oligonucleotide has a T,T, of about 85-90 C. Still preferred, the T,,, of said oligonucleotide to a target gene at 1M monovalent cation concentration is about 65-90 C. The Gibbs free energy is measured between that part of the target gene that corresponds to the oligonucleotide, that part typically being the 5' UTR, 3'UTR, translational start site or the translational termination site.
The oligonucleotide sequence can be derived from any of the genes listed in Tables 1 and 2, or any other gene the modulation of whose expression is likely to produce a desirable therapeutic result in a muscle-wasting-associated condition. Table 3, 4 and 5 show representative antisense sequences that may be used in embodiments of the invention; these sequences are merely representative, and any sequence that acts as an antisense oligonucleotide and that modulates expression of a gene involved in a muscle-wasting condition may be used in compositions and methods of the invention.
-12-WSGR Docket No. 31249-722.601 In some embodiments, one or more of the antisense oligonucleotides of the invention is a modified oligonucleotide. Linkage and backbone modifications have shown a great promise for oligonucleotides to be used in vivo, such as 2'-O-methyls, 2'-O-allyls, locked nucleic acids and peptide nucleic acids.
In a preferred embodiment, the antisense oligonucleotides of the invention are modified to provide increased acid resistance as compared to unmodified oligonucleotide, or to provide increased resistance to endonuclease, or both. Further modifications are described below.
An antisense oligonucleotide can be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest).
Although the specific antisense sequences described herein (e.g., in Tables 3, 4 and 5) depict the sequences as oligonucleotides containing only deoxyribonucleotide residues, it is to be understood that the present invention also includes embodiments wherein the oligonucleotides are composed of ribonucleotide residues (e.g., by substituting uridine for thymidine, and ribosyl substituents for deoxyribosyl substituents). Moreover, it is to be understood that the present invention also includes the embodiments in which the oligonucleotides are composed of only deoxyribonucleotide residues, of only ribonucleotide residues, or of mixtures of deoxyribonucleotide and ribonucleotide residues.
In some embodiments, antisense oligonucleotides of the present invention display greater than or equal to 60, 70, 80, 90, 95, or 99 percent sequence identity to a nucleotide sequence selected from the group of SEQ ID NO: 1 - 191.
The degree of similarity between two sequences can be determined using methods well known to the art (e.g., computer programs including Fasta (Oxford Molecular Group Inc.) and BLAST (www.ncbi.nlm.nih.gov) (Altschul et al. (1997) Nucleic Acid Res. 25, 33 89-3402).
These methods can be employed to take into account gaps in the sequences due to deletions or insertions. Homology or sequence identity at the nucleotide or amino acid sequence level determined by BLAST (Basic Local Alignment Search Tool) analysis uses the algorithm employed by the programs blastp, blastn, blastx, tblastn and tblastx (Altschul et al. (1997) Nucleic Acids Res. 25, 3389-3402 and Karlin et al. (1990) Proc. Natl. Acad.
Sci. USA 87, 2264-2268, both fully incorporated by reference) which are tailored for sequence similarity searching.
The approach used by the BLAST program is to first consider similar segments, with gaps (non-contiguous) and without gaps (contiguous), between a query sequence and a database sequence,
In a preferred embodiment, the antisense oligonucleotides of the invention are modified to provide increased acid resistance as compared to unmodified oligonucleotide, or to provide increased resistance to endonuclease, or both. Further modifications are described below.
An antisense oligonucleotide can be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest).
Although the specific antisense sequences described herein (e.g., in Tables 3, 4 and 5) depict the sequences as oligonucleotides containing only deoxyribonucleotide residues, it is to be understood that the present invention also includes embodiments wherein the oligonucleotides are composed of ribonucleotide residues (e.g., by substituting uridine for thymidine, and ribosyl substituents for deoxyribosyl substituents). Moreover, it is to be understood that the present invention also includes the embodiments in which the oligonucleotides are composed of only deoxyribonucleotide residues, of only ribonucleotide residues, or of mixtures of deoxyribonucleotide and ribonucleotide residues.
In some embodiments, antisense oligonucleotides of the present invention display greater than or equal to 60, 70, 80, 90, 95, or 99 percent sequence identity to a nucleotide sequence selected from the group of SEQ ID NO: 1 - 191.
The degree of similarity between two sequences can be determined using methods well known to the art (e.g., computer programs including Fasta (Oxford Molecular Group Inc.) and BLAST (www.ncbi.nlm.nih.gov) (Altschul et al. (1997) Nucleic Acid Res. 25, 33 89-3402).
These methods can be employed to take into account gaps in the sequences due to deletions or insertions. Homology or sequence identity at the nucleotide or amino acid sequence level determined by BLAST (Basic Local Alignment Search Tool) analysis uses the algorithm employed by the programs blastp, blastn, blastx, tblastn and tblastx (Altschul et al. (1997) Nucleic Acids Res. 25, 3389-3402 and Karlin et al. (1990) Proc. Natl. Acad.
Sci. USA 87, 2264-2268, both fully incorporated by reference) which are tailored for sequence similarity searching.
The approach used by the BLAST program is to first consider similar segments, with gaps (non-contiguous) and without gaps (contiguous), between a query sequence and a database sequence,
-13-WSGR Docket No. 31249-722.601 then to evaluate the statistical significance of all matches that are identified and finally to summarize only those matches which satisfy a preselected threshold of significance.
In some embodiments the antisense oligonucleotides of the invention have a Guanine:Cytosine (GC content) greater than 35 percent. The GC content is preferably greater than 40 percent and most preferably, greater than 45 percent.
2. Ribozymes "Ribozyme" refers to a nucleic acid molecule which is capable of cleaving a specific nucleic acid sequence. Ribozymes may be composed of RNA, DNA, nucleic acid analogues (e.g., phosphorothioates), or any combination of these (e.g., DNA/RNA
chimerics). In some embodiments, a ribozyme refers to RNA molecules that contain anti-sense sequences for specific recognition, and an RNA-cleaving enzymatic activity.
As noted above, the present invention provides ribozymes having the ability to cleave or otherwise inhibit nucleic acid molecules which are either directly, or indirectly (e.g., they encode proteins) involved in muscle wasting disorders. Several different types of ribozymes may be constructed for use within the present invention, including for example, hammerhead ribozymes (Rossi, J. J. et al., Pharmac. Ther. 50:245-254, 1991) (Forster and Symons, Ce1148:211-220, 1987; Haseloff and Gerlach, Nature 328:596-600, 1988; Walbot and Bruening, Nature 334:196, 1988; Haseloff and Gerlach, Nature 334:585, 1988; Haseloff et al., U.S. Pat.
No. 5,254,678), hairpin ribozymes (Hampel et al., Nucl. Acids Res. 18:299-304, 1990, and U.S.
Pat. No.
5,254,678), hepatitis delta virus ribozymes (Perrotta and Been, Biochem.
31:16, 1992), Group I
intron ribozymes (Cech et al., U.S. Pat. No. 4,987,071) and RNase P ribozymes (Takada et al., Cell 35:849, 1983); (see also, WO 95/29241, entitled "Ribozymes with Product Ejection by Strand Displacement"; and WO 95/31551, entitled "Novel Enzymatic RNA
Molecules."
The sequence requirement at the cleavage site for the hammerhead ribozyme is any RNA
sequence consisting of NUH (where N is any of G, U, C, or A and H represents C, U, or A) can be targeted. Accordingly, the same target within the hairpin leader sequence, GUC, is useful for the hammerhead ribozyme. The additional nucleotides of the hammerhead ribozyme or hairpin ribozyme is determined by the target flanking nucleotides and the hammerhead consensus sequence (see Ruffner et al., Biochemistry 29:10695-10702, 1990).
Ribozymes, as well as DNA encoding such ribozymes and other suitable nucleic acid molecules, can be chemically synthesized using methods well known in the art for the synthesis of nucleic acid molecules (see e.g., Heidenreich et al., J FASEB 70(1):90-6, 1993; Sproat, Curr.
Opin. Biotechnol. 4(1):20-28, 1993). Alternatively, commercial suppliers such as Promega,
In some embodiments the antisense oligonucleotides of the invention have a Guanine:Cytosine (GC content) greater than 35 percent. The GC content is preferably greater than 40 percent and most preferably, greater than 45 percent.
2. Ribozymes "Ribozyme" refers to a nucleic acid molecule which is capable of cleaving a specific nucleic acid sequence. Ribozymes may be composed of RNA, DNA, nucleic acid analogues (e.g., phosphorothioates), or any combination of these (e.g., DNA/RNA
chimerics). In some embodiments, a ribozyme refers to RNA molecules that contain anti-sense sequences for specific recognition, and an RNA-cleaving enzymatic activity.
As noted above, the present invention provides ribozymes having the ability to cleave or otherwise inhibit nucleic acid molecules which are either directly, or indirectly (e.g., they encode proteins) involved in muscle wasting disorders. Several different types of ribozymes may be constructed for use within the present invention, including for example, hammerhead ribozymes (Rossi, J. J. et al., Pharmac. Ther. 50:245-254, 1991) (Forster and Symons, Ce1148:211-220, 1987; Haseloff and Gerlach, Nature 328:596-600, 1988; Walbot and Bruening, Nature 334:196, 1988; Haseloff and Gerlach, Nature 334:585, 1988; Haseloff et al., U.S. Pat.
No. 5,254,678), hairpin ribozymes (Hampel et al., Nucl. Acids Res. 18:299-304, 1990, and U.S.
Pat. No.
5,254,678), hepatitis delta virus ribozymes (Perrotta and Been, Biochem.
31:16, 1992), Group I
intron ribozymes (Cech et al., U.S. Pat. No. 4,987,071) and RNase P ribozymes (Takada et al., Cell 35:849, 1983); (see also, WO 95/29241, entitled "Ribozymes with Product Ejection by Strand Displacement"; and WO 95/31551, entitled "Novel Enzymatic RNA
Molecules."
The sequence requirement at the cleavage site for the hammerhead ribozyme is any RNA
sequence consisting of NUH (where N is any of G, U, C, or A and H represents C, U, or A) can be targeted. Accordingly, the same target within the hairpin leader sequence, GUC, is useful for the hammerhead ribozyme. The additional nucleotides of the hammerhead ribozyme or hairpin ribozyme is determined by the target flanking nucleotides and the hammerhead consensus sequence (see Ruffner et al., Biochemistry 29:10695-10702, 1990).
Ribozymes, as well as DNA encoding such ribozymes and other suitable nucleic acid molecules, can be chemically synthesized using methods well known in the art for the synthesis of nucleic acid molecules (see e.g., Heidenreich et al., J FASEB 70(1):90-6, 1993; Sproat, Curr.
Opin. Biotechnol. 4(1):20-28, 1993). Alternatively, commercial suppliers such as Promega,
-14-WSGR Docket No. 31249-722.601 Madison, Wis., USA, provide a series of protocols suitable for the production of nucleic acid molecules such as ribozymes.
During synthesis, the ribozyme can be modified by ligation to a DNA molecule having the ability to stabilize the ribozyme and make it resistant to RNase (Rossi et al., Pharmac. Ther.
50:245-254, 1991). In another embodiment, the ribozyme can be modified to a phosphothio-analog for use in liposome delivery systems. This modification also renders the ribozyme resistant to endonuclease activity. In yet another embodiment, the ribozyme can be modified to contain propanediol linkages or to incorporate 2'-O-methylated nucleotides.
Any ribozyme that modulates expression of a gene involved in muscle wasting conditions, or that promotes muscle growth where muscle growth is desirable, e.g., the genes of Tables 1 and 2, may be used in the compositions and methods of the invention.
3. Interfering RNA (RNAi) In another embodiment of the present invention, double stranded nucleic acids can be used to inhibit expression of genes associated with muscle wasting (e.g., myostatin and myostatin receptor genes) by RNA interference. RNA interference ("RNAi") is a mechanism of post-transcriptional gene silencing in which double-stranded RNA (dsRNA) corresponding to a gene (or coding region) of interest is introduced into a cell or an organism, resulting in degradation of the corresponding mRNA. The RNAi effect persists for multiple cell divisions before gene expression is regained. RNAi is therefore an extremely powerful method for making targeted knockouts or "knockdowns" at the RNA level. RNAi has proven successful in human cells, including human embryonic kidney and HeLa cells. See, e.g., Elbashir et al. Nature May 24, 2001;411(6836):494-8); Tuschl et al. (1999), Genes and Development 13:3191-3197;
Zamore (2000), Cell 101:25-33, and U.S. Patent No. 6,506,559, all of which are incorporated herein by reference in their entirety.
Thus, the invention further provides RNAi's that inhibit expression of genes involved in muscle wasting disease. In this connection, the invention provides an RNAi that modulates expression of myostatin or a myostatin receptor. As an example, this aspect of the invention provides small (less than about 50, or less than about 40, or less than about 30 or less than about 20 nt) dsRNA that specifically inhibits gene expression of genes involved in muscle wasting or in limiting muscle growth (reviewed in Caplen (2002) Trends in Biotechnology 20:49-51). In some embodiments, the RNAi includes: (a) double-stranded RNA of 21 -25 nucleotides with overhangs of 2 nucleotides at both 3' ends; (b) 30 - 52% of the G+C content of the double stranded region; and (c) A/U base-pairing in positions 15 -19 in sense strand;
and (d) no internal repeats.
During synthesis, the ribozyme can be modified by ligation to a DNA molecule having the ability to stabilize the ribozyme and make it resistant to RNase (Rossi et al., Pharmac. Ther.
50:245-254, 1991). In another embodiment, the ribozyme can be modified to a phosphothio-analog for use in liposome delivery systems. This modification also renders the ribozyme resistant to endonuclease activity. In yet another embodiment, the ribozyme can be modified to contain propanediol linkages or to incorporate 2'-O-methylated nucleotides.
Any ribozyme that modulates expression of a gene involved in muscle wasting conditions, or that promotes muscle growth where muscle growth is desirable, e.g., the genes of Tables 1 and 2, may be used in the compositions and methods of the invention.
3. Interfering RNA (RNAi) In another embodiment of the present invention, double stranded nucleic acids can be used to inhibit expression of genes associated with muscle wasting (e.g., myostatin and myostatin receptor genes) by RNA interference. RNA interference ("RNAi") is a mechanism of post-transcriptional gene silencing in which double-stranded RNA (dsRNA) corresponding to a gene (or coding region) of interest is introduced into a cell or an organism, resulting in degradation of the corresponding mRNA. The RNAi effect persists for multiple cell divisions before gene expression is regained. RNAi is therefore an extremely powerful method for making targeted knockouts or "knockdowns" at the RNA level. RNAi has proven successful in human cells, including human embryonic kidney and HeLa cells. See, e.g., Elbashir et al. Nature May 24, 2001;411(6836):494-8); Tuschl et al. (1999), Genes and Development 13:3191-3197;
Zamore (2000), Cell 101:25-33, and U.S. Patent No. 6,506,559, all of which are incorporated herein by reference in their entirety.
Thus, the invention further provides RNAi's that inhibit expression of genes involved in muscle wasting disease. In this connection, the invention provides an RNAi that modulates expression of myostatin or a myostatin receptor. As an example, this aspect of the invention provides small (less than about 50, or less than about 40, or less than about 30 or less than about 20 nt) dsRNA that specifically inhibits gene expression of genes involved in muscle wasting or in limiting muscle growth (reviewed in Caplen (2002) Trends in Biotechnology 20:49-51). In some embodiments, the RNAi includes: (a) double-stranded RNA of 21 -25 nucleotides with overhangs of 2 nucleotides at both 3' ends; (b) 30 - 52% of the G+C content of the double stranded region; and (c) A/U base-pairing in positions 15 -19 in sense strand;
and (d) no internal repeats.
-15-WSGR Docket No. 31249-722.601 3. DNAzymes Like RNAi, DNAzyme technology also represents an ideal choice for gene suppression.
Such catalytic DNA molecules offer several advantages over ribozymes and are easier to synthesize at relatively low cost. Moreover, DNAzymes have a moderate-throughput capacity and act in a sequence-specific manner. This capacity for highly flexible binding and discrimination of nucleic acid substrates by virtue of Watson-Crick interactions enable DNAzymes to facilitate gene-type specific reactions for gene function validation with very high precision. See, e.g., Sun, L.Q., Cairns, M.J., Saravolac, E.G., Baker, A. and Gerlach, W.L.
(2000) Pharmacol. Rev. 52(3), 325 - 347; and U.S. Patent Nos. 6,617,438, 6,326,174, which are incorporated herein by reference in their entirety.
Thus, this aspect of the invention provides DNAzymes that inhibit expression of genes involved in muscle wasting disease. In some embodiments, the invention provides a DNAzyme that modulates expression of myostatin or a myostatin receptor. In some embodiments, the invention includes a DNAzyme that contains: (a) a catalytic domain that comprises the nucleotide sequence GGCTAGCTACAACGA (SEQ ID NO. 1) and that specifically cleaves mRNA coding for myostatin or a myostatin receptor at any purine:pyrimidine site to which the catalytic domain is directed, (b) a first binding domain contiguous with the 5'end of the catalytic domain, and (c) a second binding domain contiguous with the 3'end of the catalytic domain, where each binding domain hybridizes with a region immediately flanking the cleavage site.
In some embodiments, the invention provides a composition that includes at least one antisense oligonucleotide targeted to myostatin and at least one antisense oligonucleotide targeted to a myostatin receptor, e.g., ARIIb. In some embodiments, the invention provides a composition that includes at least one antisense oligonucleotide targeted to human myostatin and at least one antisense oligonucleotide targeted to a human myostatin receptor, e.g., ARIIb. In some embodiments, the invention provides a composition that includes at least one antisense oligonucleotide targeted to human myostatin wherein the sequence of the oligonucleotide is selected from SEQ ID NOs 1-191 and at least one antisense oligonucleotide targeted to a myostatin receptor, e.g., ARIIb.
In some embodiments, the invention provides a composition that includes at least one antisense oligonucleotide targeted to myostatin and at least one antisense oligonucleotide targeted to a gene product that converts inactive myostatin to an active form, e.g., TLL2. In some embodiments, the invention provides a composition that includes at least one antisense oligonucleotide targeted to human myostatin and at least one antisense oligonucleotide targeted to a human gene product that converts inactive myostatin to an active form, e.g., TLL2. In some
Such catalytic DNA molecules offer several advantages over ribozymes and are easier to synthesize at relatively low cost. Moreover, DNAzymes have a moderate-throughput capacity and act in a sequence-specific manner. This capacity for highly flexible binding and discrimination of nucleic acid substrates by virtue of Watson-Crick interactions enable DNAzymes to facilitate gene-type specific reactions for gene function validation with very high precision. See, e.g., Sun, L.Q., Cairns, M.J., Saravolac, E.G., Baker, A. and Gerlach, W.L.
(2000) Pharmacol. Rev. 52(3), 325 - 347; and U.S. Patent Nos. 6,617,438, 6,326,174, which are incorporated herein by reference in their entirety.
Thus, this aspect of the invention provides DNAzymes that inhibit expression of genes involved in muscle wasting disease. In some embodiments, the invention provides a DNAzyme that modulates expression of myostatin or a myostatin receptor. In some embodiments, the invention includes a DNAzyme that contains: (a) a catalytic domain that comprises the nucleotide sequence GGCTAGCTACAACGA (SEQ ID NO. 1) and that specifically cleaves mRNA coding for myostatin or a myostatin receptor at any purine:pyrimidine site to which the catalytic domain is directed, (b) a first binding domain contiguous with the 5'end of the catalytic domain, and (c) a second binding domain contiguous with the 3'end of the catalytic domain, where each binding domain hybridizes with a region immediately flanking the cleavage site.
In some embodiments, the invention provides a composition that includes at least one antisense oligonucleotide targeted to myostatin and at least one antisense oligonucleotide targeted to a myostatin receptor, e.g., ARIIb. In some embodiments, the invention provides a composition that includes at least one antisense oligonucleotide targeted to human myostatin and at least one antisense oligonucleotide targeted to a human myostatin receptor, e.g., ARIIb. In some embodiments, the invention provides a composition that includes at least one antisense oligonucleotide targeted to human myostatin wherein the sequence of the oligonucleotide is selected from SEQ ID NOs 1-191 and at least one antisense oligonucleotide targeted to a myostatin receptor, e.g., ARIIb.
In some embodiments, the invention provides a composition that includes at least one antisense oligonucleotide targeted to myostatin and at least one antisense oligonucleotide targeted to a gene product that converts inactive myostatin to an active form, e.g., TLL2. In some embodiments, the invention provides a composition that includes at least one antisense oligonucleotide targeted to human myostatin and at least one antisense oligonucleotide targeted to a human gene product that converts inactive myostatin to an active form, e.g., TLL2. In some
-16-WSGR Docket No. 31249-722.601 embodiments, the invention provides a composition that includes at least one antisense oligonucleotide targeted to human myostatin wherein the sequence of the oligonucleotide is selected from SEQ ID NOs 1-191 and at least one antisense oligonucleotide targeted to a gene product that converts inactive myostatin to an active form, human TLL2.
Any of these combinations may include a plurality of antisense oligonucleotides targeted to one or more of the target genes, e.g., combinations of oligonucleotides targeted to the 5' UTR, the 3'UTR, the start signal, coding sequences, and/or the termination signal, of one or more of the target genes.
B. Modifications of nucleic acids The oligonucleotides that are employed in accordance with the present invention may be modified. An oligonucleotide that comprises at least one modification has one or more chemical modifications at the molecular level of the natural molecular structures of all or any of the nucleic acid bases, sugar moieties, internucleoside phosphate linkages, as well as molecules having added substituents, such as diamines, cholesteryl or other lipophilic groups, or a combination of modifications at these sites. For example, oligonucleotides can be end-blocked, protonated, exhibit substantial acid resistance, substantial nuclease resistance, and contain achiral internucleoside phosphate linkages and modified ribose or deoxyribose substituents.
The term "end-blocked" as used herein refers to a nucleic acid with a chemical modification at the molecular level that prevents the degradation of selected nucleotides, e.g., by exonuclease action. This chemical modification is positioned such that it protects the integral portion of the nucleic acid, for example the portion of an RNA or DNA that is chemically similar to the gene involved in the physiological condition. An end block may be a 3' end block, a 5' end block, or both. For example, a 3' end block may be at the 3'-most position of the molecule, or it may be internal to the 3' ends, provided it is 3' of the integral sequences of the nucleic acid.
The term "protonated compound" refers to a molecule of the invention that, when dissolved in water having a pH of 7 causes the pH of the solution to fall.
Generally, compounds are protonated by adding protons to the reactive sites on the molecule, although other modifications of the molecule are possible, and are intended to be encompassed by this term.
Such protonation can be accomplished, for example by incubating the compound in the presence of a strong acid, most preferably one with a volatile conjugate base. The term "protonation" and "acidification" as used interchangeably herein refers to the process by which protons (or positively charged hydrogen ions) are added to proton acceptor sites on a compound of the invention. The proton acceptor sites include the substituted or unsubstituted phosphates of the
Any of these combinations may include a plurality of antisense oligonucleotides targeted to one or more of the target genes, e.g., combinations of oligonucleotides targeted to the 5' UTR, the 3'UTR, the start signal, coding sequences, and/or the termination signal, of one or more of the target genes.
B. Modifications of nucleic acids The oligonucleotides that are employed in accordance with the present invention may be modified. An oligonucleotide that comprises at least one modification has one or more chemical modifications at the molecular level of the natural molecular structures of all or any of the nucleic acid bases, sugar moieties, internucleoside phosphate linkages, as well as molecules having added substituents, such as diamines, cholesteryl or other lipophilic groups, or a combination of modifications at these sites. For example, oligonucleotides can be end-blocked, protonated, exhibit substantial acid resistance, substantial nuclease resistance, and contain achiral internucleoside phosphate linkages and modified ribose or deoxyribose substituents.
The term "end-blocked" as used herein refers to a nucleic acid with a chemical modification at the molecular level that prevents the degradation of selected nucleotides, e.g., by exonuclease action. This chemical modification is positioned such that it protects the integral portion of the nucleic acid, for example the portion of an RNA or DNA that is chemically similar to the gene involved in the physiological condition. An end block may be a 3' end block, a 5' end block, or both. For example, a 3' end block may be at the 3'-most position of the molecule, or it may be internal to the 3' ends, provided it is 3' of the integral sequences of the nucleic acid.
The term "protonated compound" refers to a molecule of the invention that, when dissolved in water having a pH of 7 causes the pH of the solution to fall.
Generally, compounds are protonated by adding protons to the reactive sites on the molecule, although other modifications of the molecule are possible, and are intended to be encompassed by this term.
Such protonation can be accomplished, for example by incubating the compound in the presence of a strong acid, most preferably one with a volatile conjugate base. The term "protonation" and "acidification" as used interchangeably herein refers to the process by which protons (or positively charged hydrogen ions) are added to proton acceptor sites on a compound of the invention. The proton acceptor sites include the substituted or unsubstituted phosphates of the
-17-WSGR Docket No. 31249-722.601 central group, as well as any additional proton acceptor sites on either the central group or the end blocking groups. As the pH of the solution is decreased, the number of these acceptor sites which are protonated increases, resulting in a more highly protonated compound.
Many nucleic acid backbones are not stable at low pH (e.g., pH 1-3) and experience depurination, although a number of backbones are relatively stable at pH 4-5.
One aspect of the present invention reflects the recognition that certain modifications, including 2'-halide, 2'-O-alkyl, 3'-O-alkyl, and 2'-O-alkyl-n(O-alkyl) nucleic acid molecules are stable at the desired pH of 2 to 1. These modifications enhance the ability of the oligonucleotides of the pharmacological compositions of the present invention to affect a condition in vivo. Thus, the composition of the present invention may include nucleic acid molecules that are substantially acid resistant. The compositions of the present invention may also include nucleic acid molecules that are nuclease resistant. This includes nucleic acid molecules completely derivatized by 2'-O-methylphosphodiesters, 2'-O-alkyl, 2'-O-alkyl-n(O-alkyl), 2'-fluoro, 2'-deoxy-erythropentofuranosyl, chimeric linkages, and any other backbone modifications, as well as other modifications, which render the nucleic acid molecules substantially resistant to endogenous nuclease activity. Additional suitable methods of rendering nucleic acid molecules nuclease resistant include, but are not limited to, covalently modifying the purine or pyrimidine bases that comprise the nucleic acid. For example, bases may be methylated, hydroxymethylated, or otherwise substituted (e.g., glycosylated) such that the nucleic acid molecules comprising the modified bases are rendered substantially nuclease resistant. Nuclease resistance also aids the oligonucleotides of the compositions of the present invention in retaining their effect in vivo.
Preferably, the oligonucleotides of the of the present invention remain relatively unchanged chemically upon administration to a subject and retain their activity in acidic conditions (pH less than 6.0) or in the presence of an endonuclease or exonuclease (e.g., in an in vivo setting).
The term "substantially acid resistant" as used herein refers to nucleic acid molecules that are resistant to acid degradation as compared to unmodified nucleic acid molecules. Typically, the relative acid resistance of a nucleic acid will be measured by comparing the percent degradation of a resistant nucleic acid with the percent degradation of its unmodified counterpart (i.e., a corresponding nucleic acid of the same length and sequence having a"normal" backbone and bases). A nucleic acid that is acid resistant is preferably at least one and a half times more resistant to acid degradation, more preferably at least two times more resistant, even more preferably at least five times more resistant, and most preferably at least ten times more resistant than their unmodified counterpart.
Many nucleic acid backbones are not stable at low pH (e.g., pH 1-3) and experience depurination, although a number of backbones are relatively stable at pH 4-5.
One aspect of the present invention reflects the recognition that certain modifications, including 2'-halide, 2'-O-alkyl, 3'-O-alkyl, and 2'-O-alkyl-n(O-alkyl) nucleic acid molecules are stable at the desired pH of 2 to 1. These modifications enhance the ability of the oligonucleotides of the pharmacological compositions of the present invention to affect a condition in vivo. Thus, the composition of the present invention may include nucleic acid molecules that are substantially acid resistant. The compositions of the present invention may also include nucleic acid molecules that are nuclease resistant. This includes nucleic acid molecules completely derivatized by 2'-O-methylphosphodiesters, 2'-O-alkyl, 2'-O-alkyl-n(O-alkyl), 2'-fluoro, 2'-deoxy-erythropentofuranosyl, chimeric linkages, and any other backbone modifications, as well as other modifications, which render the nucleic acid molecules substantially resistant to endogenous nuclease activity. Additional suitable methods of rendering nucleic acid molecules nuclease resistant include, but are not limited to, covalently modifying the purine or pyrimidine bases that comprise the nucleic acid. For example, bases may be methylated, hydroxymethylated, or otherwise substituted (e.g., glycosylated) such that the nucleic acid molecules comprising the modified bases are rendered substantially nuclease resistant. Nuclease resistance also aids the oligonucleotides of the compositions of the present invention in retaining their effect in vivo.
Preferably, the oligonucleotides of the of the present invention remain relatively unchanged chemically upon administration to a subject and retain their activity in acidic conditions (pH less than 6.0) or in the presence of an endonuclease or exonuclease (e.g., in an in vivo setting).
The term "substantially acid resistant" as used herein refers to nucleic acid molecules that are resistant to acid degradation as compared to unmodified nucleic acid molecules. Typically, the relative acid resistance of a nucleic acid will be measured by comparing the percent degradation of a resistant nucleic acid with the percent degradation of its unmodified counterpart (i.e., a corresponding nucleic acid of the same length and sequence having a"normal" backbone and bases). A nucleic acid that is acid resistant is preferably at least one and a half times more resistant to acid degradation, more preferably at least two times more resistant, even more preferably at least five times more resistant, and most preferably at least ten times more resistant than their unmodified counterpart.
-18-WSGR Docket No. 31249-722.601 Although certain acid resistant nucleic acid molecules exhibit marked acid stability and endonuclease resistance, they are sensitive to 3' exonucleases. In order to enhance the exonuclease resistance of 2'-O-alkyl substituted nucleic acid molecules, the 3' or 5' and 3' ends of the nucleic acid are preferably attached to a chemical moiety that provides an exonuclease blocking function. For example, one or more phosphorothioate nucleotides can be placed at either end of the RNA or DNA. Additionally, one or more inverted bases can be placed on either end of the RNA or DNA, or one or more alkyl or alcohol (e.g., butanol-substituted) nucleotides or chemical groups can be placed on one or both ends. Accordingly, a preferred embodiment of the present invention is a nucleic acid comprising a nucleic acid having the following structure:
A-B-C, wherein "B" is a 2'-O-alkyl or 2'-O-alkyl-n(O-alkyl) substituted RNA
between about 1 and about 98 bases in length, and "A" and "C" are respective 5' and 3' end blocking groups (e.g., one or more phosphorothioate nucleotides (but typically fewer than six), inverted base linkages, or alkyl, alkenyl, alkynyl, 0-alkyl, and O-alkyl-n(O-alkyl) groups or substituted nucleotides). A
partial list of blocking groups includes inverted bases, dideoxynucleotides, methylphosphates, alkyl groups, aryl groups, cordycepin, cytosine arabanoside, 2'-methoxy, ethoxy nucleotides, phosphoramidates, a peptide linkage, dinitrophenyl group, 2'- or 3'-O-methyl bases with phosphorothioate linkages, 3'-O-methyl bases, fluorescein, cholesterol, biotin, acridine, rhodamine, psoralen, glyceryl, methyl phosphonates, butanol, butyl, hexanol, and 3'-O-alkyls.
An enzyme-resistant butanol preferably has the structure OH--CH2CH2CH2CH2 (4-hydroxybutyl), which is also referred to as a C4 spacer.
The term "substantially nuclease resistant" refers to nucleic acid molecules that are resistant to nuclease degradation, as compared to naturally occurring or unmodified nucleic acid molecules. Modified oligonucleotides of the invention are at least 1.25 times more resistant to nuclease degradation than an unmodified nucleic acid having the same sequence and number of nucleotides, more preferably at least 2 times more resistant, even more preferably at least 5 times more resistant, and most preferably at least 10 times more resistant than their unmodified counterpart. Such substantially nuclease resistant nucleic acid molecules include, but are not limited to, nucleic acid molecules with modified backbones such as ethylphosphotri esters, 2'-O-methylphosphorothioates, 2'-O-methyl-p-ethoxy ribonucleotides, 2'-O-alkyls, 2'-O-alkyl-n(O-alkyl), 2'-fluoros, 2'-deoxy-erythropentofuranosyls, 2'-O-methyl ribonucleosides, 3'-O-methylribonucleotides, inverted bases (e.g., inverted T's), or chimeric versions of these backbones.
The modified oligonucleotide includes RNA or DNA comprising modifications to the sugar moieties such as 2'-substituted or 3'-substituted ribonucleotides, or deoxyribonucleotide monomers, any of which are connected together via internucleoside linkages.
Modified RNA or
A-B-C, wherein "B" is a 2'-O-alkyl or 2'-O-alkyl-n(O-alkyl) substituted RNA
between about 1 and about 98 bases in length, and "A" and "C" are respective 5' and 3' end blocking groups (e.g., one or more phosphorothioate nucleotides (but typically fewer than six), inverted base linkages, or alkyl, alkenyl, alkynyl, 0-alkyl, and O-alkyl-n(O-alkyl) groups or substituted nucleotides). A
partial list of blocking groups includes inverted bases, dideoxynucleotides, methylphosphates, alkyl groups, aryl groups, cordycepin, cytosine arabanoside, 2'-methoxy, ethoxy nucleotides, phosphoramidates, a peptide linkage, dinitrophenyl group, 2'- or 3'-O-methyl bases with phosphorothioate linkages, 3'-O-methyl bases, fluorescein, cholesterol, biotin, acridine, rhodamine, psoralen, glyceryl, methyl phosphonates, butanol, butyl, hexanol, and 3'-O-alkyls.
An enzyme-resistant butanol preferably has the structure OH--CH2CH2CH2CH2 (4-hydroxybutyl), which is also referred to as a C4 spacer.
The term "substantially nuclease resistant" refers to nucleic acid molecules that are resistant to nuclease degradation, as compared to naturally occurring or unmodified nucleic acid molecules. Modified oligonucleotides of the invention are at least 1.25 times more resistant to nuclease degradation than an unmodified nucleic acid having the same sequence and number of nucleotides, more preferably at least 2 times more resistant, even more preferably at least 5 times more resistant, and most preferably at least 10 times more resistant than their unmodified counterpart. Such substantially nuclease resistant nucleic acid molecules include, but are not limited to, nucleic acid molecules with modified backbones such as ethylphosphotri esters, 2'-O-methylphosphorothioates, 2'-O-methyl-p-ethoxy ribonucleotides, 2'-O-alkyls, 2'-O-alkyl-n(O-alkyl), 2'-fluoros, 2'-deoxy-erythropentofuranosyls, 2'-O-methyl ribonucleosides, 3'-O-methylribonucleotides, inverted bases (e.g., inverted T's), or chimeric versions of these backbones.
The modified oligonucleotide includes RNA or DNA comprising modifications to the sugar moieties such as 2'-substituted or 3'-substituted ribonucleotides, or deoxyribonucleotide monomers, any of which are connected together via internucleoside linkages.
Modified RNA or
-19-WSGR Docket No. 31249-722.601 DNA may also be comprised of PNA or morpholino modified backbones where specificity of the sequence is maintained.
The ribose groups and the internucleoside linkages link the bases in a nucleic acid and are referred to as the nucleic acid backbone. A modified backbone includes modifications to the chemical linkage between nucleotides, as well as other modifications that may be used to enhance stability and affinity, such as modifications to the sugar structure.
For example, an L-anomer of deoxyribose may be used, where the base is inverted with respect to the natural D-anomer. In one embodiment, the 2'-OH of the sugar group may be altered to 2'-halogen, 2'-0-alkyl or 2'-O-alkyl-n(O-alkyl), which provides resistance to degradation without compromising affinity. Other suitable modified backbones include the following types of internucleotide linkages: 2'-O-methyl-phosphodiesters, 2'-0-alkyl, 2'-O-ethyl, 2'-O-propyl, 2'-O-butyl, 2'-0-alkyl-n(O-alkyl), 2'-methoxyethoxy, 2'-fluoro, 2'-deoxy-erythropentofuranosyl, 3'-O-methyl, p-isopropyl oligonucleotides, 2'-O(CH2CH2)XCH3, and/or butyne linkages. An oligonucleotide may have combinations of such modified backbones, may be completely modified, or may comprise all or some linkages being phosphodiester linkages.
Preferred intemucleoside linkages on the modified oligonucleotide are achiral.
The term "achiral" as used herein, refers to a molecule that is superimposable with its mirror image, whereas the term "chiral" refers to a molecule that is not superimposable with its mirror image.
Oligonucleotides containing achiral 5' to 3' internucleoside phosphate linkages have internucleotide linkages which are achiral (i.e., no stereochemistry). The achiral oligonucleotides preferably contain at least about three to eight contiguous achiral internucleoside linkages, more preferably, nine to ten contiguous achiral internucleoside linkages, even more preferably, eleven to twelve contiguous achiral intemucleoside linkages, and most preferably, is completely comprised of achiral internucleoside linkages through the entire contiguous sequence. In another embodiment, the achiral internucleoside linkages are interspersed with chiral internucleoside linkages (e.g., two contiguous achiral linkages followed by one chiral linkage followed by two contiguous achiral linkages; three contiguous achiral linkages followed by one chiral linkage;
four contiguous achiral linkages followed by two achiral linkages, etc.).
Examples of achiral internucleoside linkages include, but are not limited to, phosphodiester and diphosphorothioate linkages. Achiral RNA and DNA linkages in the backbone are routinely generated during automated synthesis of oligonucleotides if the final structure is a symmetrical molecule (i.e., a phosphate with the same atom attached to both sides).
The intemucleoside phosphate linkages can be phosphodiester, or 3' to 3', 5' to 2' or 5' to 5' linkages, and combinations of such similar linkages (to produce mixed backbone modified RNA or DNA). The modifications can be internal (single or repeated) or at the end(s) of the
The ribose groups and the internucleoside linkages link the bases in a nucleic acid and are referred to as the nucleic acid backbone. A modified backbone includes modifications to the chemical linkage between nucleotides, as well as other modifications that may be used to enhance stability and affinity, such as modifications to the sugar structure.
For example, an L-anomer of deoxyribose may be used, where the base is inverted with respect to the natural D-anomer. In one embodiment, the 2'-OH of the sugar group may be altered to 2'-halogen, 2'-0-alkyl or 2'-O-alkyl-n(O-alkyl), which provides resistance to degradation without compromising affinity. Other suitable modified backbones include the following types of internucleotide linkages: 2'-O-methyl-phosphodiesters, 2'-0-alkyl, 2'-O-ethyl, 2'-O-propyl, 2'-O-butyl, 2'-0-alkyl-n(O-alkyl), 2'-methoxyethoxy, 2'-fluoro, 2'-deoxy-erythropentofuranosyl, 3'-O-methyl, p-isopropyl oligonucleotides, 2'-O(CH2CH2)XCH3, and/or butyne linkages. An oligonucleotide may have combinations of such modified backbones, may be completely modified, or may comprise all or some linkages being phosphodiester linkages.
Preferred intemucleoside linkages on the modified oligonucleotide are achiral.
The term "achiral" as used herein, refers to a molecule that is superimposable with its mirror image, whereas the term "chiral" refers to a molecule that is not superimposable with its mirror image.
Oligonucleotides containing achiral 5' to 3' internucleoside phosphate linkages have internucleotide linkages which are achiral (i.e., no stereochemistry). The achiral oligonucleotides preferably contain at least about three to eight contiguous achiral internucleoside linkages, more preferably, nine to ten contiguous achiral internucleoside linkages, even more preferably, eleven to twelve contiguous achiral intemucleoside linkages, and most preferably, is completely comprised of achiral internucleoside linkages through the entire contiguous sequence. In another embodiment, the achiral internucleoside linkages are interspersed with chiral internucleoside linkages (e.g., two contiguous achiral linkages followed by one chiral linkage followed by two contiguous achiral linkages; three contiguous achiral linkages followed by one chiral linkage;
four contiguous achiral linkages followed by two achiral linkages, etc.).
Examples of achiral internucleoside linkages include, but are not limited to, phosphodiester and diphosphorothioate linkages. Achiral RNA and DNA linkages in the backbone are routinely generated during automated synthesis of oligonucleotides if the final structure is a symmetrical molecule (i.e., a phosphate with the same atom attached to both sides).
The intemucleoside phosphate linkages can be phosphodiester, or 3' to 3', 5' to 2' or 5' to 5' linkages, and combinations of such similar linkages (to produce mixed backbone modified RNA or DNA). The modifications can be internal (single or repeated) or at the end(s) of the
-20-WSGR Docket No. 31249-722.601 RNA or DNA molecule. These modifications can include additions to the nucleic acid molecule, such as cholesteryl, diamine compounds with varying numbers of carbon residues between amino groups and terminal ribose, and deoxyribose or phosphate modifications which cleave or cross-link to the opposite chains or to associated enzymes or other proteins.
Electrophilic groups such as ribose-dialdehyde could covalently link with an epsilon amino group of the lysyl-residue of such a protein. A nucleophilic group such as n-ethylmaleimide tethered to an RNA or DNA
could covalently attach to the 5' end of an mRNA or to another electrophilic site Efficacy of a particular composition may be determined by means known in the art.
These include in vitro and in vivo methods, such as, e.g., analysis of expression in cell culture contacted with the compositions, analysis of expression and/or phenotypic characteristics and/or physiological characteristics in an in vivo model, and clinical trials. In vivo models include established animal models for various disorders, as well as normal animals which are tested to determine the effect of a composition. For myostatin and muscle growth regulating compositions, model systems such as those provided in the Examples may be used.
C. Compositions Compositions of the present invention include compositions that contain a single gene-expression modulating oligonucleotide or combinations of gene-expression modulating oligonucleotides. The oligonucleotides are directed at genes involved in muscle-wasting disorders and/or genes that promote muscle growth where muscle growth is desired.
Compositions may include only one type of oligonucleotide, e.g., only antisense oligonucleotides. Compositions may include more than one type (e.g., any combination of antisense oligonucleotides, RNAi, ribozymes, and/or DNAzymes). Compositions may include multiple oligonucleotides directed against multiple areas of a single gene.
For example, in some embodiments, the invention provides combinations of oligonucleotides, e.g., antisense oligonucleotides, that target the 5' untranslated region (UTR), the 3'UTR, the start, and/or the termination signal of an mRNA derived from a gene. In some embodiments the gene is a myostatin gene. Compositions may include multiple oligonucleotides directed against more than one gene. Compositions may include multiple oligonucleotides directed against multiple areas of multiple genes.
The compositions of the invention typically include more than about one, two, three, four, five, six, seven, eight, nine, 10, 15, 20, 30, 40, 50, 75, or 100 different oligonucleotides.
Preferably, the compositions of the invention include about two to about 20 different oligonucleotides. More preferably, the compositions of the invention include about two to about 15 different oligonucleotides, and most preferably, the compositions of the invention include
Electrophilic groups such as ribose-dialdehyde could covalently link with an epsilon amino group of the lysyl-residue of such a protein. A nucleophilic group such as n-ethylmaleimide tethered to an RNA or DNA
could covalently attach to the 5' end of an mRNA or to another electrophilic site Efficacy of a particular composition may be determined by means known in the art.
These include in vitro and in vivo methods, such as, e.g., analysis of expression in cell culture contacted with the compositions, analysis of expression and/or phenotypic characteristics and/or physiological characteristics in an in vivo model, and clinical trials. In vivo models include established animal models for various disorders, as well as normal animals which are tested to determine the effect of a composition. For myostatin and muscle growth regulating compositions, model systems such as those provided in the Examples may be used.
C. Compositions Compositions of the present invention include compositions that contain a single gene-expression modulating oligonucleotide or combinations of gene-expression modulating oligonucleotides. The oligonucleotides are directed at genes involved in muscle-wasting disorders and/or genes that promote muscle growth where muscle growth is desired.
Compositions may include only one type of oligonucleotide, e.g., only antisense oligonucleotides. Compositions may include more than one type (e.g., any combination of antisense oligonucleotides, RNAi, ribozymes, and/or DNAzymes). Compositions may include multiple oligonucleotides directed against multiple areas of a single gene.
For example, in some embodiments, the invention provides combinations of oligonucleotides, e.g., antisense oligonucleotides, that target the 5' untranslated region (UTR), the 3'UTR, the start, and/or the termination signal of an mRNA derived from a gene. In some embodiments the gene is a myostatin gene. Compositions may include multiple oligonucleotides directed against more than one gene. Compositions may include multiple oligonucleotides directed against multiple areas of multiple genes.
The compositions of the invention typically include more than about one, two, three, four, five, six, seven, eight, nine, 10, 15, 20, 30, 40, 50, 75, or 100 different oligonucleotides.
Preferably, the compositions of the invention include about two to about 20 different oligonucleotides. More preferably, the compositions of the invention include about two to about 15 different oligonucleotides, and most preferably, the compositions of the invention include
-21-WSGR Docket No. 31249-722.601 about two to about 10 different oligonucleotides; or alternatively, compositions of the invention include about two to about eight different oligonucleotides or about two to about six different oligonucleotides. In some embodiment, compositions of the invention include about two to about four different oligonucleotides. Thus, in some embodiments, the invention provides combinations of two or more oligonucleotides targeted to modulating expression of two or more different genes involved in muscle wasting conditions. Exemplary genes to which the antisense oligonucleotides may be directed are listed in Tables 1 and 2. In some embodiments, the invention provides combinations of two or more oligonucleotides, where the oligonucleotides are selected from the group consisting of antisense oligonucleotides, RNAi, ribozymes, and DNAzymes, that are targeted to modulating expression of two or more different genes involved in muscle wasting conditions, where the genes are selected from those listed in Tables 1 and 2.
In some embodiments, the invention provides RNAi to myostatin, myostatin receptors, and/or other genes involved in muscle wasting conditions. In some embodiments, the invention provides a combination of RNAis, where the RNAis are inhibitory to at least two of the genes listed in Tables 1 and 2. In some embodiments, the invention provides ribozymes to myostatin, myostatin receptors, and/or other genes involved in muscle wasting conditions.
In some embodiments, the invention provides a combination of ribozymes, where the ribozymes are inhibitory to at least two of the genes listed in Tables 1 and 2. In some embodiments, the invention provides DNAzymes to myostatin, myostatin receptors, and/or other genes involved in muscle wasting conditions. In some embodiments, the invention provides a combination of DNAzymes, where the DNAzymes are inhibitory to at least two of the genes listed in Tables 1 and 2.
In some embodiments, the invention provides one or more antisense oligonucleotides to myostatin. In some embodiments, the invention provides a combination of antisense oligonucleotides to myostatin that includes at least two different antisense oligonucleotides to myostatin. In some embodiments, the myostatin is selected from the group consisting of human, cow, pig, chicken, mouse, horse, dog, and fish myostatin. In some embodiments, the invention provides a combination of antisense oligonucleotides to different parts of the human myostatin gene transcript, including at least two antisense oligonucleotides targeted to portions of the transcript selected from the group consisting of the 5' UTR, the 3' UTR, the start, and the termination signal. In some embodiments, the invention provides a combination of antisense oligonucleotides to human myostatin, including at least two antisense oligonucleotides selected from the group consisting of SEQ ID NOS. 1- 191.
In some embodiments, the invention provides a composition that includes at least one antisense oligonucleotide targeted to myostatin and at least one antisense oligonucleotide
In some embodiments, the invention provides RNAi to myostatin, myostatin receptors, and/or other genes involved in muscle wasting conditions. In some embodiments, the invention provides a combination of RNAis, where the RNAis are inhibitory to at least two of the genes listed in Tables 1 and 2. In some embodiments, the invention provides ribozymes to myostatin, myostatin receptors, and/or other genes involved in muscle wasting conditions.
In some embodiments, the invention provides a combination of ribozymes, where the ribozymes are inhibitory to at least two of the genes listed in Tables 1 and 2. In some embodiments, the invention provides DNAzymes to myostatin, myostatin receptors, and/or other genes involved in muscle wasting conditions. In some embodiments, the invention provides a combination of DNAzymes, where the DNAzymes are inhibitory to at least two of the genes listed in Tables 1 and 2.
In some embodiments, the invention provides one or more antisense oligonucleotides to myostatin. In some embodiments, the invention provides a combination of antisense oligonucleotides to myostatin that includes at least two different antisense oligonucleotides to myostatin. In some embodiments, the myostatin is selected from the group consisting of human, cow, pig, chicken, mouse, horse, dog, and fish myostatin. In some embodiments, the invention provides a combination of antisense oligonucleotides to different parts of the human myostatin gene transcript, including at least two antisense oligonucleotides targeted to portions of the transcript selected from the group consisting of the 5' UTR, the 3' UTR, the start, and the termination signal. In some embodiments, the invention provides a combination of antisense oligonucleotides to human myostatin, including at least two antisense oligonucleotides selected from the group consisting of SEQ ID NOS. 1- 191.
In some embodiments, the invention provides a composition that includes at least one antisense oligonucleotide targeted to myostatin and at least one antisense oligonucleotide
-22-WSGR Docket No. 31249-722.601 targeted to at least one inon-myostatin gene selected from those listed in Tables 1 and 2. Some embodiments provide combinations of antisense oligonucleotides targeted to myostatin and to two or more other genes listed in Tables 1 and 2. In some embodiments, the invention provides a composition that includes at least one antisense oligonucleotide targeted to myostatin and at least one antisense oligonucleotide targeted to at least one of NFicB, Cox 2, myo D, a myostatin receptor (e.g., ARIib), and/or a gene product that converts inactive myostatin to an active form (e.g., TLL2).
In some embodiments, the invention provides a composition that includes at least one antisense oligonucleotide targeted to myostatin and at least one antisense oligonucleotide targeted to myo D. The myostatin and myoD are human in preferred embodiments.
In some embodiments, the invention provides a composition that includes at least one antisense oligonucleotide targeted to human myostatin, wherein the sequence of the oligonucleotide is selected from SEQ ID NOs 1-191.
Any of these combinations may include a plurality of antisense oligonucleotides targeted to one or more of the target genes, e.g., combinations of oligonucleotides targeted to the 5' UTR, the 3'UTR, the start signal, and/or the termination signal, of one or more of the target genes.
D. Pharmaceutical, nutritional supplement, and homeopathic compositions The invention further provides pharmaceutical, nutritional supplement, and homeopathic compositions.
Pharmaceutical compositions The present invention includes pharmaceutical compositions comprising at least about one oligonucleotide as described herein. In some embodiments, the invention provides pharmaceutical compositions that include at least two, three, four, five, six, seven, eight, nine, 10, 15, 20, 30, 40, 50, 75, or 100 different oligonucleotides, as described herein. In some embodiments, the oligonucleotides are antisense oligonucleotides, ribozymes, siRNA, DNAzymes, or a combination thereof. In some embodiments, one or more of the oligonucleotides is a modified oligonucleotide. In some embodiments, the pharmaceutical composition contains one or more antisense oligonucleotides, any or all of which may be modified as described herein. The pharmaceutical compositions further comprise a pharmaceutically suitable excipient.
As used herein, the term "pharmaceutical composition" refers to a therapeutic composition that is used to treat a particular disease or pathological disorder that is suitable for parenteral, oral or topical administration in humans.
The compositions containing the oligonucleotides of the invention in an admixture with a pharmaceutically acceptable carrier can be prepared according to known techniques. The carrier
In some embodiments, the invention provides a composition that includes at least one antisense oligonucleotide targeted to myostatin and at least one antisense oligonucleotide targeted to myo D. The myostatin and myoD are human in preferred embodiments.
In some embodiments, the invention provides a composition that includes at least one antisense oligonucleotide targeted to human myostatin, wherein the sequence of the oligonucleotide is selected from SEQ ID NOs 1-191.
Any of these combinations may include a plurality of antisense oligonucleotides targeted to one or more of the target genes, e.g., combinations of oligonucleotides targeted to the 5' UTR, the 3'UTR, the start signal, and/or the termination signal, of one or more of the target genes.
D. Pharmaceutical, nutritional supplement, and homeopathic compositions The invention further provides pharmaceutical, nutritional supplement, and homeopathic compositions.
Pharmaceutical compositions The present invention includes pharmaceutical compositions comprising at least about one oligonucleotide as described herein. In some embodiments, the invention provides pharmaceutical compositions that include at least two, three, four, five, six, seven, eight, nine, 10, 15, 20, 30, 40, 50, 75, or 100 different oligonucleotides, as described herein. In some embodiments, the oligonucleotides are antisense oligonucleotides, ribozymes, siRNA, DNAzymes, or a combination thereof. In some embodiments, one or more of the oligonucleotides is a modified oligonucleotide. In some embodiments, the pharmaceutical composition contains one or more antisense oligonucleotides, any or all of which may be modified as described herein. The pharmaceutical compositions further comprise a pharmaceutically suitable excipient.
As used herein, the term "pharmaceutical composition" refers to a therapeutic composition that is used to treat a particular disease or pathological disorder that is suitable for parenteral, oral or topical administration in humans.
The compositions containing the oligonucleotides of the invention in an admixture with a pharmaceutically acceptable carrier can be prepared according to known techniques. The carrier
-23-WSGR Docket No. 31249-722.601 may take a wide variety of forms depending on the form of preparation desired for administration, e.g., intravenous, oral, topical, aerosol (for topical or inhalation therapy), suppository, parenteral, or spinal injection. The excipient may contain any number of carriers. In the case of homeopathic pharmaceuticals the carriers would preferably be homeopathic carriers, e.g., homeopathic agents that may increase the efficacy of the homeopathic composition or help to alleviate symptoms associated with a physiological condition. In addition, the composition may contain stabilizers, preservatives, and other ingredients, preferably in amounts from about 0.5 to 2.0 percent by weight, provided they do not adversely affect the ability of the pharmacological composition to treat the physiological condition. It is well within the skill of one in the art to determine an appropriate mode of administration and to select an appropriate delivery system.
Administration of the composition will introduce the modified oligonucleotides to the individual in a diluted amount. Exemplary unit dosages for oral or topical administration may be more than about 0.01, 0.05, 0.1, 0.5, 1, or 5 mg/kg, and/or less than about 10, 5, 1, 0.5, 0.1, or 0.05 mg/kg. Exemplary unit dosage ranges may be between about 0.01 mg/kg and 10 mg/kg, or between about 0.010 mg/kg and 1.0 mg/kg, or between about 0.10 mg/kg and 1.0 mg/kg for a composition that contains a single oligonucleotide. In some embodiments, the oligonucleotide compositions of the present invention are administered at unit dosages of about 0.01 to about 100 ug per kg of body weight, or about 0.1 to about 100 ug per kg of body weight, or about 0.1 to about 10 ug per kg of body weight, or about 1 to about 10 ug per kg of body weight, or about 1 to about 5 ug per kg of body weight. When more than one oligonucleotide is present in the composition, dosages of each oligonucleotide may be in the latter ranges, or dosage of one or more of the oligonucleotides may be decreased, based on the expected overall effect of the combination. In some embodiments, unit dosages per single oligonucleotide are at or below 100 ug per kg of body weight, or at or below 10 ug per kg of body weight, or at or below I ug per kg of body weight, or at or below 0.1 ug per kg of body weight, or at or below 0.01 ug per kg of body weight.
When orally administered, one dosage unit may be administered once every 10, 9, 8, 7, 6, 5, 4, 3, 2, or one day, or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more than 10 times per day until relief is achieved or until the symptoms disappear or are satisfactorily attenuated. In some embodiments, one dosage unit is administered about once to about four times per day. In some embodiments,, a patient is instructed to orally take two to three dosage units per day. The dosage unit may be placed under the tongue of the patient or simply swallowed for such oral administration.
The pharmaceutical compositions of the present invention may be formulated for administration to humans and animals in liquid form, or in tablets, pills, granules, powders, or in
Administration of the composition will introduce the modified oligonucleotides to the individual in a diluted amount. Exemplary unit dosages for oral or topical administration may be more than about 0.01, 0.05, 0.1, 0.5, 1, or 5 mg/kg, and/or less than about 10, 5, 1, 0.5, 0.1, or 0.05 mg/kg. Exemplary unit dosage ranges may be between about 0.01 mg/kg and 10 mg/kg, or between about 0.010 mg/kg and 1.0 mg/kg, or between about 0.10 mg/kg and 1.0 mg/kg for a composition that contains a single oligonucleotide. In some embodiments, the oligonucleotide compositions of the present invention are administered at unit dosages of about 0.01 to about 100 ug per kg of body weight, or about 0.1 to about 100 ug per kg of body weight, or about 0.1 to about 10 ug per kg of body weight, or about 1 to about 10 ug per kg of body weight, or about 1 to about 5 ug per kg of body weight. When more than one oligonucleotide is present in the composition, dosages of each oligonucleotide may be in the latter ranges, or dosage of one or more of the oligonucleotides may be decreased, based on the expected overall effect of the combination. In some embodiments, unit dosages per single oligonucleotide are at or below 100 ug per kg of body weight, or at or below 10 ug per kg of body weight, or at or below I ug per kg of body weight, or at or below 0.1 ug per kg of body weight, or at or below 0.01 ug per kg of body weight.
When orally administered, one dosage unit may be administered once every 10, 9, 8, 7, 6, 5, 4, 3, 2, or one day, or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more than 10 times per day until relief is achieved or until the symptoms disappear or are satisfactorily attenuated. In some embodiments, one dosage unit is administered about once to about four times per day. In some embodiments,, a patient is instructed to orally take two to three dosage units per day. The dosage unit may be placed under the tongue of the patient or simply swallowed for such oral administration.
The pharmaceutical compositions of the present invention may be formulated for administration to humans and animals in liquid form, or in tablets, pills, granules, powders, or in
-24-WSGR Docket No. 31249-722.601 ointments, creams, injectables, or suppositories. Ointments and creams are impregnated with a low liquid potency or, sometimes, mother tinctures and are generally prescribed as specific remedies. Liquid compositions may be supplied in amber glass dropper bottles to protect them from light.
In preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like in the case of oral liquid preparations (such as, for example, suspensions, elixirs, and solutions); or carriers such as starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like in the case of oral solid preparations (such as, for example, powders, capsules and tablets).
For administration by injection, preparations may comprise an aqueous solution of a water soluble, or solubilized, and pharmacologically acceptable form of the nucleic acid in an appropriate liquid, e.g., water or saline solution. Injectable suspensions may also be prepared using appropriate liquid carriers, suspending agents, agents for adjusting the isotonicity, preserving agents, and the like. Actual methods for preparing administrable pharmacological compositions and adjustments necessary for administration to subjects will be known or apparent to those skilled in the art.
For topical administration, the carrier may take a wide variety of forms depending on the preparation, which may be a cream, dressing, gel, lotion, ointment, or liquid.
A surfactant can be included in the composition to provide deeper penetration of the ingredients.
Although natural surfactants are preferred, others such as isopropyl myristate can be used. In one embodiment, the composition is a cosmetic composition for topical administration to the skin.
As used herein, the term "cosmetic composition" refers to a composition that is applied topically to the skin to improve the appearance of the skin.
Aerosols are prepared by dissolving or suspending the nucleic acid in a propellant such as ethyl alcohol or in propellant and solvent phases. The pharmaceutical compositions for topical or aerosol form will generally contain from about 0.001 percent by weight (of the nucleic acid) to about 40 percent by weight, preferably about 0.02 percent to about 10 percent by weight, and more preferably about 0.05 percent to about 5 percent by weight depending on the particular form employed. Suppositories are prepared by mixing the nucleic acid with a lipid vehicle such as theobroma oil, cacao butter, glycerin, gelatin, or polyoxyethylene glycols.
The nucleic acid molecule(s) may be combined with a lipid, cationic lipid, or anionic lipid and the active agent delivered via a nucleic acid/lipid emulsion, or a liposomal suspension.
By assembling nucleic acid molecules into lipid-associated structures, the nucleic acid molecules may exhibit an increased half-life in vivo. Examples of suitable anionic lipids for use with RNA
In preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like in the case of oral liquid preparations (such as, for example, suspensions, elixirs, and solutions); or carriers such as starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like in the case of oral solid preparations (such as, for example, powders, capsules and tablets).
For administration by injection, preparations may comprise an aqueous solution of a water soluble, or solubilized, and pharmacologically acceptable form of the nucleic acid in an appropriate liquid, e.g., water or saline solution. Injectable suspensions may also be prepared using appropriate liquid carriers, suspending agents, agents for adjusting the isotonicity, preserving agents, and the like. Actual methods for preparing administrable pharmacological compositions and adjustments necessary for administration to subjects will be known or apparent to those skilled in the art.
For topical administration, the carrier may take a wide variety of forms depending on the preparation, which may be a cream, dressing, gel, lotion, ointment, or liquid.
A surfactant can be included in the composition to provide deeper penetration of the ingredients.
Although natural surfactants are preferred, others such as isopropyl myristate can be used. In one embodiment, the composition is a cosmetic composition for topical administration to the skin.
As used herein, the term "cosmetic composition" refers to a composition that is applied topically to the skin to improve the appearance of the skin.
Aerosols are prepared by dissolving or suspending the nucleic acid in a propellant such as ethyl alcohol or in propellant and solvent phases. The pharmaceutical compositions for topical or aerosol form will generally contain from about 0.001 percent by weight (of the nucleic acid) to about 40 percent by weight, preferably about 0.02 percent to about 10 percent by weight, and more preferably about 0.05 percent to about 5 percent by weight depending on the particular form employed. Suppositories are prepared by mixing the nucleic acid with a lipid vehicle such as theobroma oil, cacao butter, glycerin, gelatin, or polyoxyethylene glycols.
The nucleic acid molecule(s) may be combined with a lipid, cationic lipid, or anionic lipid and the active agent delivered via a nucleic acid/lipid emulsion, or a liposomal suspension.
By assembling nucleic acid molecules into lipid-associated structures, the nucleic acid molecules may exhibit an increased half-life in vivo. Examples of suitable anionic lipids for use with RNA
-25-WSGR Docket No. 31249-722.601 or DNA include, but are not limited to, cardiolipin, dimyristoyl, dipalmitoyl, or dioleoyl phosphatidyl choline or phosphatidyl glycerol, palmitoyloleoyl phosphatidyl choline or phosphatidyl glycerol, phosphatidic acid, lysophosphatidic acid, phosphatidyl serine, phosphatidyl inositol, and anionic forms of cholesterol.
Nutritional sLipplements As used herein, the term "nutritional supplement"
refers to a composition that is intended to supplement the diet. A nutritional supplement includes any dietary substance used in mammals to supplement the diet by increasing total dietary intake; or a concentrate, metabolite, constituent, extract, etc. Nutritional supplement includes any product that is intended for ingestion in tablet, capsule, powder, soft-gel, gel-cap, or liquid form. As used herein, the term "nutritional supplement" is used synonymously with the term "dietary supplement" and "nutraceutical" throughout the specification.
The present invention provides a composition which is useful as a nutritional supplement generally, and specifically for those suffering from a muscle wasting condition.
The nutritional supplement composition of the present invention include compositions with a single oligonucleotide and/or a combination of about two or more oligonucleotides. The oligonucleotides or combinations of oligonucleotides may be any of those described herein. The use of the nutritional supplement compositions of the present invention can be used to treat any of the aforementioned indications. These agents may be combined in an oral dosage with other well known nutritional supplements and/or non-flavonoid antioxidants (e.g., selenium, vitamin E
(tocopherol, particularly alpha-tocopherol), vitamin C (ascorbic acid) and coenzyme Q10).
Dietary fiber supplements may also be used in the composition.
Other additives may be incorporated in the nutritional supplement of the present invention. Such additives include minerals, (e.g., boron, etc. and trace metals such as zinc, magnesium, manganese, chromium, molybdenum, copper, iron, calcium, and potassium; and other micronutrients such as thiamine, riboflavin, niacin, pantothenic acid, pyridoxine, choline, biotin, inositol, para-aminobenzoic acid, vitamin D, vitamin K, vitamin A). In another embodiment of the invention a dietary fiber supplement such as oat bran or other natural fiber source may also be added to the composition.
Typically the nutritional supplement will further include a pharmaceutically acceptable carrier such as lactose, glucose, sucrose, corn starch, potato starch, cellulose acetate, ethyl cellulose, etc. Diluents and other additives such as one or more pharmaceutically acceptable binding agents, fillers, supports, thickening agents, taste-improving agents, coloring agents, preservatives, stabilizers, regulators, emulsifiers or mixtures thereof may be used depending on the form of the composition employed.
Nutritional sLipplements As used herein, the term "nutritional supplement"
refers to a composition that is intended to supplement the diet. A nutritional supplement includes any dietary substance used in mammals to supplement the diet by increasing total dietary intake; or a concentrate, metabolite, constituent, extract, etc. Nutritional supplement includes any product that is intended for ingestion in tablet, capsule, powder, soft-gel, gel-cap, or liquid form. As used herein, the term "nutritional supplement" is used synonymously with the term "dietary supplement" and "nutraceutical" throughout the specification.
The present invention provides a composition which is useful as a nutritional supplement generally, and specifically for those suffering from a muscle wasting condition.
The nutritional supplement composition of the present invention include compositions with a single oligonucleotide and/or a combination of about two or more oligonucleotides. The oligonucleotides or combinations of oligonucleotides may be any of those described herein. The use of the nutritional supplement compositions of the present invention can be used to treat any of the aforementioned indications. These agents may be combined in an oral dosage with other well known nutritional supplements and/or non-flavonoid antioxidants (e.g., selenium, vitamin E
(tocopherol, particularly alpha-tocopherol), vitamin C (ascorbic acid) and coenzyme Q10).
Dietary fiber supplements may also be used in the composition.
Other additives may be incorporated in the nutritional supplement of the present invention. Such additives include minerals, (e.g., boron, etc. and trace metals such as zinc, magnesium, manganese, chromium, molybdenum, copper, iron, calcium, and potassium; and other micronutrients such as thiamine, riboflavin, niacin, pantothenic acid, pyridoxine, choline, biotin, inositol, para-aminobenzoic acid, vitamin D, vitamin K, vitamin A). In another embodiment of the invention a dietary fiber supplement such as oat bran or other natural fiber source may also be added to the composition.
Typically the nutritional supplement will further include a pharmaceutically acceptable carrier such as lactose, glucose, sucrose, corn starch, potato starch, cellulose acetate, ethyl cellulose, etc. Diluents and other additives such as one or more pharmaceutically acceptable binding agents, fillers, supports, thickening agents, taste-improving agents, coloring agents, preservatives, stabilizers, regulators, emulsifiers or mixtures thereof may be used depending on the form of the composition employed.
-26-WSGR Docket No. 31249-722.601 In addition to providing the aforementioned compositions, the invention also includes a method for orally administering the nutritional supplement composition in dosages effective to aid in the maintenance and improvement of an individual's health. The supplement is preferably administered orally. Suitable forms for the nutritional supplement composition for oral administration include tablets, capsules, lozenges, syrups, granules, solutions and suspensions which contain unit doses of the supplement for administration once or several times a day. The nutritional supplement composition of the invention will typically be administered orally as a liquid, tablet or a capsule. Tablets, gel tabs, capsules, liquid and sustained release formulations can be formulated and prepared according to manufacturing techniques well known in the pharmaceutical industry and in a variety of dosage forms.
The amount of oligonucleotides of the invention that is contained in a nutritional supplement depends on the desired nutritional effect. As the modified oligonucleotides described herein are generally very well tolerated, large amounts may be given in the form of nutritional supplements. Exemplary dosages include about 0.1 mg/kg to 100 mg/kg per day, or between about 1.0 mg/kg and 50 mg/kg per day, or between about 1.0 and 20 mg/kg per day. As described above, when combinations of oligonucleotides are used, dosages of individual oligonucleotides in the nutritional supplement may be adjusted downward if necessary or desirable. Nutritional supplements of the invention may include modified oligonucleotides, as described herein.
Homeopathic compositions In some embodiments, the invention provides homeopathic compositions. Homeopathic compositions may be made by methods known in the art. One exemplary method of making a homeopathic composition comprises (i) triturating solid oligonucleotide of the invention in a 1/9 ratio with lactose to produce a 1X
solid and (ii) repeating the process until the desired attenuation is achieved. In a related vein, a method of making a homeopathic composition comprising (i) dissolving 1 part oligonucleotide of the invention by weight in liquid to produce ten volumes of liquid attenuation labeled 1X and optionally (ii) mixing 1 ml of the 1X attenuation with 9 ml of diluent to produce a lower concentration, is also addressed.
In some embodiments, the invention includes homeopathic compositions containing modified oligonucleotides. Any oligonucleotide or combination of oligonucleotides described herein may be used in the homeopathic compositions. In one embodiment, tablets for homeopathic use are preferably produced as placebo tablets that are then medicated by dripping or spraying liquid potencies onto the tablets in such a manner as to ensure a coefficient of impregnation of almost 100 percent. The placebo tablets are preferably formed by compression.
Pills or granules are preferably spherical in shape, of about 4 millimeters diameter and 3 to 5
The amount of oligonucleotides of the invention that is contained in a nutritional supplement depends on the desired nutritional effect. As the modified oligonucleotides described herein are generally very well tolerated, large amounts may be given in the form of nutritional supplements. Exemplary dosages include about 0.1 mg/kg to 100 mg/kg per day, or between about 1.0 mg/kg and 50 mg/kg per day, or between about 1.0 and 20 mg/kg per day. As described above, when combinations of oligonucleotides are used, dosages of individual oligonucleotides in the nutritional supplement may be adjusted downward if necessary or desirable. Nutritional supplements of the invention may include modified oligonucleotides, as described herein.
Homeopathic compositions In some embodiments, the invention provides homeopathic compositions. Homeopathic compositions may be made by methods known in the art. One exemplary method of making a homeopathic composition comprises (i) triturating solid oligonucleotide of the invention in a 1/9 ratio with lactose to produce a 1X
solid and (ii) repeating the process until the desired attenuation is achieved. In a related vein, a method of making a homeopathic composition comprising (i) dissolving 1 part oligonucleotide of the invention by weight in liquid to produce ten volumes of liquid attenuation labeled 1X and optionally (ii) mixing 1 ml of the 1X attenuation with 9 ml of diluent to produce a lower concentration, is also addressed.
In some embodiments, the invention includes homeopathic compositions containing modified oligonucleotides. Any oligonucleotide or combination of oligonucleotides described herein may be used in the homeopathic compositions. In one embodiment, tablets for homeopathic use are preferably produced as placebo tablets that are then medicated by dripping or spraying liquid potencies onto the tablets in such a manner as to ensure a coefficient of impregnation of almost 100 percent. The placebo tablets are preferably formed by compression.
Pills or granules are preferably spherical in shape, of about 4 millimeters diameter and 3 to 5
-27-WSGR Docket No. 31249-722.601 centigrams in weight. They are preferably prepared (from pure lactose) and medicated in the same manner as tablets. For example, solid oligonucleotides or combinations of oligonucleotides can be triturated (i.e., ground up) in a 1/9 ratio with lactose (1 gram of oligonucleotide+9 grams of lactose) to produce a 1X solid. The process is repeated (1 gram of that material plus 9 grams of lactose) until the desired attenuation is achieved.
For homeopathic compositions, the excipient may contain any number of carriers, and preferably homeopathic carriers, e.g., homeopathic agents that may increase the efficacy of the homeopathic composition or help to alleviate symptoms associated with a physiological condition. For example, oligonucleotides or combinations of oligonucleotides can be dissolved in a liquid 1 part by weight to produce a ten volumes of liquid attenuation labeled 1X. To produce lower dilutions 1 ml of the 1X attenuation is used (mixed thoroughly) with 9 ml of diluent to produce 2X. This process is repeated until the desired attenuation is achieved. A homeopathic carrier solution such as that described in U.S. Pat. No. 5,603,915 may be used for increasing the efficacy of the homeopathic agent. This carrier solution is sequentially subjected to an alternating current electrical treatment and a direct current electrical treatment, after which additional ingredients such as seawater, brain hormones, and biologically active enzymes are added. The electrical treatment of the carrier, along with the addition of homeopathically active substances, can be used to increase the efficacy of the homeopathic composition.
Alternatively, an electromagnetic carrier, such as described in U.S. Pat. No. 5,830,140 may be employed. For homeopathic preparations for example, oligonucleotides or combinations of oligonucleotides can be dissolved in a liquid 1 part by weight to produce a ten volumes of liquid attenuation labeled 1X. To produce lower dilutions 1 ml of the 1X attenuation is used (mixed thoroughly) with 9 ml of diluent to produce 2X. This process is repeated until the desired attenuation is achieved.
Typical homeopathic unit doses are given in Table 7.
II. Methods of the invention The invention further provides methods of treatment using the compositions of the invention. Methods include methods of modulating gene expression in cells by contacting cells with compositions of the invention. Methods also include methods of treatment of muscle wasting disorders or conditions. As used herein, the term "muscle wasting disorder," used synonymously herein with the term "muscle wasting condition," encompasses disorders or conditions in which muscle wasting is one of the primary symptoms, such as muscular dystrophy, spinal cord injury, neurodegenerative diseases, anorexia, sarcopenia, cachexia, muscular atrophy due to immobilization, prolonged bed rest, or weightlessness, and the like, as well as disorders in which an abnormally high fat-to-muscle ratio is implicated in a disease or
For homeopathic compositions, the excipient may contain any number of carriers, and preferably homeopathic carriers, e.g., homeopathic agents that may increase the efficacy of the homeopathic composition or help to alleviate symptoms associated with a physiological condition. For example, oligonucleotides or combinations of oligonucleotides can be dissolved in a liquid 1 part by weight to produce a ten volumes of liquid attenuation labeled 1X. To produce lower dilutions 1 ml of the 1X attenuation is used (mixed thoroughly) with 9 ml of diluent to produce 2X. This process is repeated until the desired attenuation is achieved. A homeopathic carrier solution such as that described in U.S. Pat. No. 5,603,915 may be used for increasing the efficacy of the homeopathic agent. This carrier solution is sequentially subjected to an alternating current electrical treatment and a direct current electrical treatment, after which additional ingredients such as seawater, brain hormones, and biologically active enzymes are added. The electrical treatment of the carrier, along with the addition of homeopathically active substances, can be used to increase the efficacy of the homeopathic composition.
Alternatively, an electromagnetic carrier, such as described in U.S. Pat. No. 5,830,140 may be employed. For homeopathic preparations for example, oligonucleotides or combinations of oligonucleotides can be dissolved in a liquid 1 part by weight to produce a ten volumes of liquid attenuation labeled 1X. To produce lower dilutions 1 ml of the 1X attenuation is used (mixed thoroughly) with 9 ml of diluent to produce 2X. This process is repeated until the desired attenuation is achieved.
Typical homeopathic unit doses are given in Table 7.
II. Methods of the invention The invention further provides methods of treatment using the compositions of the invention. Methods include methods of modulating gene expression in cells by contacting cells with compositions of the invention. Methods also include methods of treatment of muscle wasting disorders or conditions. As used herein, the term "muscle wasting disorder," used synonymously herein with the term "muscle wasting condition," encompasses disorders or conditions in which muscle wasting is one of the primary symptoms, such as muscular dystrophy, spinal cord injury, neurodegenerative diseases, anorexia, sarcopenia, cachexia, muscular atrophy due to immobilization, prolonged bed rest, or weightlessness, and the like, as well as disorders in which an abnormally high fat-to-muscle ratio is implicated in a disease or
-28-WSGR Docket No. 31249-722.601 pre-disease state, e.g., Type II diabetes or Syndrome X. Methods include allopathic, nutritional, and homeopathic therapeutic methods. Conventional means of diagnosis may be used to determine the presence and severity of these conditions. In addition, the invention provides methods of increasing muscle mass in animals where such an increase is desirable, e.g., in food animals such as mammals and fish. Also, the compositions described herein can be used as an adjunct to other therapies e.g. those employing other therapeutic agents, dietary modifications, physical therapy, and the like.
Atrophy of skeletal muscle occurs in muscles of adult animals as a result of lack of use, aging, starvation, and as a consequence of a variety of diseases, disorders, and conditions such as sepsis, muscular dystrophy, AIDS, aging, and cancer. The loss of muscle is generally characterized by decreases in protein content, force production, fatigue resistance, and muscle fiber diameter. These decreases can be attributed to both a decrease in protein synthesis and an increase in protein degradation. Muscle wasting and related conditions to which the compositions and methods of the invention are directed include any condition in which enhanced muscle growth, or diminishment of muscle wasting, produces a therapeutically or otherwise desirable result. Conditions include muscular dystrophy, sarcopenia, cachexia, diabetes mellitus, and the improvement of muscle mass where such improvement is ethical and desirable, e.g., in food animals.
Diseases associated with muscle wasting generally are associated with altered or abnormal expression of a number of genes compared to the normal state. As used herein, the term "abnormal," when used in reference to the amount, development or metabolic activity of muscle or adipose tissue, is used in a relative sense in comparison to an amount, development or metabolic activity that a skilled clinician or other relevant artisan would recognize as being normal or ideal. Such normal or ideal values are known to the clinician and are based on average values generally observed or desired in a healthy individual in a corresponding population. For example, in patients with obesity-related diseases such as diabetes, the clinician would know that obesity is associated with a body weight that is about twenty percent above an "ideal" weight range for a person of a particular height and body type. However, the clinician would recognize that a body builder is not necessarily obese simply by virtue of having a body weight that is twenty percent or more above the weight expected for a person of the same height and body type in an otherwise corresponding population. Similarly, the artisan would know that a patient presenting what appears to abnormally decreased muscle activity could be identified as having abnormal muscle development, for example, by subjecting the patient to various strength tests and comparing the results with those expected for an average healthy individual in a corresponding population.
Atrophy of skeletal muscle occurs in muscles of adult animals as a result of lack of use, aging, starvation, and as a consequence of a variety of diseases, disorders, and conditions such as sepsis, muscular dystrophy, AIDS, aging, and cancer. The loss of muscle is generally characterized by decreases in protein content, force production, fatigue resistance, and muscle fiber diameter. These decreases can be attributed to both a decrease in protein synthesis and an increase in protein degradation. Muscle wasting and related conditions to which the compositions and methods of the invention are directed include any condition in which enhanced muscle growth, or diminishment of muscle wasting, produces a therapeutically or otherwise desirable result. Conditions include muscular dystrophy, sarcopenia, cachexia, diabetes mellitus, and the improvement of muscle mass where such improvement is ethical and desirable, e.g., in food animals.
Diseases associated with muscle wasting generally are associated with altered or abnormal expression of a number of genes compared to the normal state. As used herein, the term "abnormal," when used in reference to the amount, development or metabolic activity of muscle or adipose tissue, is used in a relative sense in comparison to an amount, development or metabolic activity that a skilled clinician or other relevant artisan would recognize as being normal or ideal. Such normal or ideal values are known to the clinician and are based on average values generally observed or desired in a healthy individual in a corresponding population. For example, in patients with obesity-related diseases such as diabetes, the clinician would know that obesity is associated with a body weight that is about twenty percent above an "ideal" weight range for a person of a particular height and body type. However, the clinician would recognize that a body builder is not necessarily obese simply by virtue of having a body weight that is twenty percent or more above the weight expected for a person of the same height and body type in an otherwise corresponding population. Similarly, the artisan would know that a patient presenting what appears to abnormally decreased muscle activity could be identified as having abnormal muscle development, for example, by subjecting the patient to various strength tests and comparing the results with those expected for an average healthy individual in a corresponding population.
-29-WSGR Docket No. 31249-722.601 The compositions and methods of the invention target individual genes as well as, preferably, combinations of genes involved in these conditions. By employing combination compositions and therapies, reversible reactions may be avoided, and multiple pathways may be targeted simultaneously, leading to greater therapeutic effect than when single genes are targeted.
Toxicity, if any, may be lower by using combination therapies due to potentially lower amounts of each particular gene modulator being used. In addition, combinations of inhibitors, and combinations of targets in single genes are encompassed by the methods of the invention. In general, gene modulators used in compositions and methods of the invention are targeted at genes whose expression is desired to be inhibited; however, in some cases, some of the gene modulators used in embodiments of the invention may result in an increase in expression.
The invention also encompasses modified oligonucleotides for use in gene modulation, where the modified oligonucleotides are typically more stable and resistant to degradation than natural oligonucleotides; the modified oligonucleotides of the present invention are less toxic than many presently-used modifications (e.g., S-oligonucleotides), thus allowing dosages to be higher without adverse side effects.
A. Muscle wasting conditions The compositions and methods of the invention are of use in conditions where muscle wasting occurs, and/or where increased muscle mass and/or decreased fat mass is desirable.
Exemplary conditions of mammals that may be treated by the compositions and methods of the invention include, but are not limited to:
Muscular dystrophy The muscular dystrophies are a heterogeneous group of neuromuscular disorders. The diseases include the most common type, Duchenne muscular dystrophy (DMD), multiple types of limb girdle MD (LGMD) and other congenital MDs (CMD). Progressive muscle damage and muscle loss, tissue inflammation and replacement of healthy muscle with fibrous and fatty tissues result in muscle wasting in muscular dystrophy.
Extreme muscle loss is one of the most prominent signs of the disease, and leads to complications and symptoms, including death.
Sarcopenia Sarcopenia is the age-related loss of muscle mass, strength and function. It begins in the fourth decade of life and accelerates after the age of approximately 75 years. Many factors, including physical inactivity, motor-unit remodeling, decreased hormone levels, and decreased protein synthesis, may all contribute to sarcopenia. With the exception of physical inactivity, all of these may be subject to genetic control where gene modulation may be useful.
For example, the rate of muscle protein synthesis and protein breakdown affects sarcopenia. The balance of protein synthesis and breakdown determines the protein content in the body.
Toxicity, if any, may be lower by using combination therapies due to potentially lower amounts of each particular gene modulator being used. In addition, combinations of inhibitors, and combinations of targets in single genes are encompassed by the methods of the invention. In general, gene modulators used in compositions and methods of the invention are targeted at genes whose expression is desired to be inhibited; however, in some cases, some of the gene modulators used in embodiments of the invention may result in an increase in expression.
The invention also encompasses modified oligonucleotides for use in gene modulation, where the modified oligonucleotides are typically more stable and resistant to degradation than natural oligonucleotides; the modified oligonucleotides of the present invention are less toxic than many presently-used modifications (e.g., S-oligonucleotides), thus allowing dosages to be higher without adverse side effects.
A. Muscle wasting conditions The compositions and methods of the invention are of use in conditions where muscle wasting occurs, and/or where increased muscle mass and/or decreased fat mass is desirable.
Exemplary conditions of mammals that may be treated by the compositions and methods of the invention include, but are not limited to:
Muscular dystrophy The muscular dystrophies are a heterogeneous group of neuromuscular disorders. The diseases include the most common type, Duchenne muscular dystrophy (DMD), multiple types of limb girdle MD (LGMD) and other congenital MDs (CMD). Progressive muscle damage and muscle loss, tissue inflammation and replacement of healthy muscle with fibrous and fatty tissues result in muscle wasting in muscular dystrophy.
Extreme muscle loss is one of the most prominent signs of the disease, and leads to complications and symptoms, including death.
Sarcopenia Sarcopenia is the age-related loss of muscle mass, strength and function. It begins in the fourth decade of life and accelerates after the age of approximately 75 years. Many factors, including physical inactivity, motor-unit remodeling, decreased hormone levels, and decreased protein synthesis, may all contribute to sarcopenia. With the exception of physical inactivity, all of these may be subject to genetic control where gene modulation may be useful.
For example, the rate of muscle protein synthesis and protein breakdown affects sarcopenia. The balance of protein synthesis and breakdown determines the protein content in the body.
-30-WSGR Docket No. 31249-722.601 Research has consistently reported that muscle protein synthesis rates are lower in older adults when compared to younger adults. A decrease in muscle protein catabolism, effected by, e.g., gene modulation, could result in slowing or reversal of the loss of muscle mass.
Cachexia Cachexia is a condition associated with a variety of serious diseases, including cancer, AIDS, septicemia and congestive heart failure. Its major effect is massive loss of both adipose tissue and skeletal muscle, which is not caused by malnutrition.
Cachexia contributes to nearly one-third of all cancer deaths. In a process that is not yet well understood, cvtokines and tumor factors mediate wasting by suppressing muscle gene products. Cachectic factors have been shown to be selective in targeting the myosin heavy chain. In myotubes and mouse muscles, TNF-alpha plus IFN-gamma strongly reduced myosin expression through an RNA-dependent mechanism. Cachexia involves a complex disruption of several systems that also leads to anemia, insulin resistance, immunosuppression, and activation of an acute-phase response.
See, e.g., Acharyya et al., J. Clin. Invest. 114:370-78 (2004). The resulting progressive weakness can make patients with cancer more susceptible to the toxic effects of radiation and chemotherapy; many such patients die from cachexia-related syndromes, rather than from their tumors. Thus, the therapies of the present invention aimed at reversal of muscle wasting in cachexia are considered one promising approach to the condition.
Diabetes Diabetes mellitus is the most common of the serious metabolic diseases.
Obesity and a high body mass index (BMI) are risk factors for diabetes. Type I
diabetes, also known as juvenile-onset diabetes, results from destruction of the beta-cells of the pancreas, and generally requires exogenous administration of insulin for treatment. Type II
diabetes, also known as adult-onset diabetes, accounts for over 80% of the cases of diabetes, and its incidence is increasing at a rapid rate. In Type II diabetes, onset is generally gradual and is related to a number of factors, including obesity. Type II diabetes can often be ameliorated and in some cases controlled through lifestyle changes, which can include weight loss and increase in skeletal muscle mass. Studies in transgenic mice have shown that alterations in muscle mass and body composition induced by modulation of gene activity can alter the parameters associated with diabetes. For example, the dramatic reduction in overall fat accumulation in myostatin mutant mice as compared to wild type mice indicates that myostatin activity can be manipulated to treat or prevent obesity or type II diabetes. See, e.g., U.S. Patent No. 6,656,475, incorporated by reference herein in its entirety.
It will be appreciated by those of skill in the art that the above conditions are merely exemplary of conditions in which modulation of genes involved in muscle wasting by the compositions and methods of the invention may be effective. Other disorders that may be treated by modulation of gene expression involved in muscle wasting include, but are not limited
Cachexia Cachexia is a condition associated with a variety of serious diseases, including cancer, AIDS, septicemia and congestive heart failure. Its major effect is massive loss of both adipose tissue and skeletal muscle, which is not caused by malnutrition.
Cachexia contributes to nearly one-third of all cancer deaths. In a process that is not yet well understood, cvtokines and tumor factors mediate wasting by suppressing muscle gene products. Cachectic factors have been shown to be selective in targeting the myosin heavy chain. In myotubes and mouse muscles, TNF-alpha plus IFN-gamma strongly reduced myosin expression through an RNA-dependent mechanism. Cachexia involves a complex disruption of several systems that also leads to anemia, insulin resistance, immunosuppression, and activation of an acute-phase response.
See, e.g., Acharyya et al., J. Clin. Invest. 114:370-78 (2004). The resulting progressive weakness can make patients with cancer more susceptible to the toxic effects of radiation and chemotherapy; many such patients die from cachexia-related syndromes, rather than from their tumors. Thus, the therapies of the present invention aimed at reversal of muscle wasting in cachexia are considered one promising approach to the condition.
Diabetes Diabetes mellitus is the most common of the serious metabolic diseases.
Obesity and a high body mass index (BMI) are risk factors for diabetes. Type I
diabetes, also known as juvenile-onset diabetes, results from destruction of the beta-cells of the pancreas, and generally requires exogenous administration of insulin for treatment. Type II
diabetes, also known as adult-onset diabetes, accounts for over 80% of the cases of diabetes, and its incidence is increasing at a rapid rate. In Type II diabetes, onset is generally gradual and is related to a number of factors, including obesity. Type II diabetes can often be ameliorated and in some cases controlled through lifestyle changes, which can include weight loss and increase in skeletal muscle mass. Studies in transgenic mice have shown that alterations in muscle mass and body composition induced by modulation of gene activity can alter the parameters associated with diabetes. For example, the dramatic reduction in overall fat accumulation in myostatin mutant mice as compared to wild type mice indicates that myostatin activity can be manipulated to treat or prevent obesity or type II diabetes. See, e.g., U.S. Patent No. 6,656,475, incorporated by reference herein in its entirety.
It will be appreciated by those of skill in the art that the above conditions are merely exemplary of conditions in which modulation of genes involved in muscle wasting by the compositions and methods of the invention may be effective. Other disorders that may be treated by modulation of gene expression involved in muscle wasting include, but are not limited
-31-WSGR Docket No. 31249-722.601 to, spinal cord injury, neurodegenerative disorders, traumatic injury, congestive obstructive pulmonary disease (COPD), anorexia, AIDS, atrophy due to immobilization, bed rest, or weightlessness, and any other disorder in which there is a disruption of normal skeletal muscle mass or strength. In accordance with the present invention, genes whose expression is altered in these disorders, or whose modulation would achieve therapeutic benefit even if their expression is not directly altered, e.g., myostatin, myostatin regulatory elements, and the like, may be modulated to achieve muscle specific expression of a target gene to promote muscle growth and increase muscle mass for the treatment of a muscle associated disorder. Other genes that are abnormally expressed, or whose modulated expression promotes a therapeutic effect for the condition, may be separately or simultaneously modulated by the methods and compositions of the invention.
B. Gene targets for therapy Gene targets for therapy include, but are not limited to, those genes summarized in Tables 1 and 2, and described more fully below.
Myostatin Myostatin is a major gene involved in regulating muscle growth that may be involved, directly or indirectly, in almost every muscle wasting condition. As a secreted growth factor, myostatin acts as a negative regulator of skeletal muscle mass in mammals and other animals. Myostatin is almost exclusively expressed in the skeletal muscle lineage, where it negatively regulates myocyte differentiation/growth and determines muscle size. It is a member of the transforming growth factor 0 family and is expressed in both developing and adult muscles. During development, myostatin is initially expressed in the myotome layer of somites, which give rise to skeletal muscle. In adults, myostatin is expressed in all skeletal muscles. Mice lacking the myostatin gene have 25-30% increased muscle mass. See, e.g., McPherron et al., (1997) Nature, 387 (6628), 83-90. Individual muscles, such as the pectoralis and quadriceps, of myostatin mutant mice are 2-3-fold heavier than those of wild type mice. See, e.g., Whittemore et al. (2003) Biochem. Biophys. Res. Commun., 300(4), 965-971, and Grobet et al. (2003) Genesis, 35(4), 227-238.
This modulation occurs both in early development and in adults. Blockage of myostatin function in adult mice using a myostatin antibody or conditional knockout technology results in the increment of muscle mass. Like endocrine hormones, myostatin circulates in the serum in high amounts. An increased level of myostatin has been reported in disease conditions with muscle wasting. Thus, myostatin is regarded as a unique drug target and therapeutics that modulate skeletal muscle growth would be useful for disease conditions such as muscular dystrophy, sarcopenia, cachexia, diabetes, and similar muscle-wasting disorders.
B. Gene targets for therapy Gene targets for therapy include, but are not limited to, those genes summarized in Tables 1 and 2, and described more fully below.
Myostatin Myostatin is a major gene involved in regulating muscle growth that may be involved, directly or indirectly, in almost every muscle wasting condition. As a secreted growth factor, myostatin acts as a negative regulator of skeletal muscle mass in mammals and other animals. Myostatin is almost exclusively expressed in the skeletal muscle lineage, where it negatively regulates myocyte differentiation/growth and determines muscle size. It is a member of the transforming growth factor 0 family and is expressed in both developing and adult muscles. During development, myostatin is initially expressed in the myotome layer of somites, which give rise to skeletal muscle. In adults, myostatin is expressed in all skeletal muscles. Mice lacking the myostatin gene have 25-30% increased muscle mass. See, e.g., McPherron et al., (1997) Nature, 387 (6628), 83-90. Individual muscles, such as the pectoralis and quadriceps, of myostatin mutant mice are 2-3-fold heavier than those of wild type mice. See, e.g., Whittemore et al. (2003) Biochem. Biophys. Res. Commun., 300(4), 965-971, and Grobet et al. (2003) Genesis, 35(4), 227-238.
This modulation occurs both in early development and in adults. Blockage of myostatin function in adult mice using a myostatin antibody or conditional knockout technology results in the increment of muscle mass. Like endocrine hormones, myostatin circulates in the serum in high amounts. An increased level of myostatin has been reported in disease conditions with muscle wasting. Thus, myostatin is regarded as a unique drug target and therapeutics that modulate skeletal muscle growth would be useful for disease conditions such as muscular dystrophy, sarcopenia, cachexia, diabetes, and similar muscle-wasting disorders.
-32-WSGR Docket No. 31249-722.601 Recently, antibody mediated myostatin blockage in mdx mice was employed for the improvement of dystrophy. Blocking myostatin in mdx mice not only increased the number of normal muscle cells but also augmented muscle strength. The mechanism by which myostatin blockage resulted in the recovery of muscle function is not clear, but, without being limited by theory, it is proposed that balancing the muscle loss by wasting with increased muscle mass by myostatin blockage would be beneficial for dystrophic muscles. Since myostatin blockage is effective for increment of muscle mass even in adults, myostatin blockers are also promising as a treatment for dystrophy and other muscle wasting diseases.
In sarcopenia, serum myostatin increases in human aging associated with muscle wasting, and has been viewed as a biomarker of age associated sarcopenia. The human myostatin gene product is proposed to be a suppressor of skeletal muscle growth with advancing age. Thus, myostatin blockage would be beneficial for preventing sarcopenia.
In addition, even if myostatin is not directly implicated in a disorder, its modulation is useful in that it may serve as an alternative pathway for stimulating muscle growth, bypassing a pathway that may be blocked or modified in a particular disorder.
Myostatin receptors Signaling of myostatin is similar to that of activins and TGF-3. It efficiently binds the type II receptor ActRIIB and forms a heteromeric complex with the type I
receptor ALK4 or ALK5, which leads to phosphorylation of the members of Smad family to control gene transcription and mediates the effects of myostatin. Smads are a family of signaling molecules that transmit signals from cell surface receptors directly to the nucleus. In the nucleus, they regulate transcription by interacting with both DNA elements and transcriptional coactivators and corepressors. Smads binds numerous transcriptional regulators like p53, CBP
and the fos/jun family and are involved in cell-type specific gene expression.
Transcription factors Myogenic transcription factor MyoD is a putative regulator of the actions of myostatin. A family of transcription factors specifically expressed in the muscles, including myoD, myogenin, myf-5, and MRF-4/herculin/myf-6, have been cloned.
These factors are phosphorylated nuclear proteins containing a helix-loop-helix (bHLH) motif, as required for both dimerization and DNA binding, and are believed to be determinants of the cell-specific differentiation program. When one of these factors is introduced into non-myogenic cells, differentiation into mature muscle cells is initiated. The myoD family, a group of transcription factors, has been found to direct muscle formation, inhibit proliferation, activate differentiation and induce a contractile phenotype. While myoD and myf-5 are expressed within the proliferating myoblasts, myogenin and MRF-4 are not expressed until the myoblasts withdraw from the cell cycle in response to mitogen withdrawal. Based on these findings, it was
In sarcopenia, serum myostatin increases in human aging associated with muscle wasting, and has been viewed as a biomarker of age associated sarcopenia. The human myostatin gene product is proposed to be a suppressor of skeletal muscle growth with advancing age. Thus, myostatin blockage would be beneficial for preventing sarcopenia.
In addition, even if myostatin is not directly implicated in a disorder, its modulation is useful in that it may serve as an alternative pathway for stimulating muscle growth, bypassing a pathway that may be blocked or modified in a particular disorder.
Myostatin receptors Signaling of myostatin is similar to that of activins and TGF-3. It efficiently binds the type II receptor ActRIIB and forms a heteromeric complex with the type I
receptor ALK4 or ALK5, which leads to phosphorylation of the members of Smad family to control gene transcription and mediates the effects of myostatin. Smads are a family of signaling molecules that transmit signals from cell surface receptors directly to the nucleus. In the nucleus, they regulate transcription by interacting with both DNA elements and transcriptional coactivators and corepressors. Smads binds numerous transcriptional regulators like p53, CBP
and the fos/jun family and are involved in cell-type specific gene expression.
Transcription factors Myogenic transcription factor MyoD is a putative regulator of the actions of myostatin. A family of transcription factors specifically expressed in the muscles, including myoD, myogenin, myf-5, and MRF-4/herculin/myf-6, have been cloned.
These factors are phosphorylated nuclear proteins containing a helix-loop-helix (bHLH) motif, as required for both dimerization and DNA binding, and are believed to be determinants of the cell-specific differentiation program. When one of these factors is introduced into non-myogenic cells, differentiation into mature muscle cells is initiated. The myoD family, a group of transcription factors, has been found to direct muscle formation, inhibit proliferation, activate differentiation and induce a contractile phenotype. While myoD and myf-5 are expressed within the proliferating myoblasts, myogenin and MRF-4 are not expressed until the myoblasts withdraw from the cell cycle in response to mitogen withdrawal. Based on these findings, it was
-33-WSGR Docket No. 31249-722.601 demonstrated that myogenin and MRF-4 activate and maintain the expression of muscle-specific genes, while myoD and myf-5 are thought to play a role in the proliferation of myoblasts.
The dystrophin gene The compositions and methods of the invention may include a gene modulator, e.g., an antisense oligonucleotide, that causes a change in the mutation seen in Duchenne muscular dystrophy (DMD) to a in-frame mutation. DMD, the most severe form of the disease, results from an abnormality in exon 19 of the dystrophin gene, which causes an out-of-frame shift of the amino acids reading frame of dystrophin mRNA. In contrast, in Becker muscular dystrophy (BMD), a much milder form of the disease, the reading frame is kept intact (i.e., in-frame) in spite of a partial deletion present in the gene and a dystrophin protein therefore is synthesized, though it differs in size from wild dystrophin. If the abnormal reading frame shift of DMD is converted to an in-frame arrangement, then DMD is converted to BMD, and amelioration of the symptoms would be expected. Exon 19 skipping can be artificially induced by administering to the patient an antisense oligonucleotide against exon 19, thus, the reading frame could turn in-frame again because of the total loss of 330 nucleotides from the pre-mRNA
due to the loss of 242 nucleotides of exon 20 plus 88 nucleotides of exon 19.
It has been demonstrated that splicing out of exon 19 can be induced with an antisense oligonucleotide against exon 19 in the cells of a DMD patient having complete loss of exon 20 in mature dystrophin mRNA, and that the existing shift of the reading frame along the mature dystrophin mRNA can thereby be corrected, thus converting the dystrophin-negative cells to positive ones. Based on these results, antisense oligonucleotides targeted at parts of the dystrophin gene have been proposed as treatment of DMD. See, e.g., Japanese Laid-open Patent Application No. 11-140930, and U.S. Patent Nos. 6,727,355; and 6,653,467 all of which are incorporated herein by reference. Accordingly, the compositions and methods of the invention may include a gene modulator, e.g., an antisense oligonucleotide, that causes a change in the mutation seen in DMD to a in-frame mutation.
Genes involved in cachexia Various pathways and modulators may be involved in cachexia. The fever-producing cytokines released by inflammatory cells and tumor cells are believed to contribute to cachexia. In fact, tumor necrosis factor (TNF), or cachectin, produces a laboratory model of cachexia when given to experimental, laboratory animals.
Activins and myostatin are up-regulated in several types of cancer and infection, and could be therapeutic targets for cachexia. Myostatin has been shown to be involved in different types of cachexia.
Myostatin administration in vivo induces severe weight loss and decreased muscle mass. In addition, accelerated proteolysis in muscle in fasting or denervation atrophy can be due to activation of the nonlysosomal (cytosolic) ATP-ubiquitin-dependent proteolyte process. The proteins involved in this process are potential targets for gene modulators.
See, e.g., U.S. Patent
The dystrophin gene The compositions and methods of the invention may include a gene modulator, e.g., an antisense oligonucleotide, that causes a change in the mutation seen in Duchenne muscular dystrophy (DMD) to a in-frame mutation. DMD, the most severe form of the disease, results from an abnormality in exon 19 of the dystrophin gene, which causes an out-of-frame shift of the amino acids reading frame of dystrophin mRNA. In contrast, in Becker muscular dystrophy (BMD), a much milder form of the disease, the reading frame is kept intact (i.e., in-frame) in spite of a partial deletion present in the gene and a dystrophin protein therefore is synthesized, though it differs in size from wild dystrophin. If the abnormal reading frame shift of DMD is converted to an in-frame arrangement, then DMD is converted to BMD, and amelioration of the symptoms would be expected. Exon 19 skipping can be artificially induced by administering to the patient an antisense oligonucleotide against exon 19, thus, the reading frame could turn in-frame again because of the total loss of 330 nucleotides from the pre-mRNA
due to the loss of 242 nucleotides of exon 20 plus 88 nucleotides of exon 19.
It has been demonstrated that splicing out of exon 19 can be induced with an antisense oligonucleotide against exon 19 in the cells of a DMD patient having complete loss of exon 20 in mature dystrophin mRNA, and that the existing shift of the reading frame along the mature dystrophin mRNA can thereby be corrected, thus converting the dystrophin-negative cells to positive ones. Based on these results, antisense oligonucleotides targeted at parts of the dystrophin gene have been proposed as treatment of DMD. See, e.g., Japanese Laid-open Patent Application No. 11-140930, and U.S. Patent Nos. 6,727,355; and 6,653,467 all of which are incorporated herein by reference. Accordingly, the compositions and methods of the invention may include a gene modulator, e.g., an antisense oligonucleotide, that causes a change in the mutation seen in DMD to a in-frame mutation.
Genes involved in cachexia Various pathways and modulators may be involved in cachexia. The fever-producing cytokines released by inflammatory cells and tumor cells are believed to contribute to cachexia. In fact, tumor necrosis factor (TNF), or cachectin, produces a laboratory model of cachexia when given to experimental, laboratory animals.
Activins and myostatin are up-regulated in several types of cancer and infection, and could be therapeutic targets for cachexia. Myostatin has been shown to be involved in different types of cachexia.
Myostatin administration in vivo induces severe weight loss and decreased muscle mass. In addition, accelerated proteolysis in muscle in fasting or denervation atrophy can be due to activation of the nonlysosomal (cytosolic) ATP-ubiquitin-dependent proteolyte process. The proteins involved in this process are potential targets for gene modulators.
See, e.g., U.S. Patent
-34-WSGR Docket No. 31249-722.601 No. 5,972,636, which is incorporated herein by reference in its entirety. In fasting, the enhancement of muscle protein breakdown also requires glucocorticoids and low insulin and in febrile infections, requires interleukin-1 and TNF. A novel protein, cancer cachectic factor, also may be involved in the cachexia of, e.g., cancer, and presents another target for gene modulators as therapy. See, e.g., U.S. Patent No. 5,834,192, which is incorporated herein by reference in its entirety.
Diabetes Since proper skeletal muscle function is important for normal glucose homeostasis, loss of activity of myostatin not only increases muscle mass but also prevents an age-related increase in the total mass of adipose tissues. Myostatin-deficient mice showed a reduction in fat accumulation with increasing age. The activin-follistatin system was also shown to be involved in development of the pancreas. It was suggested that follistatin's modulation of the formation of the exocrine pancreas was by inhibiting activin-like signaling molecules.
Recently, using functional genomics tools, several secreted polypeptides with therapeutic applications in the treatment of diabetes, and BMP 9 were identified as potential inhibitors of glucose production and glycemia. Thus, in addition to adipocytokines such as leptin and adiponectin, multiple TGF-(3 family members including myostatin, activin and BMP 9 are involved in glucose homeostasis and diabetes. Obese and insulin resistant mice with myostatin KO have less fat accumulation, low blood glucose and low insulin than their counterparts with wild-type myostatin, which led to the suggestion that inhibition of myostatin may be a treatment for type 2 diabetes mellitus.
In some embodiments, the invention provides methods of modulating the expression of one or more genes in cells by contacting cells with compositions of the invention. In these methods, cells to be treated contain a polynucleotide encoding a gene product that is involved in a muscle-wasting condition, or in muscle growth or muscle growth inhibition.
Representative polynucleotides are shown in Tables 3, 4 and 5. The cell is contacted with any one of the compositions of oligonucleotides described herein for modulating expression of one or more polynucleotides. In some embodiments, the cell contains a polynucleotide encoding myostatin, myostatin transcription factor, myostatin activating protein, and/or myostatin receptor, and the composition with which the cell is contacted contains one or more oligonucleotides capable of modulating the expression of myostatin, myostatin transcription factor, myostatin activating protein, and/or myostatin receptor.
A method of the invention can be performed, for example, by contacting under suitable conditions a target cell and an oligonucleotide composition of the invention.
Suitable conditions can be provided by placing the cell, which can be an isolated cell or can be a component of a tissue or organ, in an appropriate culture medium, or by contacting the cell in situ in an
Diabetes Since proper skeletal muscle function is important for normal glucose homeostasis, loss of activity of myostatin not only increases muscle mass but also prevents an age-related increase in the total mass of adipose tissues. Myostatin-deficient mice showed a reduction in fat accumulation with increasing age. The activin-follistatin system was also shown to be involved in development of the pancreas. It was suggested that follistatin's modulation of the formation of the exocrine pancreas was by inhibiting activin-like signaling molecules.
Recently, using functional genomics tools, several secreted polypeptides with therapeutic applications in the treatment of diabetes, and BMP 9 were identified as potential inhibitors of glucose production and glycemia. Thus, in addition to adipocytokines such as leptin and adiponectin, multiple TGF-(3 family members including myostatin, activin and BMP 9 are involved in glucose homeostasis and diabetes. Obese and insulin resistant mice with myostatin KO have less fat accumulation, low blood glucose and low insulin than their counterparts with wild-type myostatin, which led to the suggestion that inhibition of myostatin may be a treatment for type 2 diabetes mellitus.
In some embodiments, the invention provides methods of modulating the expression of one or more genes in cells by contacting cells with compositions of the invention. In these methods, cells to be treated contain a polynucleotide encoding a gene product that is involved in a muscle-wasting condition, or in muscle growth or muscle growth inhibition.
Representative polynucleotides are shown in Tables 3, 4 and 5. The cell is contacted with any one of the compositions of oligonucleotides described herein for modulating expression of one or more polynucleotides. In some embodiments, the cell contains a polynucleotide encoding myostatin, myostatin transcription factor, myostatin activating protein, and/or myostatin receptor, and the composition with which the cell is contacted contains one or more oligonucleotides capable of modulating the expression of myostatin, myostatin transcription factor, myostatin activating protein, and/or myostatin receptor.
A method of the invention can be performed, for example, by contacting under suitable conditions a target cell and an oligonucleotide composition of the invention.
Suitable conditions can be provided by placing the cell, which can be an isolated cell or can be a component of a tissue or organ, in an appropriate culture medium, or by contacting the cell in situ in an
-35-WSGR Docket No. 31249-722.601 organism. For example, a medium containing the cell can be contacted with an oligonucleotide composition that, e.g., modulates expression of myostatin, myostatin signal transduction, myostatin receptors, myostatin transcription factors, myostatin-activating gene products, and the like. In general, the cell is a component of a tissue or organ in a subject, in which case contacting the cell can comprise administering the agent to the subject.
However, the cell also can be manipulated in culture, then can be maintained in culture, administered to a subject, or used to produce a transgenic nonhuman animal. The level of mRNA expression of the target gene in the cell, tissue, organ, or animal, may be assessed using techniques that are known in the art, including, but are not limited to, Northern or Western blot analysis of tissue samples obtained from the cell, tissue, organ, or animal in situ hybridization analysis, and RT-PCR.
Samples of cell, tissue, organ, or animal, may also be evaluated immunocytochemically using antibodies specific for the target gene product.
The present invention also provides methods, compositions, and kits for the treatment of animals. The term "animal" or "animal subject" as used herein includes humans as well as other mammals and non-mammals. The term "treating" and its grammatical equivalents as used herein include achieving a therapeutic benefit and/or a prophylactic benefit. By therapeutic benefit is meant eradication, amelioration, or prevention of the underlying disorder being treated. For example, in a diabetes patient, therapeutic benefit includes eradication or amelioration of the underlying diabetes, i.e., a return of blood sugar and blood insulin levels to normal or a trend toward normal. Also, a therapeutic benefit is achieved with the eradication, amelioration, or prevention of one or more of the physiological symptoms associated with the underlying disorder such that an improvement is observed in the patient, notwithstanding that the patient may still be afflicted with the underlying disorder. For example, administration of oligonucleotide compositions, described herein, to a patient suffering from muscular dystrophy, sarcopenia, spinal cord injury, neurodegenerative disease, anorexia, or cachexia, provides therapeutic benefit when an improvement is observed in the patient with respect muscular bulk, muscular strength, and the like. For prophylactic benefit, for example, the compositions of the invention may be administered to a patient at risk of developing a muscle wasting condition, for example, a patient undergoing prolonged bed rest, or to a patient reporting one or more of the physiological symptoms of a muscle wasting disorder, or suffering from a conditions that predisposes the patient to a muscle wasting disorder, even though a diagnosis of a muscle wasting disorder may not have been made. For example, the oligonucleotide compositions of the invention may be administered to a patient with cancer where cachexia has not been diagnosed.
In another example, compositions of the invention may be administered to a patient exhibiting Syndrome X
who does not yet exhibit clinical symptoms of diabetes such as resting blood glucose elevated
However, the cell also can be manipulated in culture, then can be maintained in culture, administered to a subject, or used to produce a transgenic nonhuman animal. The level of mRNA expression of the target gene in the cell, tissue, organ, or animal, may be assessed using techniques that are known in the art, including, but are not limited to, Northern or Western blot analysis of tissue samples obtained from the cell, tissue, organ, or animal in situ hybridization analysis, and RT-PCR.
Samples of cell, tissue, organ, or animal, may also be evaluated immunocytochemically using antibodies specific for the target gene product.
The present invention also provides methods, compositions, and kits for the treatment of animals. The term "animal" or "animal subject" as used herein includes humans as well as other mammals and non-mammals. The term "treating" and its grammatical equivalents as used herein include achieving a therapeutic benefit and/or a prophylactic benefit. By therapeutic benefit is meant eradication, amelioration, or prevention of the underlying disorder being treated. For example, in a diabetes patient, therapeutic benefit includes eradication or amelioration of the underlying diabetes, i.e., a return of blood sugar and blood insulin levels to normal or a trend toward normal. Also, a therapeutic benefit is achieved with the eradication, amelioration, or prevention of one or more of the physiological symptoms associated with the underlying disorder such that an improvement is observed in the patient, notwithstanding that the patient may still be afflicted with the underlying disorder. For example, administration of oligonucleotide compositions, described herein, to a patient suffering from muscular dystrophy, sarcopenia, spinal cord injury, neurodegenerative disease, anorexia, or cachexia, provides therapeutic benefit when an improvement is observed in the patient with respect muscular bulk, muscular strength, and the like. For prophylactic benefit, for example, the compositions of the invention may be administered to a patient at risk of developing a muscle wasting condition, for example, a patient undergoing prolonged bed rest, or to a patient reporting one or more of the physiological symptoms of a muscle wasting disorder, or suffering from a conditions that predisposes the patient to a muscle wasting disorder, even though a diagnosis of a muscle wasting disorder may not have been made. For example, the oligonucleotide compositions of the invention may be administered to a patient with cancer where cachexia has not been diagnosed.
In another example, compositions of the invention may be administered to a patient exhibiting Syndrome X
who does not yet exhibit clinical symptoms of diabetes such as resting blood glucose elevated
-36-WSGR Docket No. 31249-722.601 above the clinically accepted threshold value for diabetes. Thus, the method of treating of the present invention covers any treatment of symptoms of a disorder in an animal, preferably a mammal, particularly a human, and includes:
(a) preventing symptoms of a disorder from occurring in a subject that may be predisposed to a condition but has not yet been diagnosed as having it;
(b) inhibiting symptoms of a disorder (i.e., arresting its development); or (c) relieving symptoms of a disorder (i.e., ameliorating and/or causing regression of the condition); and/or (d) maintaining homeostasis (i.e., the normal balance of RNA or DNA in a subj ect).
One of ordinary skill will appreciate that, from a medical practitioner's or patient's perspective, virtually any alleviation or prevention of an undesirable symptom would be desirable.
The dosages of the oligonucleotide composition in animals will depend on the disease or condition being, treated, the route of administration, and the physical characteristics of the animal being treated, and whether the treatment is nutritional, allopathic, or homeopathic.
The compositions of the present invention are formulated to contain a "nutritionally effective" or "allopathically effective" or "homeopathically effective" amount of one or more nucleic acid molecules. As used herein, the term "nutritionally effective"
amount is meant to refer to an amount of a oligonucleotide composition that is non-toxic and greater than the minimum amount necessary to maintain a desired physiological effect. As used herein, the term "allopathically effective" amount is meant to refer to an amount of a oligonucleotide composition that is non-toxic and greater than the minimum amount necessary to produce a desired physiological effect. As used herein, the term "homeopathically effective"
amount is meant to refer to an amount of a oligonucleotide composition that is non-toxic and is the lowest amount necessary to provide a desired physiological effect. A homeopathic effect, in accordance with the present invention, is achieved by a dose of modified nucleic acid that will be effective in treating (i.e., relieving, ameliorating, or preventing) symptoms of a particular condition or disease. Such treatment may be prophylactic in nature (i.e., completely or partially preventing the future occurrence of a symptom) and/or it may be therapeutic in nature (i.e., providing a partial or complete cessation or amelioration of a symptom).
Accordingly, in embodiments wherein the treatment utilizes allopathically effective amounts of compositions, the oligonucleotide compositions of the present invention may be administered at a unit dosage more than about 0.01, 0.05, 0.1, 0.5, 1, or 5 mg/kg, and/or less than about 10, 5, 1, 0.5, 0.1, or 0.05 mg/kg. Exemplary unit dosage ranges may be between about
(a) preventing symptoms of a disorder from occurring in a subject that may be predisposed to a condition but has not yet been diagnosed as having it;
(b) inhibiting symptoms of a disorder (i.e., arresting its development); or (c) relieving symptoms of a disorder (i.e., ameliorating and/or causing regression of the condition); and/or (d) maintaining homeostasis (i.e., the normal balance of RNA or DNA in a subj ect).
One of ordinary skill will appreciate that, from a medical practitioner's or patient's perspective, virtually any alleviation or prevention of an undesirable symptom would be desirable.
The dosages of the oligonucleotide composition in animals will depend on the disease or condition being, treated, the route of administration, and the physical characteristics of the animal being treated, and whether the treatment is nutritional, allopathic, or homeopathic.
The compositions of the present invention are formulated to contain a "nutritionally effective" or "allopathically effective" or "homeopathically effective" amount of one or more nucleic acid molecules. As used herein, the term "nutritionally effective"
amount is meant to refer to an amount of a oligonucleotide composition that is non-toxic and greater than the minimum amount necessary to maintain a desired physiological effect. As used herein, the term "allopathically effective" amount is meant to refer to an amount of a oligonucleotide composition that is non-toxic and greater than the minimum amount necessary to produce a desired physiological effect. As used herein, the term "homeopathically effective"
amount is meant to refer to an amount of a oligonucleotide composition that is non-toxic and is the lowest amount necessary to provide a desired physiological effect. A homeopathic effect, in accordance with the present invention, is achieved by a dose of modified nucleic acid that will be effective in treating (i.e., relieving, ameliorating, or preventing) symptoms of a particular condition or disease. Such treatment may be prophylactic in nature (i.e., completely or partially preventing the future occurrence of a symptom) and/or it may be therapeutic in nature (i.e., providing a partial or complete cessation or amelioration of a symptom).
Accordingly, in embodiments wherein the treatment utilizes allopathically effective amounts of compositions, the oligonucleotide compositions of the present invention may be administered at a unit dosage more than about 0.01, 0.05, 0.1, 0.5, 1, or 5 mg/kg, and/or less than about 10, 5, 1, 0.5, 0.1, or 0.05 mg/kg. Exemplary unit dosage ranges may be between about
-37-WSGR Docket No. 31249-722.601 0.01 mg/kg and 10mg/kg, or between about 0.010 mg/kg and 1.0 mg/kg, or between about 0.10 mg/kg and 1.0 mg/kg for a composition that contains a single oligonucleotide.
In some embodiments, the oligonucleotide compositions of the present invention are administered at unit dosages of about 0.01 to about 100 ug per kgof body weight, or about 0.1 to about 100 ug per kg of body weight, or about 0.1 to about 10 ug per kg of body weight, or about 1 to about 10 ug per kg of body weight, or about 1 to about 5 ug per kg of body weight. When more than one oligonucleotide is present in the composition, dosages of each oligonucleotide may be in the latter ranges, or dosage of one or more of the oligonucleotides may be decreased, based on the expected overall effect of the combination. In some embodiments, unit dosages per single oligonucleotide are at or below 100 ug per kg of body weight, or at or below 10 ug per kg of body weight, or at or below 1 ug per kg of body weight, or at or below 0.1 ug per kg of body weight, or at or below 0.01 ug per kg of body weight.
When orally administered, one dosage unit may be administered once every 10, 9, 8, 7, 6, 5, 4, 3, 2, or one day, or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more than 10 times per day until relief is achieved or until the symptoms disappear or are satisfactorily attenuated. In some embodiments, one dosage unit is administered about once to about four times per day. In some embodiments,, a patient is instructed to orally take two to three dosage units per day. The dosage unit may be placed under the tongue of the patient or simply swallowed for such oral administration.
Modified oligonucleotides as described herein, e.g., achiral oligonucleotides of naturally occurring phosphodiester DNA and RNA linkages with 3' nuclease protection and sometimes also 5' nuclease protection, are not toxic, allowing a wide range of dosages to be possible with compositions of the present invention. For example, the dietary supplement recommendation for nucleic acids is 0.5 to 2.0 gm/day. Metabolites are naturally occurring compounds that occur in foods and as byproducts of cell catabolism. Furthermore, such compounds do not elicit an immune response. Accordingly, in some embodiments, dosages range from about 10 ug to 100 mg/kg/per day, or 0.01 gm to 10 gm/kg per day, or 0.01 to 1 gm/kg/day, or 0.01 to 0.1 gm/kg/day.
Homeopathic compositions typically employ substantially less nucleic acid than is employed in allopathic or nutritional compositions. Exemplary dosages to be employed in accordance with the present invention are described in Table 7. Furthermore, for homeopathic use, the oligonucleotide compositions of the present invention can be combined with any homeopathic drug and still elicit a therapeutic effect.
Oligonucleotide compositions of the present invention may be co-administered with other active pharmaceutical agents depending on the condition being treated.
Pharmaceutical agents useful in the treatment of muscle wasting disorders, their optimal dosages and routes of
In some embodiments, the oligonucleotide compositions of the present invention are administered at unit dosages of about 0.01 to about 100 ug per kgof body weight, or about 0.1 to about 100 ug per kg of body weight, or about 0.1 to about 10 ug per kg of body weight, or about 1 to about 10 ug per kg of body weight, or about 1 to about 5 ug per kg of body weight. When more than one oligonucleotide is present in the composition, dosages of each oligonucleotide may be in the latter ranges, or dosage of one or more of the oligonucleotides may be decreased, based on the expected overall effect of the combination. In some embodiments, unit dosages per single oligonucleotide are at or below 100 ug per kg of body weight, or at or below 10 ug per kg of body weight, or at or below 1 ug per kg of body weight, or at or below 0.1 ug per kg of body weight, or at or below 0.01 ug per kg of body weight.
When orally administered, one dosage unit may be administered once every 10, 9, 8, 7, 6, 5, 4, 3, 2, or one day, or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more than 10 times per day until relief is achieved or until the symptoms disappear or are satisfactorily attenuated. In some embodiments, one dosage unit is administered about once to about four times per day. In some embodiments,, a patient is instructed to orally take two to three dosage units per day. The dosage unit may be placed under the tongue of the patient or simply swallowed for such oral administration.
Modified oligonucleotides as described herein, e.g., achiral oligonucleotides of naturally occurring phosphodiester DNA and RNA linkages with 3' nuclease protection and sometimes also 5' nuclease protection, are not toxic, allowing a wide range of dosages to be possible with compositions of the present invention. For example, the dietary supplement recommendation for nucleic acids is 0.5 to 2.0 gm/day. Metabolites are naturally occurring compounds that occur in foods and as byproducts of cell catabolism. Furthermore, such compounds do not elicit an immune response. Accordingly, in some embodiments, dosages range from about 10 ug to 100 mg/kg/per day, or 0.01 gm to 10 gm/kg per day, or 0.01 to 1 gm/kg/day, or 0.01 to 0.1 gm/kg/day.
Homeopathic compositions typically employ substantially less nucleic acid than is employed in allopathic or nutritional compositions. Exemplary dosages to be employed in accordance with the present invention are described in Table 7. Furthermore, for homeopathic use, the oligonucleotide compositions of the present invention can be combined with any homeopathic drug and still elicit a therapeutic effect.
Oligonucleotide compositions of the present invention may be co-administered with other active pharmaceutical agents depending on the condition being treated.
Pharmaceutical agents useful in the treatment of muscle wasting disorders, their optimal dosages and routes of
-38-WSGR Docket No. 31249-722.60I
administration, are known in the art. Co-administration can include simultaneous administration of the two agents in the same dosage form, simultaneous administration in separate dosage forms, and separate administration. In addition, oligonucleotide compositions of the present invention may be used in conjunction with other therapies, such as dietary therapy, dietary supplementation, physical therapy, exercise, and the like, which are used in the treatment of the disorders described herein.
The oligonucleotide composition can be administered by injection, topically, orally, transdermally, or rectally. Preferably, the composition is administered orally. The oral form in which the oligonucleotide is administered can include powder, tablet, capsule, solution, or emulsion. The effective amount can be administered in a single dose or in a series of doses separated by appropriate time intervals, such as hours.
In some embodiments, one or more of the oligonucleotides comprises at least one modification according to the present invention. A preferred modification is the incorporation of at least about three to eight contiguous achiral intemucleoside phosphate linkages into the oligonucleotide backbone, or at least about nine to ten continuous achiral internucleoside phosphate linkages or at least about eleven to fifteen achiral intemucleoside phosphate linkages, or the entire oligonucleotide contains achiral internucleoside phosphate linkages. In some embodiments the oligonucleotide is 3' end-blocked.
The methods of the present invention can be used to treat disorders including, but not limited to, muscular dystrophy, spinal cord injuries, neurodegenerative diseases, atrophy due to immobilization, bed rest, or weightlessness, sarcopenia, cachexia, and diabetes. Table 6 lists the target genes or combinations of target genes that are preferably employed in preparation of gene-modulating compositions of use in remedies for the treatment of various symptoms and conditions. In Table 6, the use a combination of target genes is denoted by a"/" (for example, "A/B/C" denotes the combination of target genes A, B and C); where two or more different combinations are preferred, each such combination is presented on a separate line. The gene-modulating compositions targeted at the genes are usually used in a 1:1:1 ratio, but this can vary.
For example, in homeopathic treatments, a combination of 4X, 5X, and 6X
solutions may be used, which deviates from 1:1:1. Any other ratio of compositions may also be used in combinations, depending on the condition to be treated, the state of the subject, and other factors that are known in the art.
Preferably, animals, e.g., mammals, are treated using compositions of the present invention having agents with compositions containing nucleic acid molecules having a sequence appropriate for the particular animal. Targeted species include, but are not limited to birds, fish, and mammals (especially chickens, pigs, goats, sheep, cows, dogs, horses, cats, and most
administration, are known in the art. Co-administration can include simultaneous administration of the two agents in the same dosage form, simultaneous administration in separate dosage forms, and separate administration. In addition, oligonucleotide compositions of the present invention may be used in conjunction with other therapies, such as dietary therapy, dietary supplementation, physical therapy, exercise, and the like, which are used in the treatment of the disorders described herein.
The oligonucleotide composition can be administered by injection, topically, orally, transdermally, or rectally. Preferably, the composition is administered orally. The oral form in which the oligonucleotide is administered can include powder, tablet, capsule, solution, or emulsion. The effective amount can be administered in a single dose or in a series of doses separated by appropriate time intervals, such as hours.
In some embodiments, one or more of the oligonucleotides comprises at least one modification according to the present invention. A preferred modification is the incorporation of at least about three to eight contiguous achiral intemucleoside phosphate linkages into the oligonucleotide backbone, or at least about nine to ten continuous achiral internucleoside phosphate linkages or at least about eleven to fifteen achiral intemucleoside phosphate linkages, or the entire oligonucleotide contains achiral internucleoside phosphate linkages. In some embodiments the oligonucleotide is 3' end-blocked.
The methods of the present invention can be used to treat disorders including, but not limited to, muscular dystrophy, spinal cord injuries, neurodegenerative diseases, atrophy due to immobilization, bed rest, or weightlessness, sarcopenia, cachexia, and diabetes. Table 6 lists the target genes or combinations of target genes that are preferably employed in preparation of gene-modulating compositions of use in remedies for the treatment of various symptoms and conditions. In Table 6, the use a combination of target genes is denoted by a"/" (for example, "A/B/C" denotes the combination of target genes A, B and C); where two or more different combinations are preferred, each such combination is presented on a separate line. The gene-modulating compositions targeted at the genes are usually used in a 1:1:1 ratio, but this can vary.
For example, in homeopathic treatments, a combination of 4X, 5X, and 6X
solutions may be used, which deviates from 1:1:1. Any other ratio of compositions may also be used in combinations, depending on the condition to be treated, the state of the subject, and other factors that are known in the art.
Preferably, animals, e.g., mammals, are treated using compositions of the present invention having agents with compositions containing nucleic acid molecules having a sequence appropriate for the particular animal. Targeted species include, but are not limited to birds, fish, and mammals (especially chickens, pigs, goats, sheep, cows, dogs, horses, cats, and most
-39-WSGR Docket No. 31249-722.601 preferably, humans). One of skill in the art can determine if a particular therapeutic course of treatment is successful by several methods known to those of skill in the art, including muscle fiber analysis or biopsy.
In a further aspect, the invention provides methods of increasing muscle mass of an animal where such an increase is desirable, e.g., in food or non-human sport animals, by administering to the animal an oligonucleotide composition of the invention, e.g., to modulate the expression of the myostatin gene. These methods produce animals having increased muscle and protein content, and, when the animals are used for food, also advantageously the muscles have reduced fat content. Oligonucleotide-based compositions as described herein that directly or indirectly regulate the expression of the myostatin region may be used to reduce expression of the myostatin gene product. Such oligonucleotide compositions may be administered to a livestock animal, including but not limited to cattle, sheep, pig, turkey, chicken, and fish, or to companion animals, particularly cats and dogs, to result in the decreased expression of myostatin in the animal and consequent higher than normal levels of muscle tissue, preferably without increased fat and/or cholesterol levels. A polynucleotide encoding a promyostatin or myostatin, or myostatin transcription factor, receptor, signal transduction factor, myostatin activating gene product can be derived from any organism where increased muscle mass may be desirable, preferably a food, sport or research animal, including, for example, mouse, rat, cow, pig, chicken, turkey, zebrafish, salmon, finfish, other aquatic organisms and other species. Examples of aquatic organisms include those belonging to the class Piscina, such as trout, char, ayu, carp, crucian carp, goldfish, roach, whitebait, eel, conger eel, sardine, flying fish, sea bass, sea bream, parrot bass, snapper, mackerel, horse mackerel, tuna, bonito, yellowtail, rockfish, fluke, sole, flounder, blowfish, filefish; those belonging to the class Cephalopoda, such as squid, cuttlefish, octopus; those belonging to the class Pelecypoda, such as clams (e.g., hardshell, Manila, Quahog, Surf, Soft-shell); cockles, mussels, periwinkles; scallops (e.g., sea, bay, calloo); conch, snails, sea cucumbers; ark shell; oysters (e.g., C. virginica, Gulf, New Zealand, Pacific); those belonging to the class Gastropoda such as turban shell, abalone (e.g. green, pink, red); and those belonging to the class Crustacea such as lobster, including but not limited to Spiny, Rock, and American; prawn; shrimp, including but not limited to M. rosenbergii, P.
styllrolls, P. indicus, P.
jeponious, P. monodon, P. vannemel, M. ensis, S. melantho, N. norvegious, cold water shrimp;
crab, including, but not limited to, Blue, rook, stone, king, queen, snow, brown, dungeness, Jonah, Mangrove, soft-shelled; squilla, krill, langostinos; crayfish/crawfish, including, but not limited, to Blue, Marron, Red Claw, Red Swamp, Soft-shelled, white; Annelida;
Chordata, including, but not limited to, reptiles such as alligators and turtles;
Amphibia, including frogs;
and Echinodermata, including, but not limited to, sea urchins.
In a further aspect, the invention provides methods of increasing muscle mass of an animal where such an increase is desirable, e.g., in food or non-human sport animals, by administering to the animal an oligonucleotide composition of the invention, e.g., to modulate the expression of the myostatin gene. These methods produce animals having increased muscle and protein content, and, when the animals are used for food, also advantageously the muscles have reduced fat content. Oligonucleotide-based compositions as described herein that directly or indirectly regulate the expression of the myostatin region may be used to reduce expression of the myostatin gene product. Such oligonucleotide compositions may be administered to a livestock animal, including but not limited to cattle, sheep, pig, turkey, chicken, and fish, or to companion animals, particularly cats and dogs, to result in the decreased expression of myostatin in the animal and consequent higher than normal levels of muscle tissue, preferably without increased fat and/or cholesterol levels. A polynucleotide encoding a promyostatin or myostatin, or myostatin transcription factor, receptor, signal transduction factor, myostatin activating gene product can be derived from any organism where increased muscle mass may be desirable, preferably a food, sport or research animal, including, for example, mouse, rat, cow, pig, chicken, turkey, zebrafish, salmon, finfish, other aquatic organisms and other species. Examples of aquatic organisms include those belonging to the class Piscina, such as trout, char, ayu, carp, crucian carp, goldfish, roach, whitebait, eel, conger eel, sardine, flying fish, sea bass, sea bream, parrot bass, snapper, mackerel, horse mackerel, tuna, bonito, yellowtail, rockfish, fluke, sole, flounder, blowfish, filefish; those belonging to the class Cephalopoda, such as squid, cuttlefish, octopus; those belonging to the class Pelecypoda, such as clams (e.g., hardshell, Manila, Quahog, Surf, Soft-shell); cockles, mussels, periwinkles; scallops (e.g., sea, bay, calloo); conch, snails, sea cucumbers; ark shell; oysters (e.g., C. virginica, Gulf, New Zealand, Pacific); those belonging to the class Gastropoda such as turban shell, abalone (e.g. green, pink, red); and those belonging to the class Crustacea such as lobster, including but not limited to Spiny, Rock, and American; prawn; shrimp, including but not limited to M. rosenbergii, P.
styllrolls, P. indicus, P.
jeponious, P. monodon, P. vannemel, M. ensis, S. melantho, N. norvegious, cold water shrimp;
crab, including, but not limited to, Blue, rook, stone, king, queen, snow, brown, dungeness, Jonah, Mangrove, soft-shelled; squilla, krill, langostinos; crayfish/crawfish, including, but not limited, to Blue, Marron, Red Claw, Red Swamp, Soft-shelled, white; Annelida;
Chordata, including, but not limited to, reptiles such as alligators and turtles;
Amphibia, including frogs;
and Echinodermata, including, but not limited to, sea urchins.
-40-WSGR Docket No. 31249-722.601 Methods for increasing muscle mass in an animal where such increase is desirable are essentially the same as those used in treating disorders. Dosages, routes of administration, and durations of treatment may be adjusted as desired to produce the optimum development and timing of development, as appropriate for the use of the animal.
Table 1:Exemplary human target genes involved in muscle wasting conditions Genes Accession Number Myostatin AF104922 MyoD NM002478 ARIIb NM001106 IL6R NM000565&NM181359 Bcl-3 NM005178 FOXO-3 NM001455&NM201559 E3a1 haIl AY061884 Nfkb-1 NM003998 ILlb NM000576 NF-xB M62399&L19067 TNF-a NM000594 Caspase-3 NM004346 Cas ase-1 NM033292 Atro in-1 NM058229&NM148177 Smad-2 AF027964
Table 1:Exemplary human target genes involved in muscle wasting conditions Genes Accession Number Myostatin AF104922 MyoD NM002478 ARIIb NM001106 IL6R NM000565&NM181359 Bcl-3 NM005178 FOXO-3 NM001455&NM201559 E3a1 haIl AY061884 Nfkb-1 NM003998 ILlb NM000576 NF-xB M62399&L19067 TNF-a NM000594 Caspase-3 NM004346 Cas ase-1 NM033292 Atro in-1 NM058229&NM148177 Smad-2 AF027964
-41-WSGR Docket No. 31249-722.601 Table 2: Exemplary animal target genes involved in muscle growth and develo ment Genes Accession Number Myostatin (Cow) NM001001525 Myostatin (Horse) AB033541 Myostatin (sheep) AF019622 Myostatin (goat) AY436347 Myostatin (Rabbit) AY169410 Myostatin (Pig) NM214435&AF033855 Myostatin (Chicken) AF019621&AF346599 Myostatin (Dog) AY367768 Myostatin (Fish) AY825248 Myostatin (Mouse) NM01834 TLII (mouse) AF073526 AcRIIB (mouse) NM007397 M oDl (mouse) NM010866 Atrogin-1 (mouse) AF441120 E3a1 ha-II (mouse) XM358323 Foxo3 (mouse) NM019740 Foxol (mouse) NM019739 MuRF 1 (mouse) AF294790 Caspase3 (mouse) NM009810 NFkB (mouse) NM003998 TNF-alpha (mouse) NM013693 TNF-R1 (mouse) NM011609 Cas ase-1 (mouse) BC008152 TACE (mouse) AB021709 IL-lb (mouse) NM008361 IL-6 (mouse) NM031168 MMP2 (mouse) NM008610
-42-WSGR Docket No. 31249-722.601 p65 (mouse) M61909 IL-6R (mouse) X53802 Smad2 (mouse) NM010754 Cathepsin-B (mouse) BC006656 Table 3: Antisense oligonucleotides targeted at human genes involved in muscle wastin Genes Accession number Antisense oligonucleotide sequences Se ID#
'-TgCCACACCA T AATCT-3' 1 Myostatin AF104922 5 '- CA TTTTTgCATgATTTTAA-3' 2 5'-TAAATCTCAT AgCACCC-3' 3 5 '-CA A A T CC AACT-3' 4 5 '-T C C CAC TCCT -3' 5 MyoD NM002478 5 '-A TA CTCCATATCCT -3' 6 5'-AgAgCACCT TATATCg-3' 7 5 '-CA C CC TCAT TTC-3' 8 ARIlb NM001106 5 '- g Tg CTCgTACgT AC-3' 9 5 '-T TCCT CTTA AT C-3' 10 5 '- C C CCCCCT TCTTC-3' 11 5 '-A A TT C T CAC A-3' 12 5 '- gCAT TggC C C-3' 13 5 '-TCCCA ggCT T CA A-3' 14 5 '-A CCC AA CA ATAC g-3' 15 5 '-TCAT ATTCTT C ACT-3' 16 5'-CAT ATTCTT CgACT -3' 17 5 '-CCACT CgACTTTCAT -3' 18 5 '-TCA C ACACAA T C-3' 19 5 '-CTTCA C ACACAA AT -3' 20 TACE NM003183 5'-TTCTACC CCA CTC A-3' 21 5 '-ACT CCTCAT TTCCC -3' 22 5'-CCTCATgTTCCC CCCC-3' 23
'-TgCCACACCA T AATCT-3' 1 Myostatin AF104922 5 '- CA TTTTTgCATgATTTTAA-3' 2 5'-TAAATCTCAT AgCACCC-3' 3 5 '-CA A A T CC AACT-3' 4 5 '-T C C CAC TCCT -3' 5 MyoD NM002478 5 '-A TA CTCCATATCCT -3' 6 5'-AgAgCACCT TATATCg-3' 7 5 '-CA C CC TCAT TTC-3' 8 ARIlb NM001106 5 '- g Tg CTCgTACgT AC-3' 9 5 '-T TCCT CTTA AT C-3' 10 5 '- C C CCCCCT TCTTC-3' 11 5 '-A A TT C T CAC A-3' 12 5 '- gCAT TggC C C-3' 13 5 '-TCCCA ggCT T CA A-3' 14 5 '-A CCC AA CA ATAC g-3' 15 5 '-TCAT ATTCTT C ACT-3' 16 5'-CAT ATTCTT CgACT -3' 17 5 '-CCACT CgACTTTCAT -3' 18 5 '-TCA C ACACAA T C-3' 19 5 '-CTTCA C ACACAA AT -3' 20 TACE NM003183 5'-TTCTACC CCA CTC A-3' 21 5 '-ACT CCTCAT TTCCC -3' 22 5'-CCTCATgTTCCC CCCC-3' 23
-43-WSGR Docket No. 31249-722.601 '-ACTAAATTA CACTCT T-3' 24 5 '-CA TT A gTT ACT-3' 25 TNF-R1 NM001065 5'- CCCAT CCA ACA CTA-3' 26 5 -CgCA CCTCATCT A-3' 27 5 '-TCCCTCT CCC CTCA-3' 28 IL6R NM000565&NM181359 5 '-CC AC CCA CAT CTT-3' 29 5 '-CATTCT g AA AA TA-3' 30 5 '-CA CCTCCAgCCACC CC-3' 31 MMP2 NM004530 5'- CCTCCATC TA C CTC-3' 32 5 '- CA CCTA CCA TC gA-3' 33 5'- CCgCTTgCTCTCCCCA-3' 34 5 '-A A A AAC CA C-3' 35 5 '-CTC gCCAT T ACCCC-3' 36 5 '-ACCCTCA CCT ACACCC-3' 37 5 '- C CATCg g CAT -3' 38 Bcl-3 NM005178 5'-gCCCCCCCATCCCCCTCA-3' 39 5 '- g A AC T AC C-3' 40 FOXO-3 NM001455&NM201559 5 '-CATCTTC CC CCC C-3' 41 5 '-CCTTCA CCT CACCCA-3' 42 5 '-CAATCA TCCC gCC -3' 43 E3alphall AY061884 5 '-TCCTCCCCAgC CTACC -3' 44 5 '-CTCTa CTCC ACgCCAT-3' 45 E3a1 halI AY061884 5 '-TT T T CAATAATTA-3' 46 5'-TCTC CTCACTCTCTCAC-3' 47 5 '-g AA CAg g AAgC-3' 48 Nfkb-1 NM003998 5 '- C C C gAg gAAgC-3' 49 5'-CTgCCATTCT AA CC -3' 50 5'-gAAATT TCA CAg CTA-3' 51 ILlb NM000576 5 '- AgAATCCCA A CA CC-3' 52 5 '-CCAT CT CTTCA ACA-3' 53
-44-WSGR Docket No. 31249-722.601 '- TACA CTCTCTTTA -3' 54 5 '-A A C Cg CC TCAT g-3' 55 NF-IL6 M83667 5 '-g AA CAg AA C-3' 56 5 '-CCTTTTCTA CCCCG -3' 57 5 '- AACA TTCgTCCAT -3' 58 5 '-A CCATTCGCC AATTC-3' 59 NF-KB M62399&L19067 5'-gT CACTACA AC A CC-3' 60 5 '-CT CCATTCT AA CC -3' 61 5 '- CCCA CT C ACCCgg-3' 62 5 '- TCT Ta TT CTT-3' 63 5 '-CCA g A A A T-3' 64 TNF-a NM000594 5' CTCAT T TCCTTTCC-3' 65 5 '-CAT CTTTCA TgCTCAT-3' 66 5'- T TTC TCCTCCTCAC-3' 67 5 '-A gA CC C TCT CACT-3' 68 5'-TTCTACAACC CCTCACA-3' 69 Caspase-3 NM004346 5'-TCTCCAT ATACCTTTA-3' 70 5'-ACCAACCATTTCTTTA T-3' 71 5'-ACCAACCATTTCTTTA T-3' 72 Caspase- 1 NM033292 5 '-TATTTTAAT TCCTg A-3' 73 Atro in-1 NM058229&NM148177 5 '-g AT g A C CC-3' 74 5 '- AATg CAT CACC C-3' 75 Atrogin-1 NM058229&NM 148177 5'-TTCTACAACC CCTCACA-3' 76 5 '-T TATC AACCTCCC C-3' 77 5 '-gAC ACAT TTCTTACCA-3' 78 Smad-2 AF027964 5 '-gCAA TggAC ACAT T-3' 79 5 '-TTTAT ACAT CTT TT A C-3' 80 5'-T T AA CTTTAT ACA-3' 81 PIF AY90150 5 '-CTgT T CT gA T g T-3' 82 5 '-AT AACCTCAT CTTCT -3' 83
-45-WSGR Docket No. 31249-722.601 5'-TCTCCTTACAgCTATA T-3' 84 '-CTCTTTC TTCCC gT -3' 85 IL-6 NM000600 5 '-AAG A TTCATA CTgg -3' 86 5'-CCAT CTACATTT CC A-3' 87 Table 4: Antisense oligonucleotide sequences targeted at animal genes involved in muscle 5 growth and development Gene Accession number Antisense oligonucleotide sequences (5'-3') SeqID#
CA ATCC gACA CAAATgC 88 CAT'1"TTT"I'CTTACACCTCAC 90 CT CCATCCA A CCACC gA 92 Myostatin (chicken) AF019621 &AF346599 TCTgCTTCCAC TACAA CAT 93 CTT TTCCAg C CA TTT C 94 T CA T A A CTTTg T 95 Ca ACTCC Ta CATT T A 97 Myostatin (chicken) AF019621&AF346599 Ta A CTAAACTTAAAgAAgC 98 CC TT Ta TTTTT ACTT 99 TgTTT A CCAATTTT CA C 101 gTgTCTgTAACTCTgACCTCT 103 C gTAgC ACAACATCg A 104 AATTC CATTCTCC AgCAg 106 gCCTgCT AgCCTCT TT 107
CA ATCC gACA CAAATgC 88 CAT'1"TTT"I'CTTACACCTCAC 90 CT CCATCCA A CCACC gA 92 Myostatin (chicken) AF019621 &AF346599 TCTgCTTCCAC TACAA CAT 93 CTT TTCCAg C CA TTT C 94 T CA T A A CTTTg T 95 Ca ACTCC Ta CATT T A 97 Myostatin (chicken) AF019621&AF346599 Ta A CTAAACTTAAAgAAgC 98 CC TT Ta TTTTT ACTT 99 TgTTT A CCAATTTT CA C 101 gTgTCTgTAACTCTgACCTCT 103 C gTAgC ACAACATCg A 104 AATTC CATTCTCC AgCAg 106 gCCTgCT AgCCTCT TT 107
-46-WSGR Docket No. 31249-722.601 TACAgCATgTTTATAggggAC 108 ACgATCTACAACCATggCTgg 109 TCATgAgCACCCgCAACgATC 110 TCTCACgTCAgCCAAAATTCA 111 T CCT CACT TCT AgAgAC 112 T CT'TI T A TAAC CCAA C 113 CATA ATTT CAgTTTTTgCA 116 TCA ATCCACg ACCA CAA 117 ACATgCATTACACAgCCCCTC 118 Myostatin (pig) NM214435&AF033855 TCCA CgAA TTTACT A 119 TTCcAA A CCATCACT CT 121 A AA ATCA ACTCTgTA C 122 TCTTGAC TCTCAgATATA 124 Ca TgCCT g TTCAT TCAA 126 ggATTCAgCCCATCTTCTCCT 129 gAgTgCTCATCACAgTCgAgT 130 Myostatin (pig) NM214435&AF033855 T CAATAATCCA TCCCATCC 131 ACAA AT A T TgA TAT 132 ACCAT gCT AATTTTCCCA 134 Myostatin (cow) NM001525 _gAgTAAcGcCAAgCCAAAC T 136 TCCCTTgTTCTTACTTCTTCC 137
-47-W S GR Docket No. 31249-722.601 gCA TTTTT CAT TTTTAA 138 CCTTCTgCTC CT TTCTCAT 139 TTT CTgAT TTA A CT T 141 At ACC TTTCC TCCT C 143 gTTTTCCTTCCACTT CgTTA 144 CACA TT gCCTTTACTA T 145 ACACT TC CA gA TCTT A 146 TCT CCAAATACCA T CCTg 148 TCCATCTTCTCCT gTTCT g 150 CCTA ATcTTTTTg T T TC 151 TagAg gTAAC ACA CATC 152 TCTCCAGAGCA TAATT gCC 153 TgA TAAC CCAA CCAA 156 Myostatin (horse) AB033541 CA TTTTT CAT gTTTT 157 TCAT AACACCCACAgC 158 Myostatin (sheep) AF019622 CAgTTTTT CATg TTTT 160 T A TAAC CCAAgCCAA 162 Myostatin (goat) AY436347 CA TTTTT CAT gTTTT 163 TCAT AACACCCACAgC 164
-48-WSGR Docket No. 31249-722.601 Table 5: Antisense oligonucleotides equences targeted at human myostatin gene Antisense oli onucleotide sequences 5'-3' * SequencelD#
gTT CA TTTTT CAT~ATTT 167 A CT TTTCCA AC AAgTT 172 TC CT CT TCATCCCTCT g 174 CC TT Ta C T ATAATC T 175 TTgTA A TCTC AC g TC 178 CATAg TTTATgAgTCTCAg 179 A T CCT TTCATgTCAAg 180 AT CCTAAgTT gATTCA T 182 ATCCAATCCCATCCAAAAgCT 186 TCCA AgCA TAATT CCTT 187 TC CTg AATTTTCCCATATA 190 ATATAAATCTCATgAgCACCC 191 *Based on AF104922.
gTT CA TTTTT CAT~ATTT 167 A CT TTTCCA AC AAgTT 172 TC CT CT TCATCCCTCT g 174 CC TT Ta C T ATAATC T 175 TTgTA A TCTC AC g TC 178 CATAg TTTATgAgTCTCAg 179 A T CCT TTCATgTCAAg 180 AT CCTAAgTT gATTCA T 182 ATCCAATCCCATCCAAAAgCT 186 TCCA AgCA TAATT CCTT 187 TC CTg AATTTTCCCATATA 190 ATATAAATCTCATgAgCACCC 191 *Based on AF104922.
-49-WSGR Docket No. 31249-722.601 Table 6: Exemplary combinations of oligonucleotides for treatment of muscle wasting Combinations of oligonucleotides tar etin the following genes Myo Myo/myoD
Myo/ActRIIB
Myo/myoD/ActRIIB
M o/ActRIIB/Smad2 M o/NF-kB
Myo/Atro in-1 M o/MuRF 1 Myo/Atro in-1 /MuRF 1 Atro in-1/FOXO1 Atro in-1/FOX03 Atro in-1/FOXO1/FOX03 M o/M oD/ActIIB/Samd2/NF-kB
Atro in-1/FOXO1/FOX03/MuRF1 Table 7: Homeopathic RNA/DNA Dosages Dilution/Potency /
2x 50 3x 5 4x 0.5 5x 0.05 6x 0.005 III. Kits [0002] In still another aspect, the present invention provides kits for the treatment of muscle wasting conditions and/or for the improvement of muscle growth and
Myo/ActRIIB
Myo/myoD/ActRIIB
M o/ActRIIB/Smad2 M o/NF-kB
Myo/Atro in-1 M o/MuRF 1 Myo/Atro in-1 /MuRF 1 Atro in-1/FOXO1 Atro in-1/FOX03 Atro in-1/FOXO1/FOX03 M o/M oD/ActIIB/Samd2/NF-kB
Atro in-1/FOXO1/FOX03/MuRF1 Table 7: Homeopathic RNA/DNA Dosages Dilution/Potency /
2x 50 3x 5 4x 0.5 5x 0.05 6x 0.005 III. Kits [0002] In still another aspect, the present invention provides kits for the treatment of muscle wasting conditions and/or for the improvement of muscle growth and
-50-WSGR Docket No. 31249-722.601 maintenance. These kits comprise a composition containing a gene-modulating oligonucleotide as described herein and instructions teaching the use of the kit according to the various methods and approaches described herein. Such kits may also include information, such as scientific literature references, package insert materials, clinical trial results, and/or summaries of these and the like, which indicate or establish the activities and/or advantages of the composition. Such information may be based on the results of various studies, for example, studies using experimental animals involving in vivo models and studies based on human clinical trials. Kits described herein can be provided, marketed and/or promoted to health providers, including physicians, nurses, pharmacists, naturopaths, homeopaths, chiropractors, formulary officials, and the like.
Kits for nutritional or homeopathic use may be provided, marketed and/or promoted directly to consumers.
EXAMPLES
Example 1: Determination of Combined effect of Myostatin RNA Oligonucleotides in Cell Culture System Cell growth and culture C2C12 is a mouse myoblast cell line (ATCC CRL-1772), which differentiates rapidly, forming contractile myotubes and producing characteristic muscle proteins. The cells were maintained in Dulbecco's Modified Eagle Medium (DMEM) (Gibco-BRL) supplemented with 10% FCS, 1% L-glutamine, 0.5% penicillin and 0.5% streptomycin. They were incubated at 37 C under 5% C02 in a moist atmosphere. Cells approaching 50 - 70% confluency were washed in phosphate buffered saline (PBS) and detached with 0.25% (w/v) Trypsin- 0.53 mM
EDTA solution. The detached cells were resuspended in serum-supplemented media and centrifuged at 1000 rpm at room temperature for 5 minutes. The supernatant was discarded and the cells were subcultured at a diluted cell concentration.
Transfection The RNA oligonucleotides were tested in cells singly and in combinations. The uptake of RNA
oligonucleotides into cells was enhanced by complexing with Lipofectamine 2000.
Approximately 1 x 105 C2C 12 cells were seeded in 0.5 ml of growth medium without antibiotics in 24-well dishes 1 day before transfection. Cells reached approximately 50%
confluency after being incubated at 37 C overnight.
Kits for nutritional or homeopathic use may be provided, marketed and/or promoted directly to consumers.
EXAMPLES
Example 1: Determination of Combined effect of Myostatin RNA Oligonucleotides in Cell Culture System Cell growth and culture C2C12 is a mouse myoblast cell line (ATCC CRL-1772), which differentiates rapidly, forming contractile myotubes and producing characteristic muscle proteins. The cells were maintained in Dulbecco's Modified Eagle Medium (DMEM) (Gibco-BRL) supplemented with 10% FCS, 1% L-glutamine, 0.5% penicillin and 0.5% streptomycin. They were incubated at 37 C under 5% C02 in a moist atmosphere. Cells approaching 50 - 70% confluency were washed in phosphate buffered saline (PBS) and detached with 0.25% (w/v) Trypsin- 0.53 mM
EDTA solution. The detached cells were resuspended in serum-supplemented media and centrifuged at 1000 rpm at room temperature for 5 minutes. The supernatant was discarded and the cells were subcultured at a diluted cell concentration.
Transfection The RNA oligonucleotides were tested in cells singly and in combinations. The uptake of RNA
oligonucleotides into cells was enhanced by complexing with Lipofectamine 2000.
Approximately 1 x 105 C2C 12 cells were seeded in 0.5 ml of growth medium without antibiotics in 24-well dishes 1 day before transfection. Cells reached approximately 50%
confluency after being incubated at 37 C overnight.
-51-WSGR Docket No. 31249-722.601 For each transfection sample, dilute the appropriate amount of RNA was diluted oligonucleotides in 50 l of Opti-MEM I Reduced Serum Medium without serum.
Then one l of Lipofectamine 2000 in 50 l of Opti-MEM I Medium was added. Mixed gently and incubated for 5 minutes at room temperature. After the 5-minute incubation, combined the diluted RNA oligonucleotides with the diluted Lipofectamine. 2000 (total volume is 100 l). The sample was then mixed gently and incubated for 20 minutes at room temperature to allow the RNA oligonucleotide:Lipofectamine. 2000 complexes to form.
100 1 of siRNA:Lipofectamine. 2000 complexes was added to each well (2 uM
of final concentration of RNA oligonucleotides). The cells were incubated at 37 C in a C02 incubator for 24-72 hours until they were ready to assay for gene knockdown.
Protein analysis The cellular protein of treated and untreated C2C 12 cells was extracted for immunoblot analysis. The cells were harvested and placed on ice before being resuspended in RIPA buffer (100 mM Tris-Cl, 300 mM NaCI, 0.1 %SDS, 2% NP-40, 1% sodium deoxychoate) with freshly added 100 g/ml PMSF and 1 g/ml aprotinin. The cell extracts were then sheared by passing through a 22-gauge needle 13 times and an extra 1 l of PMSF was added. After standing on ice for 30-60 minutes, the cell lysate was centrifuged at 10,000 xg for 10 minutes at 4 C. The protein-containing supematant was collected and its concentration estimated using the Biorad protein assay system (Biorad Laboratories, Richmond, CA).
Protein analysis was accomplished by immunoblots also known as Western blots.
Approximately 40 g of each sample was run on a 10% SDS-PAGE gel (Invitrogen).
Gel was then electrotransferred onto nitro-cellulose membrane in cold transfer buffer at 30V for an hour.
The membrane was blocked with 3% BSA in TBS-T (10 mM Tris-Cl, 150 mM NaCI, 0.1 %
Tween-20) for 30 minutes. The membrane was then treated with Blotto A (5% skim milk powder in TBS-T) with the appropriate primary antibody (anti-myostatin and anti-MyoD) for an hour at room temperature followed by washing with TBS-T. The membrane was then probed with horseradish peroxidase conjugated secondary antibody for 45 minutes at room temperature and then washed as described above. The immunocomplexes were detected by chemiluminescence reaction using reagents provided in the Amersham RCL kit (Amersham) and then exposed onto Hyperfilm (Amersham). The film was then developed to reveal protein bands.
To ensure even loading, (3-actin primary antibody was used to immunoblot the membrane as a control. A densitometry was performed to quantitate the intensities of each band produced from Western analysis.
Then one l of Lipofectamine 2000 in 50 l of Opti-MEM I Medium was added. Mixed gently and incubated for 5 minutes at room temperature. After the 5-minute incubation, combined the diluted RNA oligonucleotides with the diluted Lipofectamine. 2000 (total volume is 100 l). The sample was then mixed gently and incubated for 20 minutes at room temperature to allow the RNA oligonucleotide:Lipofectamine. 2000 complexes to form.
100 1 of siRNA:Lipofectamine. 2000 complexes was added to each well (2 uM
of final concentration of RNA oligonucleotides). The cells were incubated at 37 C in a C02 incubator for 24-72 hours until they were ready to assay for gene knockdown.
Protein analysis The cellular protein of treated and untreated C2C 12 cells was extracted for immunoblot analysis. The cells were harvested and placed on ice before being resuspended in RIPA buffer (100 mM Tris-Cl, 300 mM NaCI, 0.1 %SDS, 2% NP-40, 1% sodium deoxychoate) with freshly added 100 g/ml PMSF and 1 g/ml aprotinin. The cell extracts were then sheared by passing through a 22-gauge needle 13 times and an extra 1 l of PMSF was added. After standing on ice for 30-60 minutes, the cell lysate was centrifuged at 10,000 xg for 10 minutes at 4 C. The protein-containing supematant was collected and its concentration estimated using the Biorad protein assay system (Biorad Laboratories, Richmond, CA).
Protein analysis was accomplished by immunoblots also known as Western blots.
Approximately 40 g of each sample was run on a 10% SDS-PAGE gel (Invitrogen).
Gel was then electrotransferred onto nitro-cellulose membrane in cold transfer buffer at 30V for an hour.
The membrane was blocked with 3% BSA in TBS-T (10 mM Tris-Cl, 150 mM NaCI, 0.1 %
Tween-20) for 30 minutes. The membrane was then treated with Blotto A (5% skim milk powder in TBS-T) with the appropriate primary antibody (anti-myostatin and anti-MyoD) for an hour at room temperature followed by washing with TBS-T. The membrane was then probed with horseradish peroxidase conjugated secondary antibody for 45 minutes at room temperature and then washed as described above. The immunocomplexes were detected by chemiluminescence reaction using reagents provided in the Amersham RCL kit (Amersham) and then exposed onto Hyperfilm (Amersham). The film was then developed to reveal protein bands.
To ensure even loading, (3-actin primary antibody was used to immunoblot the membrane as a control. A densitometry was performed to quantitate the intensities of each band produced from Western analysis.
-52-WSGR Docket No. 31249-722.601 Results The results showed that C2C 12 cells could be efficiently transfected with RNA
oligos at a efficiency of over 50%. When seven RNA oligos were screened in the cells, all showed activity at inhibition of the myostatin expression with three being most active: A (ATg Tag CgT CCg AgA gAC, targeted at the 5'UTR) , B (TgC ATC ATT TTA AAA ATC AgC, targeted at the translation start site) and C (ACC TAA TgC AAA gCT CAT, targeted at the translation stop region), as assayed by western blots. All three RNA oligos are modified with 2'-Omethyl and 3'-butanol blocked.
Example 2: Effect of single and combined RNA oligos on the muscle weight in mice This Example was designed to test the effect of antisense oligonucleotides directed to myostatin genes.
Materials Oligonucleotides: 3 oligonucleotides (A, B, C as in the Example 1) were straight 2'-methoxy.
Sample preparation: Each oligo was dissolved in saline. For the A+B+C Group, 3 RNA oligos were mixed in equal volume. 100 ul of each mixture was used to inject mice at a dose of 5 mg/kg.
Experimental procedure Female mice (6-8 weeks) were housed for 7 days before injections started (Day 1). Mice were divided into five groups randomly: Group A (RNA oligo A), Group B (RNA oligo B) and Group C (RNA oligo C), Group D (RNA oligos A+B+C
mixture) and Group D (saline). In each cycle of the treatment, tail vein IV
injection was performed at day 1, IP injection followed at day 2 and 3. Ten treatment cycles were planned in the protocol. During the experiment, the protocol was adjusted after the cycle 5 with only IV
injections performed. Each day, body weight was measured before injections. At the end of the experiment, a portion of the quadriceps (rectus femoris) were dissected and weighed. Samples were divided for pathology (fixed) and molecular analysis (liquid nitrogen).
Results Bodyweight All mice were measured for their body weight each day, and all mice grew normally with a consistent increase of body weight.
Effect of oligos on muscle weight The muscle weight was measured for each group. As shown in the following table 8, compared with the saline control group, the all RNA
oligo-treated group
oligos at a efficiency of over 50%. When seven RNA oligos were screened in the cells, all showed activity at inhibition of the myostatin expression with three being most active: A (ATg Tag CgT CCg AgA gAC, targeted at the 5'UTR) , B (TgC ATC ATT TTA AAA ATC AgC, targeted at the translation start site) and C (ACC TAA TgC AAA gCT CAT, targeted at the translation stop region), as assayed by western blots. All three RNA oligos are modified with 2'-Omethyl and 3'-butanol blocked.
Example 2: Effect of single and combined RNA oligos on the muscle weight in mice This Example was designed to test the effect of antisense oligonucleotides directed to myostatin genes.
Materials Oligonucleotides: 3 oligonucleotides (A, B, C as in the Example 1) were straight 2'-methoxy.
Sample preparation: Each oligo was dissolved in saline. For the A+B+C Group, 3 RNA oligos were mixed in equal volume. 100 ul of each mixture was used to inject mice at a dose of 5 mg/kg.
Experimental procedure Female mice (6-8 weeks) were housed for 7 days before injections started (Day 1). Mice were divided into five groups randomly: Group A (RNA oligo A), Group B (RNA oligo B) and Group C (RNA oligo C), Group D (RNA oligos A+B+C
mixture) and Group D (saline). In each cycle of the treatment, tail vein IV
injection was performed at day 1, IP injection followed at day 2 and 3. Ten treatment cycles were planned in the protocol. During the experiment, the protocol was adjusted after the cycle 5 with only IV
injections performed. Each day, body weight was measured before injections. At the end of the experiment, a portion of the quadriceps (rectus femoris) were dissected and weighed. Samples were divided for pathology (fixed) and molecular analysis (liquid nitrogen).
Results Bodyweight All mice were measured for their body weight each day, and all mice grew normally with a consistent increase of body weight.
Effect of oligos on muscle weight The muscle weight was measured for each group. As shown in the following table 8, compared with the saline control group, the all RNA
oligo-treated group
-53-WSGR Docket No. 31249-722.601 showed a increase in the muscle weight (P< 0.05), with the combined oligos being the most effective Table 8. Comparison of single and combined effect on muscle weight A B C A+B+C
Increase in muscle 0.8 2.4 7.2 8.8 weight(%) This example demonstrates that treatment with modified RNA antisense oligonucleotides of the invention promotes muscle growth.
Example 3: Specificity of the effect of RNA oligo on the muscle weight in mice This Example was designed to test the effect of the combined antisense oligonucleotides directed to myostatin gene on muscle weight and the target gene expression.
Materials Oligonucleotides: 3 oligonucleotides (A, B, C as in the Example 1) were straight 2'-methoxy.
Sample preparation: 3 RNA oligos were mixed in equal volume. 100 ul of each mixture was used to inject mice at a dose of 5 mg/kg.
Experimental procedure Female mice (6-8 weeks) were housed for 7 days before injections started (Day 1). Mice were divided into three groups randomly:
Group A (RNA oligos A+B+C), Group B (three control DNA oligos) and Group C (saline). In each cycle of the treatment, tail vein IV injection was performed at day 1, IP injection followed at day 2 and 3.
Ten treatment cycles were planned in the protocol. During the experiment, the protocol was adjusted after the cycle 5 with only IV injections performed. Each day, body weight was measured before injections. At the end of the experiment, a portion of the quadriceps (rectus femoris) were dissected and weighed. Samples were divided for pathology (fixed) and molecular analysis (liquid nitrogen).
Results Bodyweight All mice were measured for their body weight each day, and all mice grew normally with a consistent increase of body weight.
Increase in muscle 0.8 2.4 7.2 8.8 weight(%) This example demonstrates that treatment with modified RNA antisense oligonucleotides of the invention promotes muscle growth.
Example 3: Specificity of the effect of RNA oligo on the muscle weight in mice This Example was designed to test the effect of the combined antisense oligonucleotides directed to myostatin gene on muscle weight and the target gene expression.
Materials Oligonucleotides: 3 oligonucleotides (A, B, C as in the Example 1) were straight 2'-methoxy.
Sample preparation: 3 RNA oligos were mixed in equal volume. 100 ul of each mixture was used to inject mice at a dose of 5 mg/kg.
Experimental procedure Female mice (6-8 weeks) were housed for 7 days before injections started (Day 1). Mice were divided into three groups randomly:
Group A (RNA oligos A+B+C), Group B (three control DNA oligos) and Group C (saline). In each cycle of the treatment, tail vein IV injection was performed at day 1, IP injection followed at day 2 and 3.
Ten treatment cycles were planned in the protocol. During the experiment, the protocol was adjusted after the cycle 5 with only IV injections performed. Each day, body weight was measured before injections. At the end of the experiment, a portion of the quadriceps (rectus femoris) were dissected and weighed. Samples were divided for pathology (fixed) and molecular analysis (liquid nitrogen).
Results Bodyweight All mice were measured for their body weight each day, and all mice grew normally with a consistent increase of body weight.
-54-WSGR Docket No. 31249-722.601 Effect of oligos on muscle weight The muscle weight was measured for each group. As shown in the following table 9, compared with the saline and DNA oligo control groups, the combined RNA oligo-treated group showed a increase in the muscle weight (P< 0.05).
Table 9. Specific Effect of the combined RNA oligos on muscle weight Combined RNA Control oligos Increase in muscle 11.3 -0.4 wei ht (%) When the muscle tissues were collected and assayed for the expression of the myostatin gene by Western blots, it was shown that the combined RNA oligos could significantly inhibit the myostatin expression, while no effect was observed for the house-keeping gene (3-actin.
This example demonstrates that treatment with modified RNA antisense oligonucleotides of the invention could specifically inhibit the target gene expression, leading to the increase in the muscle weight.
Example 4: Delivery of RNA oligos via different routes This Example was designed to test the effect of the combined antisense oligonucleotides directed to myostatin gene on muscle weight by three different delivery routes.
Materials Oligonucleotides: 3 oligonucleotides (A, B, C as in the Example 1) were straight 2'-methoxy.
Sample preparation: 3 RNA oligos were mixed in equal volume. 100 ul of each mixture was used to inject mice at a dose of 5 mg/kg.
Experimental procedure Female mice (6-8 weeks) were housed for 7 days before injections started (Day 1). Mice were divided into four groups randomly: Group A (iv injection, every three days), Group B (iv and ip injection at every other days), Group C
(saline, delivered as in Group B) and Group D (oral). At the end of the experiment, a portion of the quadriceps (rectus femoris) were dissected and weighed. Samples were divided for pathology (fixed) and molecular analysis (liquid nitrogen).
Results Bodyweight All mice were measured for their body weight each day, and all mice grew normally with a consistent increase of body weight.
Table 9. Specific Effect of the combined RNA oligos on muscle weight Combined RNA Control oligos Increase in muscle 11.3 -0.4 wei ht (%) When the muscle tissues were collected and assayed for the expression of the myostatin gene by Western blots, it was shown that the combined RNA oligos could significantly inhibit the myostatin expression, while no effect was observed for the house-keeping gene (3-actin.
This example demonstrates that treatment with modified RNA antisense oligonucleotides of the invention could specifically inhibit the target gene expression, leading to the increase in the muscle weight.
Example 4: Delivery of RNA oligos via different routes This Example was designed to test the effect of the combined antisense oligonucleotides directed to myostatin gene on muscle weight by three different delivery routes.
Materials Oligonucleotides: 3 oligonucleotides (A, B, C as in the Example 1) were straight 2'-methoxy.
Sample preparation: 3 RNA oligos were mixed in equal volume. 100 ul of each mixture was used to inject mice at a dose of 5 mg/kg.
Experimental procedure Female mice (6-8 weeks) were housed for 7 days before injections started (Day 1). Mice were divided into four groups randomly: Group A (iv injection, every three days), Group B (iv and ip injection at every other days), Group C
(saline, delivered as in Group B) and Group D (oral). At the end of the experiment, a portion of the quadriceps (rectus femoris) were dissected and weighed. Samples were divided for pathology (fixed) and molecular analysis (liquid nitrogen).
Results Bodyweight All mice were measured for their body weight each day, and all mice grew normally with a consistent increase of body weight.
-55-WSGR Docket No. 31249-722.601 Effect of oligos on muscle weight The muscle weight was measured for each group. As shown in the following table 10, compared with the saline control group, all three delivery routes showed a increase in the muscle weight (P< 0.05).
Table 10. Effect of combined RNA oligos on muscle weight in three different delivery route iv iv + ip Oral Increase in muscle 25.91 22.38 18.55 weight (%) This example demonstrates that treatment with modified RNA antisense oligonucleotides of the invention could promote the muscle growth via different delivery routes.
Example 5: Inhibition of Foxol leads to increase in muscle weight in both normal and cancer-bearing mice.
Experimental procedures Animal, Oligonucleotides and Delivery Methods - BALB/c female mice (6-8 weeks old) weighing 15 to 18 g were used for normal and cancer model. Sarcoma S-180 cells in 0.2 ml of PBS (5X 106 cell) were i.p. injected and grown for 7 - 10 days. Six mice per group were treated with RNA
oligos via tail vein injection (100ug/0.1 ml) every two days. Mice were weighed everyday during the treatment period. Oligoribonucleotides targeted to Foxol and a control oligo were used in the experiment. Mice were sacrificed at desired time points, and muscles were weighed and snap-frozen in liquid nitrogen and stored at -80 C.
RNA Extraction and Real-time PCR analysis - Total RNA was extracted in TRIzol (Invitrogen).
RNA was separated electrophoretically on agarose gels under denaturing conditions in order to confirm the integrity of ribosomal RNA bands. Single-strand cDNA synthesis was carried out from 2ug of total RNA by the reverse transcription (RT) reaction (Promega).
Real-time fluorescence quantitative PCR was performed by using an Applied Biosystems Prism 7000 instrument, an Applied Biosystems SYBR green master mix reagent and oligonucleotide pairs to the endogenous control gene Beta-actin , MyoD, GDF-8 and foxo-1 cDNA. The reagents were denatured at 95 ~ for 10 min, followed by 40 cycles of 15 s at 95 ~ and 60 s at 600. 5' to 3' primer sequences were as follows:
Beta-actin forward GAA CCC TAA GGC CAA CCG TGA A
Table 10. Effect of combined RNA oligos on muscle weight in three different delivery route iv iv + ip Oral Increase in muscle 25.91 22.38 18.55 weight (%) This example demonstrates that treatment with modified RNA antisense oligonucleotides of the invention could promote the muscle growth via different delivery routes.
Example 5: Inhibition of Foxol leads to increase in muscle weight in both normal and cancer-bearing mice.
Experimental procedures Animal, Oligonucleotides and Delivery Methods - BALB/c female mice (6-8 weeks old) weighing 15 to 18 g were used for normal and cancer model. Sarcoma S-180 cells in 0.2 ml of PBS (5X 106 cell) were i.p. injected and grown for 7 - 10 days. Six mice per group were treated with RNA
oligos via tail vein injection (100ug/0.1 ml) every two days. Mice were weighed everyday during the treatment period. Oligoribonucleotides targeted to Foxol and a control oligo were used in the experiment. Mice were sacrificed at desired time points, and muscles were weighed and snap-frozen in liquid nitrogen and stored at -80 C.
RNA Extraction and Real-time PCR analysis - Total RNA was extracted in TRIzol (Invitrogen).
RNA was separated electrophoretically on agarose gels under denaturing conditions in order to confirm the integrity of ribosomal RNA bands. Single-strand cDNA synthesis was carried out from 2ug of total RNA by the reverse transcription (RT) reaction (Promega).
Real-time fluorescence quantitative PCR was performed by using an Applied Biosystems Prism 7000 instrument, an Applied Biosystems SYBR green master mix reagent and oligonucleotide pairs to the endogenous control gene Beta-actin , MyoD, GDF-8 and foxo-1 cDNA. The reagents were denatured at 95 ~ for 10 min, followed by 40 cycles of 15 s at 95 ~ and 60 s at 600. 5' to 3' primer sequences were as follows:
Beta-actin forward GAA CCC TAA GGC CAA CCG TGA A
-56-WSGR Docket No. 31249-722.601 Beta -actin reverse, CTC AGT AAC AGT CCG CCT AGA A
MyoD forward 5' GCA AGA CCA CCA ACG CTG AT 3' MyoD reverse 5' GGT TCG GGT TGC TGG ACG TG 3' GDF-8 forward 5' CAG ACC CGT CAA GAC TCC TAC A 3' GDF-8 reverse 5' CAG TGC CTG GGC TCA TGT CAA G 3' FOXO 1 forward 5' GTA CGC CGA CCT CAT CAC CA 3' FOXO1 reverse 5' TGC TGT CGC CCT TAT CCT TG 3' Average CT values for MyoD, GDF-8 and foxo 1 were calculated and normalized to CT values for -AAct Beta-actin. And the normalized values were subjected to a 2 formula to calculate the fold change between the control and experiment groups. The formula and its derivations were obtained from the ABI Prism 7000 Sequence Detection System user guide. All reactions were performed in duplicates or triplicates.
Western blotting - Protein was extracted from the muscle tissue of different groups with lysis buffer containing 100 mM Tris-HCI, 0.05% CA-630,100ug/ml PMSF,.l00ug/ml DTT,lug/ml Aprotinin and lug/ml Lenpeptin. Protein concentration of each specimen was detected by the Bradford method (Bio-Rad Laboratories). The samples were heat denatured at 95 ~ for 5 min, electrophoretically separated on a 12.5% SDS-PAGE, and transferred to a PVDF
membrane. The membrane was blocked with 5% non-fat dry milk in TBST buffer(50 mM Tris-HCI, 100 mM
NaC1, and 0.1% Tween-20, pH 7.4) and incubated with monoclonal anti-MyoD
diluted at 1/200 (BD, Pharmingen) , monoclonal anti-Myostatin diluted at 1/100( Santa Cruz Biotechnology) and anti-beta actin diluted at 1/250( Santa Cruz Biotechnology ), and further incubated for 90 min at 37 0.Bound antibodies were visualized by subsequent chemiluminescent reaction with a horseradish peroxidase conjugated IgG(1:3000) in the ECL system (Amersham).
The image and data were analyzed with bandscan 5.0 software.
Statistical analysis - Data were expressed as means SD and subjected to one-way AVONA with factors of treatment, genotype or wild type. Comparisons between two groups were performed by unpaired Student's t test. A value of p < 0.05 was considered significantly different..
Results 1. Foxo 1 RNA oligonucleotide promoted muscle growth in normal mice
MyoD forward 5' GCA AGA CCA CCA ACG CTG AT 3' MyoD reverse 5' GGT TCG GGT TGC TGG ACG TG 3' GDF-8 forward 5' CAG ACC CGT CAA GAC TCC TAC A 3' GDF-8 reverse 5' CAG TGC CTG GGC TCA TGT CAA G 3' FOXO 1 forward 5' GTA CGC CGA CCT CAT CAC CA 3' FOXO1 reverse 5' TGC TGT CGC CCT TAT CCT TG 3' Average CT values for MyoD, GDF-8 and foxo 1 were calculated and normalized to CT values for -AAct Beta-actin. And the normalized values were subjected to a 2 formula to calculate the fold change between the control and experiment groups. The formula and its derivations were obtained from the ABI Prism 7000 Sequence Detection System user guide. All reactions were performed in duplicates or triplicates.
Western blotting - Protein was extracted from the muscle tissue of different groups with lysis buffer containing 100 mM Tris-HCI, 0.05% CA-630,100ug/ml PMSF,.l00ug/ml DTT,lug/ml Aprotinin and lug/ml Lenpeptin. Protein concentration of each specimen was detected by the Bradford method (Bio-Rad Laboratories). The samples were heat denatured at 95 ~ for 5 min, electrophoretically separated on a 12.5% SDS-PAGE, and transferred to a PVDF
membrane. The membrane was blocked with 5% non-fat dry milk in TBST buffer(50 mM Tris-HCI, 100 mM
NaC1, and 0.1% Tween-20, pH 7.4) and incubated with monoclonal anti-MyoD
diluted at 1/200 (BD, Pharmingen) , monoclonal anti-Myostatin diluted at 1/100( Santa Cruz Biotechnology) and anti-beta actin diluted at 1/250( Santa Cruz Biotechnology ), and further incubated for 90 min at 37 0.Bound antibodies were visualized by subsequent chemiluminescent reaction with a horseradish peroxidase conjugated IgG(1:3000) in the ECL system (Amersham).
The image and data were analyzed with bandscan 5.0 software.
Statistical analysis - Data were expressed as means SD and subjected to one-way AVONA with factors of treatment, genotype or wild type. Comparisons between two groups were performed by unpaired Student's t test. A value of p < 0.05 was considered significantly different..
Results 1. Foxo 1 RNA oligonucleotide promoted muscle growth in normal mice
-57-WSGR Docket No. 31249-722.601 In order to examine the effects of the Foxol RNA oligo on the muscle growth, the leg muscles were collected and weighed at the end of the treatment. The results showed that the mass of muscles of normal mice was increased by 10% while no significant change was observed in the control groups (Figure 1). When the muscle tissues were analyzed for the expression of the target gene, it was shown that the protein levels of GDF-8 decreased by 48.5% and the MyoD increased by 42% compared to control group (Fig. 2). At the RNA level as measured by Real Time PCR, the mRNA levels of Foxol decreased by 75%, GDF-8 decreased by 49% MyoD increased by 58%
compared to control group (Fig. 2). This result clearly demonstrated that the Foxol RNA oligo could increase the muscle growth by direct inhibition of the Foxol expression and indirect impact on the myostatin and MyoD expression.
2. Increase muscle weight in cancer cachexia model by Foxol RNA
oligonucleotide To test the RNA oligo effect on muscle mass in a relevant disease model, an ascetic tumor S 180 was used as a cancer cachexia model where the muscle loss is a characteristic.
As for in the normal mice, the group injected with Foxol RNA oligo showed a muscle mass increased by 32.8%
compared to control group (Fig 3). At protein level, myostatin decreased by 40.4%, MyoD
increased by 41.8% (Fig.4). At mRNA level, foxo 1 expression decreased by 81 %, myostatin decreased by 58%, MyoD increased by 66% compared to control group (Fig.4).
This result demonstrated that the use of Foxol oligo could impact on the muscle growth in cancer cachexia model.
Example 6: Inhibition of Myostatin gene expression by RNA oligos increased muscle growth in tumor-bearing mice Experimental procedures Animal, Oligonucleotides and Delivery Methods - BALB/c female mice (6-8 weeks old) weighing 15 to 18 g were used for cancer model. Sarcoma S-180 cells in 0.2 ml of PBS
(5X106 cell) were i.p. injected and grown for 7 - 10 days. Six mice per group were treated with RNA oligos via tail vein injection (100ug/0.1 ml) every two days. Mice were weighed everyday during the treatment period. Oligonucleotides targeted to Myostatin and a control oligo were used in the experiment.
Mice were scarified at desired time points, and leg muscles including the quadriceps (rectus femoris), the gastrocnemius, triceps, and the EDL were weighed and snap-frozen in liquid nitrogen and stored at -80 C.
compared to control group (Fig. 2). This result clearly demonstrated that the Foxol RNA oligo could increase the muscle growth by direct inhibition of the Foxol expression and indirect impact on the myostatin and MyoD expression.
2. Increase muscle weight in cancer cachexia model by Foxol RNA
oligonucleotide To test the RNA oligo effect on muscle mass in a relevant disease model, an ascetic tumor S 180 was used as a cancer cachexia model where the muscle loss is a characteristic.
As for in the normal mice, the group injected with Foxol RNA oligo showed a muscle mass increased by 32.8%
compared to control group (Fig 3). At protein level, myostatin decreased by 40.4%, MyoD
increased by 41.8% (Fig.4). At mRNA level, foxo 1 expression decreased by 81 %, myostatin decreased by 58%, MyoD increased by 66% compared to control group (Fig.4).
This result demonstrated that the use of Foxol oligo could impact on the muscle growth in cancer cachexia model.
Example 6: Inhibition of Myostatin gene expression by RNA oligos increased muscle growth in tumor-bearing mice Experimental procedures Animal, Oligonucleotides and Delivery Methods - BALB/c female mice (6-8 weeks old) weighing 15 to 18 g were used for cancer model. Sarcoma S-180 cells in 0.2 ml of PBS
(5X106 cell) were i.p. injected and grown for 7 - 10 days. Six mice per group were treated with RNA oligos via tail vein injection (100ug/0.1 ml) every two days. Mice were weighed everyday during the treatment period. Oligonucleotides targeted to Myostatin and a control oligo were used in the experiment.
Mice were scarified at desired time points, and leg muscles including the quadriceps (rectus femoris), the gastrocnemius, triceps, and the EDL were weighed and snap-frozen in liquid nitrogen and stored at -80 C.
-58-WSGR Docket No. 31249-722.601 Statistical analysis - Data were expressed as means SD and subjected to one-way AVONA with factors of treatment, genotype or wild type. Comparisons between two groups were performed by unpaired Student's t test. A value of p < 0.05 was considered significantly different..
Quantitative RT-PCR analysis of mRNA -Total RNA was isolated from cells using RNA
preparation kits from TRIZOL reagent (Invitrogen). cDNA was generated using ImpromlI
reverse transcriptase (Promega) and oligo(d)T primers, according to the manufacturers instructions, typically using 1 g of total RNA per reaction. Quantitative PCR
was performed using an Applied Biosystems Prism 7000 instrument using Applied Biosystems SYBR green master mix reagent and oligonucleotide pairs to human cell house-keeping gene beta-actin cDNA. 5' to 3' primer sequences were as follows: Beta-actin forward GAA CCC
TAA GGC
CAA CCG TGA A, Beta-actin reverse CTC AGT AAC AGT CCG CCT AGA A, GDF-8 forward CAg ACC CgT CAA gAC TCC TAC A and GDF-8 reverse CAg TgC CTg ggC TCA
TgT CAA g, MyoD forward gCA AgA CCA CCA ACg CTg AT and MyoD reverse ggT TCg ggT TgC Tgg ACg Tg. Average CT values for MyoD and GDF-8 were calculated and normalized to CT values for Beta-actin. The average Ct value from each three experiments was calculated, and the results were graphed with the corresponding standard deviation indicated with error bars in the figures. The formula and its derivations were obtained from the ABI Prism 7000 Sequence Detection System user guide.
Statistical analysis- Data were expressed as means SD and subjected to one-way AVONA with factors of treatment, genotype or wild type. Comparisons between two groups were performed by unpaired Student's t test. A value of p < 0.05 was considered significantly different.
Results RNA oligos targeted to myostatin gene decreased myostatin expression and increased the mass of muscles in S-180 implanted mice The three RNA oligos targeted at the Myostatin gene were mixed in an equal mole and the mixture was used in the experiment.
The effect on muscle mass in S-180 implanted mice was tested in S-180 implanted mice. The results showed that the muscle mass in the group treated with the RNA oligo mixture increased by 26%
compared to control group (Figure 5 A, p<0.05). As in Figure 5B, the ratio of skeletal muscle mass and body mass in the group injected RNA oligos increased by 10.4%
(p<0.05). At mRNA
Quantitative RT-PCR analysis of mRNA -Total RNA was isolated from cells using RNA
preparation kits from TRIZOL reagent (Invitrogen). cDNA was generated using ImpromlI
reverse transcriptase (Promega) and oligo(d)T primers, according to the manufacturers instructions, typically using 1 g of total RNA per reaction. Quantitative PCR
was performed using an Applied Biosystems Prism 7000 instrument using Applied Biosystems SYBR green master mix reagent and oligonucleotide pairs to human cell house-keeping gene beta-actin cDNA. 5' to 3' primer sequences were as follows: Beta-actin forward GAA CCC
TAA GGC
CAA CCG TGA A, Beta-actin reverse CTC AGT AAC AGT CCG CCT AGA A, GDF-8 forward CAg ACC CgT CAA gAC TCC TAC A and GDF-8 reverse CAg TgC CTg ggC TCA
TgT CAA g, MyoD forward gCA AgA CCA CCA ACg CTg AT and MyoD reverse ggT TCg ggT TgC Tgg ACg Tg. Average CT values for MyoD and GDF-8 were calculated and normalized to CT values for Beta-actin. The average Ct value from each three experiments was calculated, and the results were graphed with the corresponding standard deviation indicated with error bars in the figures. The formula and its derivations were obtained from the ABI Prism 7000 Sequence Detection System user guide.
Statistical analysis- Data were expressed as means SD and subjected to one-way AVONA with factors of treatment, genotype or wild type. Comparisons between two groups were performed by unpaired Student's t test. A value of p < 0.05 was considered significantly different.
Results RNA oligos targeted to myostatin gene decreased myostatin expression and increased the mass of muscles in S-180 implanted mice The three RNA oligos targeted at the Myostatin gene were mixed in an equal mole and the mixture was used in the experiment.
The effect on muscle mass in S-180 implanted mice was tested in S-180 implanted mice. The results showed that the muscle mass in the group treated with the RNA oligo mixture increased by 26%
compared to control group (Figure 5 A, p<0.05). As in Figure 5B, the ratio of skeletal muscle mass and body mass in the group injected RNA oligos increased by 10.4%
(p<0.05). At mRNA
-59-WSGR Docket No. 31249-722.601 level, myostatin decreased by 21.3% (Fig. 5 C, p<0.01), MyoD increased by 1.23-fold compared to control group (Fig.5 D, p<0.01).
While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.
While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.
-60-
Claims (20)
1. ~A composition suitable for administration to an animal comprising a modified oligonucleotide containing 7 to 75 contiguous ribose groups linked by achiral 5' to 3' internucleoside phosphate linkages, wherein the modified oligonucleotide is complementary to a region of a gene selected from the group consisting of the 5' UTR region, translational start site, the 3' UTR, and translational termination site, and wherein the gene codes for a gene product involved in a muscle wasting condition.
2. ~The composition of claim 1 wherein the modified oligonucleotide has a T m of about 75-115 °C. at a concentration of 1 mM and a length of 10 to 26 bases, or a T m of about 40 °C to 85 °C at a concentration of 1 pM and a length of 10 to 26 bases.
3. ~The composition of claim 1 wherein the oligonucleotide comprises a nucleotide selected from the group consisting of ribonucleotides and deoxyribonucleotides.
4. ~The composition of claim 1 wherein oligonucleotides comprise one or more nucleotides in which the 2' position comprises a substituent.
5. ~The composition of claim 4 wherein the 2' substituent is selected from the group consisting of hydrogen, methoxy, propoxy, methoxy-ethoxy, fluorine, chlorine, bromine and iodine.
6. ~The composition of claim 1 wherein the modified oligonucleotide is 3' and/or 5' end-modified.
7. ~The composition of claim 1 wherein the modified oligonucleotide is 3' and/or 5' end-blocked.
8. ~The composition of claim 1 wherein the oligonucleotide is an antisense oligonucleotide.
9. ~The composition of claim 8 wherein the antisense oligonucleotide is complementary to a myostatin gene
10. ~The composition of claim 9 wherein the myostatin gene is an animal myostatin gene.
11. ~The composition of claim 9 wherein the myostatin gene is a mammalian myostatin gene.
12. ~The composition of claim 9 wherein the myostatin gene is a human myostatin gene.
13. ~The composition of claim 8 wherein the oligonucleotide comprises a sequence selected from the group consisting of SEQ ID NOS 1-191.
14. ~The composition of claim 1 wherein the oligonucleotide comprises an RNAi, ribozyme or deoxyribozyme.
15. ~The composition of claims 1 further comprising a plurality of modified oligonucleotides.
16. ~The composition of claim 15 comprising two modified oligonucleotides.
17. ~A method of treating a muscle wasting condition comprising administering to an individual suffering from a muscle wasting condition an effective amount of the composition of claim 1.
18. ~A method of promoting muscle growth in an individual comprising administering to the individual an effective amount of the composition of claim 1.
19. ~The method of claim 17 or 18 wherein the individual is a mammal.
20. ~The method of claim 17 or 18 wherein the individual is a human.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2006/025657 WO2008005002A1 (en) | 2006-06-30 | 2006-06-30 | Compositions and methods for the treatment of muscle wasting |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2558160A1 true CA2558160A1 (en) | 2007-12-30 |
CA2558160C CA2558160C (en) | 2017-01-03 |
Family
ID=37102772
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2558160A Expired - Fee Related CA2558160C (en) | 2006-06-30 | 2006-06-30 | Antisense oligonucleotide targeting myostatin or fox01 for treatment of muscle wasting |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP2124968A4 (en) |
AU (1) | AU2006345724B2 (en) |
CA (1) | CA2558160C (en) |
WO (1) | WO2008005002A1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2004235396B2 (en) | 2003-04-29 | 2010-11-25 | Sarepta Therapeutics, Inc. | Compositions for enhancing transport and antisense efficacy of nucleic acid analog into cells |
US20050288246A1 (en) | 2004-05-24 | 2005-12-29 | Iversen Patrick L | Peptide conjugated, inosine-substituted antisense oligomer compound and method |
US8067571B2 (en) | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
US8097596B2 (en) | 2006-06-30 | 2012-01-17 | Lakewood-Amedex, Inc. | Compositions and methods for the treatment of muscle wasting |
US20100016215A1 (en) | 2007-06-29 | 2010-01-21 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
US9161948B2 (en) | 2011-05-05 | 2015-10-20 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
US11020417B2 (en) | 2015-06-04 | 2021-06-01 | Sarepta Therapeutics, Inc | Methods and compounds for treatment of lymphocyte-related diseases and conditions |
MX2019006882A (en) | 2016-12-19 | 2019-08-16 | Sarepta Therapeutics Inc | Exon skipping oligomer conjugates for muscular dystrophy. |
AU2019206634B2 (en) * | 2018-01-12 | 2024-06-27 | Keros Therapeutics, Inc. | Activin receptor type IIB variants and methods of use thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1002068B1 (en) * | 1997-07-14 | 2009-09-09 | University of Liège | Mutations in the myostatin gene cause double-muscling in mammals |
US6656475B1 (en) * | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
US20050124566A1 (en) * | 2001-05-18 | 2005-06-09 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA) |
EP2351765A3 (en) * | 2001-07-10 | 2012-02-22 | Lakewood-Amedex, Inc | Oligonucleotide-containing pharmacological compositions and their use |
AU2006213686A1 (en) * | 2005-02-09 | 2006-08-17 | Avi Bio Pharma, Inc. | Antisense composition and method for treating muscle atrophy |
CN100393320C (en) * | 2005-06-24 | 2008-06-11 | 奥林格斯技术有限公司 | Oligonucleotide medicine for treating myophagism |
-
2006
- 2006-06-30 CA CA2558160A patent/CA2558160C/en not_active Expired - Fee Related
- 2006-06-30 EP EP06774377.3A patent/EP2124968A4/en not_active Withdrawn
- 2006-06-30 WO PCT/US2006/025657 patent/WO2008005002A1/en active Application Filing
- 2006-06-30 AU AU2006345724A patent/AU2006345724B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
EP2124968A1 (en) | 2009-12-02 |
WO2008005002A1 (en) | 2008-01-10 |
AU2006345724B2 (en) | 2013-11-21 |
CA2558160C (en) | 2017-01-03 |
AU2006345724A1 (en) | 2008-01-10 |
EP2124968A4 (en) | 2013-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8097596B2 (en) | Compositions and methods for the treatment of muscle wasting | |
CA2558160C (en) | Antisense oligonucleotide targeting myostatin or fox01 for treatment of muscle wasting | |
JP6637121B2 (en) | Compositions and methods for modulation of SMN2 splicing in a subject | |
CN106146591B (en) | Modulation of angiopoietin-like 3 expression | |
CN108271351A (en) | For adjusting the Compounds and methods for of proangiotensin expression | |
CN103906838A (en) | Antisense modulation of GCCR expression | |
KR101142080B1 (en) | Compositions and Methods for Treatment of Prostate and Other Cancers | |
JP7476422B2 (en) | Compositions and methods for inhibiting LPA expression | |
WO2010120969A1 (en) | Targeting of the mir-30 family and let-7 family as a treatment for heart disease | |
WO2008005019A1 (en) | Compositions and methods for the treatment of muscle wasting | |
JP2024516356A (en) | Compositions and methods for inhibiting ketohexokinase (KHK) | |
CN108004310B (en) | Application of renin (prohormone) receptor (P) RR gene and inhibitor thereof | |
KR101652957B1 (en) | Novel siRNA suppressing ATF3 gene expression and use thereof | |
WO2022181532A1 (en) | Nucleic acid medicine expressing splicing variant of myostatin | |
JP7463621B2 (en) | Compositions and methods for inhibiting mitochondrial amidoxime reducing component 1 (MARC1) expression | |
TW201241179A (en) | MiRNAs in joint disease | |
US20230287416A1 (en) | Combinatory treatment of sma with sarna and mrna modulators | |
US20220340903A1 (en) | Targeting rlim to modulate body weight and obesity | |
CN116392500A (en) | micrornas and uses thereof in diagnosis and therapy | |
DE202006010725U1 (en) | Composition containing modified oligonucleotide with achiral internucleotide phosphate bonds, useful for treating muscular atrophy or promoting muscle growth | |
TW202400193A (en) | Compositions and methods for inhibiting transmembrane serine protease 6 (tmprss6) expression | |
WO2024112653A1 (en) | Inhibitory nucleic acids and methods of use thereof | |
DE202007009679U1 (en) | Compositions and uses thereof for the treatment of muscle wasting conditions | |
KR20210114661A (en) | A Method for Preventing or Treating mTOR-related Disorders via Regulation of VEGFR-3 Expression |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20220630 |